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Abstract 
The correct formation of disulfide bonds is a crucial step in the folding of many virulence 
factors in bacteria. In many Gram-negative bacteria, redox machinery in the periplasm 
ensures this occurs efficiently and correctly for secreted and membrane proteins through 
the processes of disulfide bond oxidation and isomerisation. This machinery has been well 
characterised in Escherichia coli (strain K-12) where it consists of four key disulfide bond 
forming (Dsb) proteins, DsbA, DsbB, DsbC and DsbD. E. coli DsbA is the prototypical 
bacterial oxidase, which catalyses the formation of disulfide bonds in its protein substrates. 
When the active site cysteines of DsbA become reduced, DsbA needs to be reoxidised by 
its redox partner, DsbB, to continue to function. DsbA often forms disulfide bonds 
incorrectly and DsbC corrects this by isomerising or shuffling the disulfide bonds in the 
substrate protein. As DsbC is only active when its catalytic cysteines are reduced, it also 
has a redox partner, DsbD.  
 
Over the past 27 years, Dsb-like proteins from various bacteria have been studied and it 
has become clear that there is great diversity in the number and type of proteins that 
contribute to the redox machinery in different bacteria. Some bacteria have multiple Dsb 
proteins and distinct Dsb-like systems that have specific roles.  The suppressor of copper 
sensitivity (Scs) proteins form one such system. Originally identified in Salmonella enterica 
serovar Typhimurium, the Scs locus encodes four proteins (ScsA, ScsB, ScsC and ScsD). 
The S. Typhimurium locus was found to confer copper tolerance to a copper sensitive E. 
coli mutant, so it is thought that these proteins play a role in bacterial response to copper 
stress. Three Scs proteins (ScsB, ScsC and ScsD) have predicted thioredoxin folds and 
catalytic cysteines, similar to the Dsb proteins. This thesis focuses on the characterisation 
of the ScsC and ScsB proteins from the uropathogen Proteus mirabilis.  
 
Prior to this work, ScsC had only been studied in two organisms, S. Typhimurium and 
Caulobacter crescentus. Chapter 2 is a Nature Communications paper that describes the 
genetic, biochemical and structural characterisation of P. mirabilis ScsC (PmScsC). This 
work revealed that PmScsC is a highly dynamic, trimeric disulfide isomerase that 
increases the swarming motility of P. mirabilis under copper stress. An N-terminally 
truncated PmScsC variant, PmScsCΔN, is monomeric and has little in vitro disulfide 
isomerase activity but is highly active as a dithiol oxidase. This variant could not 
complement the loss of ScsC in P. mirabilis, suggesting that PmScsC functions as a 
trimeric disulfide isomerase in vivo. The three crystal structures of PmScsC revealed that 
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the region responsible for the highly dynamic nature of the protein is an 11 amino acid 
flexible linker between the trimerisation domain and catalytic domain. Replacement of this 
flexible linker with a rigid linker revealed that it was necessary for the disulfide isomerase 
activity of PmScsC.  
 
Chapter 3 describes the structural characterisation of the PmScsC variant, PmScsCΔN 
and the biochemical and structural characterisation of another variant PmScsCΔLinker. 
The structure of PmScsCΔN is very similar to the catalytic domains of the native PmScsC 
structures, suggesting that it is the lack of the trimerisation stem and thus change in 
oligomerisation state that converts it from an isomerase to an oxidase. To assess the role 
of the flexible linker in PmScsC, the linker residues (39-49) were deleted. This deletion 
mutant (PmScsCΔLinker) crystallised as a trimer but exists in different oligomeric states in 
solution and does not function as an oxidase or an isomerase. The characterisation of 
these variants adds to our understanding of the key structural features of PmScsC and 
their influence on the function of this trimeric disulfide isomerase. This chapter has been 
submitted to Acta Crystallographica Section D for publication. 
 
Based on work performed in C. crescentus, we hypothesised that the N-terminal 
periplasmic domain of PmScsB (PmScsBα) is the redox partner of PmScsC. Chapter 4 is a 
Journal of Biological Chemistry publication that describes the experiments performed to 
confirm this hypothesis. This publication also reports the crystal structure of PmScsBα, 
(the first ScsBα structure to be solved) and a SANS derived model of the complex formed 
between PmScsC and PmScsBα. I found that PmScsBα consists of two immunoglobulin-
like domains, both of which interact with one PmScsC protomer in the SANS model. 
 
To gain more information about PmScsB, I wanted to produce the full-length 
transmembrane protein for further characterisation. Chapter 5 describes the work 
performed towards the design of robust expression and purification protocols for the 
production of PmScsB.  
 
In summary, this thesis describes the characterisation of PmScsC, PmScsC mutants, 
PmScsBα and the interaction between PmScsC and PmScsBα. It also contains the steps 
taken toward the production of the full-length transmembrane protein PmScsB for future 
analysis. This work adds to our understanding about the Suppressor of copper sensitivity 
proteins and the diversity of redox machinery in bacteria. 
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1. Introduction 
This thesis focuses on bacterial redox proteins, specifically the suppressor of copper 
sensitivity proteins from Proteus mirabilis. This chapter begins by introducing the related 
disulfide bond forming proteins from Escherichia coli and summarising the conservation of 
these proteins across different bacterial species. The antibacterial action of copper and the 
response of bacteria to copper stress are then discussed before the P. mirabilis 
suppressor of copper sensitivity proteins are introduced. This chapter also provides the 
significance and aims of the research in this thesis and outlines how the subsequent 
chapters address each aim. 
 
1.1 Disulfide bond forming proteins 
The formation of disulfide bonds is an important step in the folding of many proteins. 
These covalent bonds, which are formed between the sulfur atoms of two cysteines, add 
stability to many folded proteins, allowing them to maintain their active, three-dimensional 
structure. In bacteria, proteins that require structural disulfide bonds are often virulence 
factors that are found in the periplasm or are transported into the harsh extracellular 
environment (1,2). Many Gram-negative bacteria have periplasmic machinery that is 
dedicated to forming disulfide bonds in secreted proteins. This machinery comprises a 
family of proteins, aptly named the Disulfide bond forming (Dsb) proteins. Dsb proteins 
have at least two redox active cysteines that cycle between the disulfide-bonded and 
reduced thiol states to perform their catalytic function. The prototypical E. coli Dsb (EcDsb) 
machinery consists of four proteins; EcDsbA, EcDsbB, EcDsbC and EcDsbD. EcDsbA and 
EcDsbB are involved in the oxidation step of disulfide bond formation (1,3), whereas 
EcDsbC and EcDsbD are involved in the isomerisation of incorrect disulfide bonds (4-6) 
(Figure 1.1).  
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Figure 1.1: Overview of the prototypical E. coli Dsb system. EcDsbA and EcDsbB, 
along with quinones, make up the disulfide bond oxidation pathway, responsible for 
introducing disulfide bonds into unfolded proteins. EcDsbC and EcDsbD are the key 
proteins in the isomerisation pathway, which rearranges incorrect disulfide bonds in 
substrate proteins. The isomerisation pathway relies on a reduction cascade that 
originates in the cytoplasm with NADPH. The curved arrows in the diagram indicate the 
flow of electrons throughout the pathways.  
 
1.1.1 E. coli DsbA 
E. coli DsbA (EcDsbA) functions as the oxidase in the Dsb pathway, catalysing the 
formation of disulfide bonds in substrate proteins. The crystal structure of EcDsbA was 
published in 1993 (7) and shows that this monomeric, globular protein contains a 
thioredoxin fold. This fold (green in Figure 1.2A,B) consists of two motifs, βαβ and ββα, 
with a third α-helix situated between them (Figure 1.2A and B). EcDsbA also harbours an 
α-helical bundle between the ββα motif and the connecting α-helix of the thioredoxin fold. 
The redox active CXXC motif is positioned at the end of α-helix 1, and next to this site is a 
hydrophobic groove shown to be involved in the binding of other proteins (Figure 1.2C). 
The more N-terminal of the two catalytic cysteines (Cys30) is accessible to substrate 
proteins, whereas the second cysteine (Cys33) is buried in the protein. The pKa of Cys30 
is very low, approximately 3.5 (8), so the reactive thiolate anion form of its side chain is 
favoured at physiological pH 7. The formation of an intramolecular disulfide bond between 
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the catalytic cysteines of EcDsbA destabilises the protein (9), thus making the transfer of 
this disulfide bond favourable. This disulfide instability gives EcDsbA its highly oxidising 
nature (redox potential -122 mV (9,10)). 
 
 
Figure 1.2: Structural features of EcDsbA. A. Structure of EcDsbA (PDB ID: 1DSB) 
shown in cartoon representation. B. Topology diagram of EcDsbA. In both A and B the 
thioredoxin fold is coloured green, with the position of the catalytic cysteines shown as 
orange circles/spheres. The inserted helical domain and N-terminal β-strand are coloured 
grey. C. Electrostatic surface potential of EcDsbA. Electrostatic calculations were 
performed using APBS (11) and contoured to -7.5 and +7.5 kBT/e. Positively charged 
surfaces are shown in blue, negatively charged surfaces are red and hydrophobic surfaces 
are white. An orange circle represents the position of the catalytic cysteines; the 
hydrophobic groove is surrounded by an oval. 
 
EcDsbA-catalysed disulfide bond formation is proposed to occur via two bimolecular 
nucleophilic substitution (SN2) reactions (Figure 1.3) (12,13). In the first reaction, a thiolate 
anion of a cysteine residue in the unfolded substrate attacks Cys30 of oxidised EcDsbA, 
forming an intermolecular disulfide bond and releasing Cys33 as a thiol group (14,15). The 
intermolecular disulfide bond is then resolved in the second reaction, by the attack from 
another free thiolate anion in the substrate protein, resulting in disulfide exchange between 
EcDsbA and the substrate (15). A number of periplasmic proteins depend on EcDsbA for 
the formation of structural disulfide bonds (16). These include virulence factors such as 
FlgI, which forms part of the flagella motor (17) and EscC, which is an outer membrane 
secretin of the type III secretion system in enteropathogenic E. coli (18). Deletion of dsbA 
in E. coli results in the reduced production of properly folded virulence factors (1,17). 
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Figure 1.3: Catalytic action of EcDsbA. The mechanism of EcDsbA-catalysed disulfide 
bond formation proceeds via two SN2 reactions and results in the formation of a disulfide 
bond in the substrate protein and reduction of the catalytic cysteines in EcDsbA. EcDsbA 
is shown in green and the unfolded substrate is coloured yellow. The disulfide bonded or 
folded substrate is coloured orange. 
 
1.1.2 E. coli DsbB 
After oxidising two thiol groups of a substrate protein, the catalytic cysteines of EcDsbA 
become reduced. To continue the cycle of disulfide bond formation in the periplasm, the 
catalytic cysteines of EcDsbA need to be oxidised (converted to the disulfide bonded 
state). As EcDsbA is more stable in the reduced form (9), a redox partner is required to 
oxidise EcDsbA and reactivate the enzyme. This redox partner is EcDsbB (3). EcDsbB is 
an inner membrane protein consisting of four transmembrane helices (Figure 1.4A) (19). 
The N- and C-termini are located in the cytoplasm and the protein has two periplasmic 
loops. The second periplasmic loop is much larger than the first and also contains a short 
α-helix (α4) that is associated with the membrane. Both loops contain an essential redox 
active pair of cysteines that need to be oxidised for EcDsbB activity (19). The second pair, 
Cys104 and Cys130, are needed for the interaction with EcDsbA (20,21), whereas the first 
pair, Cys41 and Cys44 are involved in the interaction with quinones, such as ubiquinone 
and menaquinone (22,23). These quinones are essential for EcDsbB catalytic function as 
they provide the driving force for EcDsbA oxidation by passing electrons obtained from 
EcDsbA onto electron acceptors involved in respiration, maintaining EcDsbB in the 
oxidised state (24).  
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Figure 1.4: Structure of EcDsbB and the EcDsbA-EcDsbB interaction. A. Crystal 
structure of the complex between antigen-binding fragment (not shown) and EcDsbB 
Cys41Ser mutant (PDB ID: 2ZUQ). EcDsbB is coloured purple, the positions of the 
catalytic cysteines are shown by orange spheres and the part of the ubiquinone molecule 
resolved in the structure is shown as magenta sticks. The chemical structures of 
ubiquinone (UQ) and menaquinone (MQ) are shown. B. Crystal structure of the complex 
between EcDsbA and EcDsbB (PDB ID: 2HI7). The colours in A are maintained except in 
B the orange spheres represent the disulfide bonded cysteines. The inset shows how the 
second periplasmic loop of EcDsbB binds into the hydrophobic groove of EcDsbA. 
 
The interaction between EcDsbA and EcDsbB has been well characterised. A crystal 
structure of the interaction was obtained by mutating Cys33 of EcDsbA to Ala and Cys130 
of EcDsbB to Ser, which allowed the formation of an intermolecular disulfide bond between 
Cys30 (EcDsbA) and Cys104 (EcDsbB), resulting in a stable complex (Figure 1.4B) (25). 
The structure shows that the second periplasmic loop of EcDsbB binds into the 
hydrophobic groove close to the EcDsbA catalytic cysteines. There are two proposed 
mechanisms for the regeneration of EcDsbA by EcDsbB and both involve a series of 
disulfide exchange reactions and large conformational changes in EcDsbB that reposition 
the catalytic cysteine residues throughout the catalytic cycle (Figure 1.5) (26,27). For both 
mechanisms, the first step involves the attack of the reactive thiolate anion of Cys30 in 
EcDsbA on the Cys104-Cys130 disulfide bond in EcDsbB. This results in the formation of 
an intermolecular disulfide bond between Cys30 (EcDsbA) and Cys104 (EcDsbB) and the 
release of Cys130 (EcDsbB). The second and third steps differ between the reaction 
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mechanisms. In the “concerted” or “slow” model, the Cys130 thiolate anion attacks the 
Cys41-Cys44 disulfide bond of EcDsbB, forming an inter-loop disulfide between Cys130 
and Cys41 (2a, Figure 1.5). The free Cys44 then forms a charge transfer intermediate with 
quinones, which gives EcDsbB a purple colour (28,29). Cys33 of EcDsbA then attacks the 
intermolecular EcDsbA-EcDsbB disulfide, resulting in the reoxidation of the EcDsbA 
cysteines and release of Cys104 (EcDsbB) (3a, Figure 1.5). In the alternate or “rapid” 
model essentially these two steps happen the other way round, that is, oxidised EcDsbA is 
released before Cys130 of EcDsbB attacks the Cys41-Cys44 disulfide bond (2b and 3b, 
Figure 1.5). In this model, it is thought that when EcDsbA binds EcDsbB a conformational 
change occurs in EcDsbB, distancing Cys130 so it is unable to catalyse the backward 
resolution of the EcDsbA-EcDsbB disulfide bond (25). It is also proposed that free Cys130 
(EcDsbB) interacts with a loop on EcDsbA, prohibiting Cys130 (EcDsbB) from interacting 
with the Cys41-Cys44 disulfide, when EcDsbA is bound (26). Nevertheless, the fourth step 
in both pathways is the resolution of the Cys130-Cys41 disulfide by the attack of the 
Cys104 thiolate anion, resulting in the reformation of the Cys104-Cys130 bond (Figure 
1.5). The Cys41 thiolate anion then attacks the Cys44-quinone complex, reforming the 
Cys41-Cys44 disulfide bond and releasing the now reduced quinone.  
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Figure 1.5: Proposed mechanisms for the reactivation of EcDsbA by EcDsbB. The 
two proposed mechanisms for the EcDsbB-catalysed oxidation of EcDsbA differ at steps 2 
and 3. Throughout the schematic, EcDsbA is shown in green and EcDsbB is shown in both 
light and dark purple. The colour changes of the quinone (circle) represent the different 
states of the electron acceptor throughout the pathway. The quinone is coloured magenta 
when associated with EcDsbB (light purple), light purple when it forms a charge transfer 
complex (represented by the red line) with EcDsbB (which changes to dark purple to 
represent the colour change) and dark turquoise once the electrons have been accepted. 
The curved arrows represent the flow of electrons. 
 
1.1.3 Inhibition of the oxidative folding pathway as an antibacterial strategy 
Both EcDsbA and EcDsbB are considered targets for antibacterial drug discovery because 
of the important role they play in the formation of bacterial virulence factors. Further, a 
dsbAB knock-out strain of uropathogenic E. coli has reduced fitness in a mouse model of 
infection (30). The targeting of bacterial virulence as opposed to bacterial viability is an 
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emerging approach that is proposed to overcome the selective pressure for resistance that 
plagues the use of traditional antibiotics. Drug discovery targeting protein-protein 
interactions can be challenging, as there are generally no pockets on the interaction 
surface where a small molecule can easily bind. Nevertheless, fragment based drug 
discovery has been used to identify inhibitors that bind to EcDsbA (31) and peptide-based 
inhibitors have also been designed to bind to the reactive cysteine and into the 
hydrophobic groove of EcDsbA (32,33). EcDsbB has also been validated as an 
antivirulence target and high-throughput screening and fragment based drug discovery 
have been used to identify EcDsbB inhibitors (34-36). This has resulted in inhibitors that 
compete with quinone and or EcDsbA binding (34,35). Further work is needed to increase 
the potency of EcDsbA and EcDsbB inhibitors and research is now being undertaken to 
develop inhibitors of DsbA and DsbB from other bacteria (37,38).  
 
1.1.4 E. coli DsbC 
EcDsbA typically introduces disulfide bonds between cysteine residues into substrate 
proteins in a sequential manner along the unfolded polypeptide chain, as it is translocated 
into the periplasm (15). This allows for the correct folding of proteins that have disulfide 
bonds between consecutive cysteines, but results in the misfolding of substrates that need 
a different configuration of disulfide bonds, such as RNase I (17). Disulfide isomerases are 
able to shuffle disulfide bonds in a protein until it is correctly folded and are required for the 
folding of many proteins. EcDsbC is the prototypical bacterial disulfide isomerase and is a 
globular, V-shaped, homodimeric, periplasmic protein (Figure 1.6A) (4,39,40).  
 
Each EcDsbC protomer contains a catalytic DsbA-like domain, comprised of a thioredoxin 
fold harbouring the redox active CXXC motif and an inserted helical-bundle consisting of 
only two helices (α4-5 in EcDsbA are replaced by a loop in EcDsbC) (Figure 1.6C) (39). 
Like EcDsbA, the N-terminal cysteine of EcDsbC (Cys98) is solvent accessible and acidic, 
with a pKa of 4.3 (41). It is expected that the catalytic cysteines of EcDsbC are also 
stabilised in the reduced form by a hydrogen-bonding network (39) and the redox potential 
of EcDsbC, at -130 mV (42), is only slightly more reducing than that of EcDsbA (-122 mV) 
(9,10). Dimerisation of EcDsbC is mediated by an N-terminal domain in each protomer that 
consists of a single N-terminal α-helix followed by 5 β-strands (39). The first four of these 
β-strands form a β-sheet with the fifth β-strand of the other EcDsbC protomer (Figure 
1.6B). This intermolecular β-sheet holds the EcDsbC protomers together and dimerisation 
in this way is essential for the isomerase activity of EcDsbC (41,43). As the catalytic 
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domains of EcDsbA and EcDsbC are very similar, it is the dimerisation of EcDsbC that 
prevents cross talk between the Dsb oxidation and isomerisation pathways. Dimeric 
EcDsbC is required to interact with its redox partner EcDsbDα (44) and EcDsbB can only 
oxidise monomeric mutants of EcDsbC (45). The hydrophobic dimerisation cleft of EcDsbC 
is also predicted to be important for the interaction with substrates (Figure 1.6D) (39). 
Misfolded proteins typically have exposed hydrophobic patches, which are thought to be 
detected by EcDsbC and shielded by the enzyme’s hydrophobic cleft whilst the disulfide 
bonds are shuffled by the catalytic cysteines (39). EcDsbC also functions as a chaperone 
(46) and the hydrophobic dimerisation cleft is essential for this activity (39,41). 
 
 
Figure 1.6: EcDsbC structure. A. Dimeric EcDsbC with the dimerisation domain coloured 
magenta, the hinged linker helix shown in cyan and the thioredoxin fold coloured green 
with the catalytic cysteines represented by orange spheres.  Other features, including the 
inserted helical domain, are grey. B. The dimerisation interface of EcDsbC consists of an 
intermolecular β-sheet, formed by β1-4 in one protomer and β5 in another. C. Structure of 
an EcDsbC protomer, coloured as in A with the secondary structure elements and the N- 
and C-termini labelled. D. Electrostatic surface potential of dimeric EcDsbC. Electrostatic 
calculations were performed using APBS (11) and contoured to -7.5 and +7.5 kBT/e. 
Positively charged surfaces are shown in blue, negatively charged surfaces are red and 
hydrophobic surfaces are white. An orange circle represents the position of the catalytic 
cysteines. 
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The catalytic and dimerisation domains of each EcDsbC protomer are connected by a 
hinged linker helix (39). This hinged linker gives the isomerase conformational flexibility, 
allowing the catalytic domains to move relative to each other. This was evidenced by the 
conformational change observed between the EcDsbC crystal structure (PDB ID: 1EEJ) 
(39) and that of the complex between EcDsbC and its redox partner EcDsbDα (PDB ID: 
1JZD) (47). In the structure of the complex the distance between the two catalytic sites is 
~29 Å, compared to ~38 Å in the EcDsbC structure (47). This flexibility is thought to 
facilitate the disulfide isomerase and chaperone activity of EcDsbC (39,47), by allowing the 
bound misfolded substrates to sample many different shapes. EcDsbC would need to 
accommodate substrate conformational changes and enable repositioning of the 
substrate’s cysteines, allowing the correct disulfide bonds to be formed. The EcDsbC 
flexibility would also allow the enzyme to interact with a variety of different substrates.  
 
In contrast to EcDsbA, EcDsbC functions in the reduced form, with the free thiolate anion 
of the reactive cysteine (Cys98) attacking disulfide bonds in substrate proteins (Figure 1.7) 
(48). Once the EcDsbC-substrate intermediate has formed there are two ways in which the 
reaction can proceed and both have been confirmed by experimental evidence (48-50). 
The first pathway involves the intermolecular disulfide being attacked by another cysteine 
in the substrate protein, resulting in the isomerisation of the substrate’s disulfide bonds. In 
the second pathway, the intermolecular disulfide bond is resolved by Cys101 of EcDsbC, 
resulting in oxidised EcDsbC and the reduced substrate disulfide (51).  
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Figure 1.7: EcDsbC mechanism of action. EcDsbC (green) functions in the reduced 
form and can either isomerise or reduce the disulfide bonds of substrate proteins. In the 
diagram, the substrate changes colour and shape depending on whether it is oxidised 
(orange or red), reduced (yellow) or the disulfide bonds are isomerised (orange vs red). 
 
Only a handful of EcDsbC substrates have been identified, including the penicillin-
insensitive murein endopeptidase MepA, an endonuclease End1 and the ribonuclease 
RNase I (17,52). Under normal growth conditions, deletion of dsbC in E. coli has no clear 
phenotype (53) however the deletion strain does show reduced viability when exposed to 
excess copper (54). This suggests that in vivo EcDsbC could be involved in responding to 
copper stress. Excess copper catalyses disulfide bond formation, including the formation 
of disulfide bonded oligomers, in the bacterial periplasm (54). EcDsbC is thought to 
contribute to copper resistance by resolving these copper-catalysed non-native disulfide 
bonds that would otherwise disrupt the folding and function of many proteins (54). It has 
been shown that under oxidative stress EcDsbC protects the single cysteine of AraF (an 
arabinose binding protein), by reducing disulfide-bonded AraF dimers (55). 
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1.1.5 E. coli DsbD 
EcDsbC can only function as a disulfide isomerase if its catalytic cysteines are in the 
reduced form. EcDsbD is responsible for reducing the EcDsbC cysteines and transporting 
electrons from the cytoplasm to the periplasm to maintain other periplasmic proteins in the 
reduced state (56). Like EcDsbB, EcDsbD is an inner membrane protein, though its 
architecture is very different. EcDsbD consists of two periplasmic domains, one at the N-
terminus (EcDsbDα) and another at the C-terminus (EcDsbDγ), which are connected by a 
transmembrane domain (EcDsbDβ) consisting of eight predicted transmembrane helices 
(57) (Figure 1.8). Each of these domains has two redox active cysteines that are required 
for the electron transporting activity of EcDsbD (57,58). The expression of all three 
domains individually is able to complement the loss of the entire EcDsbD protein, 
suggesting that the domains do not need to be physically linked for its electron 
transporting function (59,60). The structures of both soluble domains have been solved 
showing that EcDsbDα consists of an immunoglobulin-like fold (47,61) whereas EcDsbDγ 
adopts a thioredoxin-like fold (Figure 1.8) (62,63). In both of these domains one catalytic 
cysteine is more solvent accessible than the other (61,63). These solvent accessible 
cysteines interact directly with other domains/substrates whereas the shielded cysteines 
resolve the intra/interdisulfide bonds (44,64). No structures of the full-length protein or of 
the membrane-embedded domain, EcDsbDβ, have been solved. The catalytic cysteines of 
EcDsbDβ, Cys163 and Cys285, are located on transmembrane helices 1 and 4, 
respectively (57). Solvent accessibility studies of EcDsbD have suggested that these 
helices form an hourglass-shaped pore with the catalytic cysteines in the centre, allowing 
them to be accessed from both sides of the membrane (inset, Figure 1.8) (65,66). 
 
Figure 1.8: Structure of EcDsbD. The crystal structures of EcDsbDα (PDB ID: 1JPE) and 
EcDsbDγ (PDB ID: 1UC7) are shown with the catalytic cysteines represented as orange 
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spheres. The predicted topology of EcDsbDβ is shown, with the transmembrane helices 
numbered. Inset shows the predicted hourglass-shaped structure of transmembrane (TM) 
helices 1 and 4. 
 
EcDsbDα is the domain that is responsible for directly interacting with and reducing 
EcDsbC. The structure of the EcDsbC-EcDsbDα interaction complex has been solved 
showing that EcDsbDα interacts with both EcDsbC protomers within the EcDsbC 
homodimer (Figure 1.9A) (44,47). The interaction between EcDsbC and EcDsbDα results 
in a disulfide exchange and, like the EcDsbA-substrate interaction (44), this exchange is 
predicted to proceed via two SN2 mechanisms (Figure 1.9B). Initially, the thiolate anion of 
Cys109 on EcDsbDα attacks the EcDsbC disulfide bond, forming an intermolecular 
disulfide bond between Cys109 (EcDsbDα) and Cys98 (EcDsbC) (61). Cys103 of 
EcDsbDα then resolves this bond to release reduced EcDsbC and oxidised EcDsbDα (61). 
EcDsbDα has other interaction partners including EcDsbG, another homodimeric 
thioredoxin-fold containing protein, which functions to stop the oxidation of single cysteine 
residues to sulfinic and sulfonic acids (67,68), and EcCcmG (also known as EcDsbE), 
which is involved in the maturation of cytochrome C (56,69). When dsbD is deleted from E. 
coli, these proteins remain oxidised and are unable to perform their function (6,56,68).  
 
 
Figure 1.9: The interaction between EcDsbC and EcDsbDα. A. Crystal structure of the 
EcDsbC-EcDsbDα complex. EcDsbC is shown in green and EcDsbDα is coloured purple. 
The catalytic cysteines are shown as orange spheres. B. Proposed mechanism of the 
disulfide exchange reaction between EcDsbC and EcDsbDα.  
 
EcDsbDα gains its reducing power from a disulfide exchange cascade that originates in 
the cytoplasm with the reduction of thioredoxin by NADPH-dependent thioredoxin 
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reductase (Figure 1.10). The electrons are then passed from thioredoxin to EcDsbDβ, 
EcDsbDβ to EcDsbDγ and finally from EcDsbDγ to EcDsbDα (59). The mechanism for 
these disulfide exchanges is predicted to be similar to the EcDsbDα-EcDsbC interaction 
(59). 
 
Figure 1.10: EcDsbD disulfide exchange cascade. EcDsbD transports electrons from 
the cytoplasm to the periplasm via a disulfide exchange cascade. The curved arrows 
represent the disulfide exchange reactions. The catalytic cysteines are shown in orange. 
 
1.1.6 Other E. coli Dsb proteins 
Other Dsb proteins found in E. coli include DsbG and CcmG (also known as DsbE). As 
mentioned in the previous section, EcDsbD maintains both of these proteins in the 
reduced state (68). EcDsbG is a dimeric thioredoxin-fold protein with structural features 
similar to those of EcDsbC (70), despite only 26% sequence identity between the two 
proteins (Figure 1.11A) (67). The main difference is that EcDsbG has a longer α-helix 
connecting the catalytic and dimerisation domain, meaning that the cleft between the 
catalytic domains is significantly larger (~20 Å wider and ~6 Å deeper) (70). The cleft of 
EcDsbG also contains charged residues suggesting that the protein may interact with 
folded, or at least partially folded substrates (70). As overexpression of dsbG is able to 
partially complement dsbC deletion in E. coli, it was originally suggested that EcDsbG 
functions as an isomerase with a much narrower range of substrates (68). This was 
supported by the findings that EcDsbG is expressed at much lower levels than EcDsbC in 
vivo (68) and that EcDsbG is not involved in the folding of RNase I (17) or able to function 
in the insulin reduction assay (68). More recently it was shown that EcDsbG functions as a 
chaperone (71,72) and that it protects single cysteine residues from oxidation to sulfinic 
and sulfonic acids (67). This latter study identified three EcDsbG substrates, YbiS, ErfK 
and YnhG (67), which are all L,D-transpeptidases involved in cell wall synthesis and 
require a single, reduced cysteine residue for their catalytic function (73). 
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CcmG stands for cytochrome c maturation protein G and is one of eight Ccm proteins 
encoded in E. coli (74). This protein is also called DsbE because of its similarities to the 
disulfide bond forming proteins and its interaction with EcDsbD. EcCcmG is a reductase 
but is considered to have a specialised function interacting with EcCcmH (75), to pass 
electrons onto apocytochrome c, reducing its CXXCH motif and allowing heme attachment 
(76,77). EcCcmG consists of a periplasmic C-terminal domain, which is tethered to the 
inner membrane by a single N-terminal transmembrane α-helix (75). The structure of the 
C-terminal domain (residues 19-185) has been solved revealing that it contains a 
thioredoxin fold (Figure 1.11B) (78). 
 
 
Figure 1.11: Structure of EcDsbG and EcCcmG. A Structure of EcDsbG (PDB ID: 1V57) 
with the dimerisation domain coloured magenta, the linker helix coloured cyan and the 
thioredoxin fold shown in green with the catalytic cysteines shown as orange spheres. 
Other elements of the catalytic domain are coloured grey. B. Structure of the C-terminal 
periplasmic domain of EcCcmG (PDB ID: 2B1K). The thioredoxin fold is shown in green 
and the catalytic cysteines are represented as orange spheres. Other structural elements 
are coloured grey and the single transmembrane helix is represented as a cylinder to show 
the topology of the full-length protein. 
 
1.1.7 Conservation and diversity in the Dsb protein family 
Most of the published work on the Dsb family has been performed in the non-pathogenic 
E. coli K12 strain. However, research on homologues of these proteins has suggested this 
organism may not be representative of disulfide bond formation in all bacteria (79). The 
Dsb oxidation and isomerisation pathways are generally conserved in gamma- and beta-
proteobacteria, but are more diverse in alpha-, delta- and epsilon-proteobacteria and in 
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Gram-positive bacteria (16,79,80). No DsbC/D-like disulfide isomerisation pathway has 
been identified in Gram-positive bacteria (79). Staphylococcus aureus does not have a 
detectable DsbB homologue and may instead rely on small molecules to reoxidise DsbA 
(81-83). Some bacteria have multiple DsbA/B/C/D-like or sets of Dsb-like proteins, which 
can each have specialised redox functions in vivo. For example uropathogenic E. coli and 
Salmonella enterica serovar Typhimurium, in addition to the prototypical system, have 
another set of DsbA/B-like proteins, DsbI/L, that are encoded in an operon and are 
necessary for the oxidative folding of arylsulfate-sulfotransferase (AssT) (84-87). Another 
group of accessory Dsb-like proteins are the suppressor of copper sensitivity proteins that 
contribute to the bacterial virulence trait of copper resistance, and are the focus of this 
thesis. 
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1.2 Copper in infection and immunity 
Copper (Cu) is an essential trace metal, needed for cellular processes in all aerobic forms 
of life. Its ability to cycle between two oxidation states (Cu (I) and Cu (II)) makes it a useful 
cofactor in many enzymes. The concentration of cellular copper must be tightly regulated 
as the redox activity of this metal also makes it toxic. Copper-mediated toxicity is utilised 
by the innate immune system to overcome infection (88). Animals deprived of copper in 
their diets are more susceptible to infection (89-91), whereas increasing dietary Cu intake 
(while maintaining non-toxic levels) has the opposite effect (92,93). Work has suggested 
that phagocytes may use Cu ions to kill pathogens that have been engulfed (94-96). In 
response to bacterial infection higher levels of copper can be found in the extracellular 
environment and the site of infection. For example, patients with urinary tract infections 
have increased levels of copper in their urine compared to healthy controls (92,97) and 
guinea pigs infected with Mycobacterium tuberculosis have increased copper 
concentrations in inflammatory lesions (93). 
 
1.2.1 The antibacterial nature of copper 
Copper is toxic to bacterial cells for three main reasons, two of which rely on the redox 
properties of copper. Firstly, redox cycling between free Cu(I) and Cu(II) can occur in 
bacteria causing unwanted redox reactions (88), including the formation of non-native 
disulfide bonds (54,98). Interaction of Cu(I) with hydrogen peroxide or superoxide 
produced by the host also results in the production of hydroxyl radicals and causes severe 
oxidative stress to the bacteria (94). The third, redox-independent, effect is that Cu(I) has a 
greater affinity for thiols than other metals (e.g. iron) and therefore outcompetes them for 
coordination sites in metalloproteins (88,94,99). This disrupts complexes (e.g. Fe-S 
clusters) that are required for essential bacterial cellular processes (100). 
 
1.2.2 Bacterial response to copper stress  
Bacteria deploy various strategies to evade the toxic effects of copper and these vary 
significantly across different bacterial species, with some having redundant systems in 
place (88). Four main features of the bacterial response to copper stress are copper 
sensors (A), oxidases (B), binding proteins (C) and transporters (D) (Figure 1.12) (88,99). 
Copper sensors, such as CueR in E. coli and S. Typhimurium, are activated by an 
increased concentration of copper in the bacteria and often act as transcription factors that 
turn on genes encoding other copper response proteins like copper binders and 
transporters (94,101-103). CueO is an example of a copper oxidase, which functions in the 
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periplasm of bacteria to oxidise Cu(I) to Cu(II), which is less toxic (104,105). Those 
proteins that bind excess copper, such as CueP in S. Typhimurium (106), either sequester 
it or chaperone it to other proteins, such as copper sensors or transporters/efflux systems 
that remove it from the cell (99). A key feature of many bacterial copper response systems 
is the presence of CopA, a Cu(I)-exporting ATPase that transports Cu(I) from the 
cytoplasm to the periplasm (88,107,108). Other less conserved copper exporters, such as 
E. coli CusCFBA, pump copper out of the periplasmic space (109,110). Some bacteria 
also have additional machinery that contributes to copper resistance in other ways; this 
machinery includes DsbC in E. coli (as mentioned previously) and the understudied 
suppressor of copper sensitivity proteins. 
 
Figure 1.12: Copper resistance mechanisms in bacteria. A. Metal sensors detect 
copper ions in the cytoplasm and often act as transcription factors. B. Some periplasmic 
proteins oxidise Cu (I) to Cu (II). C. Copper binders sequester copper or chaperone it to 
other copper resistance proteins. D. Copper transporters can remove copper ions from the 
cytoplasm and periplasm. 
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1.3 Suppressor of copper sensitivity proteins 
Studies of the suppressor of copper sensitivity (Scs) proteins have shown that they are 
involved in the bacterial response to copper and oxidative stress, but their specific cellular 
role is unknown. The Scs proteins have similarities to the Dsb proteins but are not present 
in E. coli, and are encoded at a single locus (111). This locus has four protein encoding 
genes and was first identified in S. Typhimurium, when it was shown to increase the 
copper tolerance of copper sensitive E. coli mutants (111). These copper sensitive E. coli 
strains had mutations in either cutA (encoding DsbD), cutC (encoding a copper 
homeostasis protein), cutE (encoding the apolipoprotein N-acyltransferase Lnt), cutF 
(encoding an outer membrane lipoprotein NlpE) or lgt (encoding a lipoprotein 
diacylglyceryl transferase) (111). Recently the transcription of the scs genes in S. 
Typhimurium, was shown to be upregulated in the presence of copper and dependent on 
the transcription factor CpxR (112). CpxR, in concert with CpxA, senses misfolded 
periplasmic proteins and allows the transcription of the Cu(II) binding protein CueP and 
other proteins under copper stress (113-116). This study also found that a promoter 
upstream of scsA, drives the transcription of all scs genes. Deletion of the scs locus in S. 
Typhimiurium results in reduced growth of the bacterial pathogen under copper stress 
(112,117). However, one study found that the Δscs strain had increased invasiveness in 
vitro and in a mouse model of infection (117). Overall, animals infected with the Δscs strain 
had a similar death rate to those infected with wild-type S. Typhimurium (117). 
 
The four proteins encoded in the S. Typhimurium scs locus, ScsA, ScsB, ScsC and ScsD, 
all contain cysteine residues predicted to form redox-active pairs and three harbour 
predicted thioredoxin folds (111). The Scs proteins are encoded in a number of pathogenic 
bacteria (112,118), though little is known about these proteins. Most of the published work 
has focused on the Scs systems in S. Typhimurium and, to a lesser extent, Caulobacter 
crescentus.  
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Figure 1.13: Predicted architecture of the Scs proteins. In each protein the predicted 
catalytic cysteines are represented as orange circles and the cyan circle in ScsA 
represents a predicted copper-binding motif. 
 
1.3.1 ScsA 
S. Typhimurium ScsA (StScsA) has no overall homology to any structurally characterised 
protein and was originally predicted to be a membrane protein with two transmembrane 
helices (Figure 1.13, residues 10-30 and 71-91) (111). The protein also has a CXXC motif 
and putative copper-binding motifs (1-MAKQQRM-7 and 20-MVCTAQRMAGLHALQM-35) 
but these reside in the first predicted transmembrane helix (111). More recent analysis 
suggests that the protein has a lipoprotein signalling sequence and if this were cleaved in 
vivo, it would remove both the CXXC motif and copper-binding motif (117). No biochemical 
or structural analyses have been performed on any ScsA protein to date, however, genetic 
analysis has provided some insight into its biological function. Deletion of scsA (ΔscsA) in 
S. Typhimurium does not increase the sensitivity of the bacteria to copper, revealing that 
the encoded protein does not play a role in the response to copper stress (112,117). Two 
studies have found that scsA deletion mutants are sensitive to H2O2 (which generates 
reactive oxygen species) suggesting that ScsA plays a role in the response to oxidative 
stress (112,117). When exposed to 6 mM H2O2 the ΔscsABCD S. Typhimurium strain 
displays the same phenotype as the ΔscsA strain (112). This deletion mutant also has 
increased protein carbonylation when exposed to H2O2 (117), a key marker of oxidative 
stress. Another study suggests that scsA is involved in cortisol-induced proliferation of S. 
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Typhimurium in host macrophages and showed that deletion of scsA results in 
upregulation of scsBCD (119). 
 
1.3.2 ScsB 
The second open reading frame in the scs locus encodes the predicted inner 
transmembrane protein; ScsB (111). Phylogenetic analysis identified ScsB as a new class 
of DsbD-like protein (118). The predicted architecture of ScsB is very similar to that of 
EcDsbD. Like EcDsbD, ScsB is predicted to have N-terminal (α) and C-terminal (γ) 
periplasmic domains that are separated by a transmembrane domain (β)  (Figure 1.13) 
(118). ScsBβ is predicted to consist of 6 or 8 transmembrane helices depending on the 
organism of origin. ScsBγ is predicted to have a thioredoxin fold and all domains contain 
two putative redox active cysteines, just like DsbD. This suggests that ScsB has a similar 
function to DsbD in transporting electrons from the cytoplasm to the periplasm (59). The 
key difference between ScsB and DsbD is the α-domain (118). In DsbD, it is this domain 
that directly interacts with substrates (59). Curiously, ScsBα is much larger than DsbDα, 
with approximately 90 more residues, suggesting that they have different structures and 
act on different substrates (118). Three substrates of C. crescentus ScsB (CcScsB) have 
been identified. These are the peroxiredoxin-like1 protein (PrxL), a thioredoxin-like protein 
TlpA and ScsC, all of which are reduced by CcScsB (118). The function of PrxL is 
unknown. TlpA reduces peroxiredoxin (PprX), which in turn reduces both hydrogen 
peroxide and organic peroxides (118). This suggests that CcScsB may have a role in 
facilitating protection from oxidative stress caused by peroxides in the bacterial periplasm.  
 
The deletion of scsB in S. Typhimurium results in a slightly extended lag phase in the 
growth of the bacteria when exposed to H2O2, suggesting that ScsB is somehow involved 
in overcoming oxidative stress in this organism too (112). Deletion mutants of S. 
Typhimurium suggest that ScsD as well as ScsC may be a substrate of ScsB. Deletion of 
scsB alone in S. Typhimurium results in the same level of copper sensitivity as the 
scsABCD deletion mutant, whereas the individual ΔscsC and ΔscsD mutants show lower 
levels of sensitivity (112). The ΔscsCD mutant, however, has a similar level of copper 
sensitivity to ΔscsB, suggesting that the function of ScsC and ScsD under copper stress is 
dependent on ScsB (112).  Prior to the work described in this thesis, no structural studies 
of ScsB had been published.  
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1.3.3 ScsC 
S. Typhimurium ScsC (StScsC) was originally predicted to be an outer membrane protein 
(111), but more recent work showed that it is a globular periplasmic protein with 
oxidoreductase activity (120). StScsC is monomeric, with a DsbA-like structure (Figure 
1.14A). The StScsC structure consists of a thioredoxin fold, harbouring the CXXC catalytic 
motif on α-helix 1 and an inserted helical domain (120). Notably, the StScsC structure is 
considerably different from S. Typhimurium DsbA and EcDsbA. Key differences in the 
StScsC structure include the presence of a short helical domain at the N-terminus, a 
change in position of β1, which interacts with β3 rather than β5, and the presence of a loop 
in place of the fourth α-helix of the helical insertion in EcDsbA (120). These features are 
generally more common in disulfide isomerases like EcDsbG and EcDsbC than oxidases 
(39,70), though the overall structure is reported to be similar to a DsbA-like protein, BdbD, 
from the Gram-positive bacteria Bacillus subtilis (120). The catalytic motif of StScsC is 
most similar to EcDsbG, as both proteins have a proline and a tyrosine separating the two 
catalytic cysteines. This explains why the redox potential of StScsC (-132 mV) is lower 
than that of EcDsbA (-122 mV), as a tyrosine residue in the second X position of the CXXC 
motif is thought to be less stabilising for the reactive thiolate anion than the histidine in 
EcDsbA (70, 120). Another similarity between StScsC and EcDsbG is that a lysine residue 
may be involved in stabilising the thiolate anion form of the solvent accessible catalytic 
cysteine (Figure 1.14) (120).  
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Figure 1.14: Structure of StScsC. A. Topology diagram of StScsC. B. Structure of 
StScsC (PDB ID: 4GXZ), with inset showing the catalytic site. C. Structure of a catalytic 
domain of EcDsbG (PDB ID: 1V57), with inset showing the catalytic site, for comparison to 
StScsC. In all panels, the thioredoxin fold is coloured green, other structural features of the 
catalytic domain are coloured grey and the catalytic cysteines are represented as orange 
circles or spheres. The N- and C-termini are labelled in each panel. 
 
StScsC has biochemical properties that are typical of Dsb oxidoreductases, including a 
redox potential of -132 mV and a pKa of 3.4 for the solvent accessible catalytic cysteine 
(120), closely resembling those of EcDsbG (redox potential -129 mV (121) and pKa 3.5 
(122)). Though, unlike EcDsbG, StScsC can catalyse the reduction of insulin, suggesting 
that it has a broader substrate range (68,120). StScsC is predominantly in the reduced 
state in vivo however it does not function as an isomerase in the scrambled RNase A 
refolding assay (120). This may be a result of the protein being monomeric, as bacterial 
disulfide isomerases typically are dimeric (123).  Loss of scsC results in reduced growth of 
S. Typhimurium in the presence of copper (112,117,120) and, as was shown for scsB, 
deletion of scsC also results in slightly increased sensitivity to H2O2 (112). 
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ScsC from C. crescentus (CcScsC) has also been characterised, revealing that it is 
structurally and functionally different to StScsC (118). Though the structure of CcScsC has 
not been solved, analysis of the protein using size exclusion chromatography suggests 
that it forms a dimer in solution (118).  Secondary structure prediction revealed that the C-
terminal domain contains a thioredoxin fold and the N-terminus forms a long alpha helix, 
which is predicted to facilitate dimerisation (118). This N-terminal alpha helix is shorter in 
StScsC, which may explain why it is monomeric. CcScsC also functions as a disulfide 
isomerase and is maintained in the reduced state in vivo by CcScsB (118). This suggests 
that there is a DsbC-DsbD like interaction between ScsC and ScsB in C. crescentus 
though this interaction has not been confirmed in organisms with a monomeric ScsC.  
 
Bioinformatic analysis of ScsC sequences shows great diversity in homologues, 
suggesting that it may have diverse structures and be involved in a variety of redox 
reactions across different groups of bacteria (118). 
 
1.3.4 ScsD 
Very little work has been done towards understanding the role of ScsD. However, ScsD 
does have homology to a number of other proteins, which give some insight into its 
potential function (111). ScsD is predicted to consist of a periplasmic thioredoxin-like 
domain anchored to the membrane by a single N-terminal transmembrane helix  (Figure 
1.13) (111). This architecture is very similar to that of CcmG, which is a thiol reducant and 
plays a role in cytochrome c biogenesis (69,75,124). S. Typhimurium ScsD is homologous 
to thioredoxin-like proteins involved in cytochrome biogenesis in other bacteria including 
TlpA from Bradyrhizobium japonicum and various protein disulfide isomerases (111). This 
information suggests that ScsD is involved in the reduction of proteins and potentially 
involved in cytochrome biogenesis in the bacterial periplasm. Given that TlpA is a 
substrate of ScsB in C. crescentus (118) and EcCcmG is reduced by EcDsbD (125), it is 
also predicted that ScsD interacts with ScsB. Finally, gene deletion studies in S. 
Typhimurium show that ScsD plays a role in resistance to copper and to a lesser extent, 
oxidative stress (112,117). 
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1.4 Significance 
The Scs proteins are a family of understudied Dsb-like proteins that have been shown to 
play a role in the bacterial response to copper and oxidative stress. This thesis describes 
the first studies that characterise the Scs proteins from the bacterial pathogen, 
Proteus mirabilis.  
 
P. mirabilis is a Gram-negative enteric bacterium that causes urinary tract infections 
(UTIs), particularly in people with catheters (126,127). Infection can lead to bacteraemia, 
infection of the bladder (cystitis) or kidneys (pyelonephritis) (128) and often, urinary stones 
(129), which severely complicate UTIs (126). P. mirabilis infection of the urinary tract is 
aided by a number of key virulence factors (127). A characteristic feature of P. mirabilis is 
its ability to differentiate into swarmer cells; highly flagellated cells that enable the bacteria 
to be extremely motile and move throughout the host. The bacterium also uses a number 
of adhesion factors to colonise the urinary tract (130) and urease, which catalyses the 
formation of urinary stones (129). Antibiotics such as quinolones and cephalosporins can 
be used to treat P. mirabilis UTIs; however, multi-drug resistant strains have been 
identified (131,132) and pose a threat to successful treatment of these infections. DsbA is 
essential for the correct formation of virulence factors in P. mirabilis, such as fimbriae for 
adhesion (133). P. mirabilis DsbA has been characterised (134) and this organism also 
has a DsbB and three predicted DsbC-like proteins. BLAST searches revealed that 
P. mirabilis does not have a DsbD protein; however, it does encode all four suppressor of 
copper sensitivity proteins, including the DsbD-like ScsB and DsbA-like ScsC. These 
proteins may play a key role in the response of P. mirabilis to copper stress, especially 
during infection of the urinary tract when host urine copper levels are elevated (97). 
 
Overall, the suppressor of copper sensitivity proteins from P. mirabilis are of interest 
because of their potential role in the virulence traits of the pathogen, including its response 
to copper stress. The findings outlined in the subsequent chapters of this thesis have 
deepened our understanding of the Scs proteins, which may prove to be useful in future 
antibacterial, biotechnology and/or bioremediation strategies. 
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1.5 Aims 
Broadly, this thesis focuses on the biochemical and structural characterisation of the ScsC 
and ScsB proteins from Proteus mirabilis. 
The specific aims of this thesis are: 
1. To characterise the ScsC protein from P. mirabilis (PmScsC) 
2. To structurally characterise the N-terminal domain of P. mirabilis ScsB (PmScsBα) 
3. To characterise the interaction between P. mirabilis ScsC and ScsBα 
4. To develop an expression and purification protocol for the production of the 
transmembrane protein P. mirabilis ScsB 
Chapter 2 and Chapter 3 describe the work performed towards Aim 1, Chapter 4 describes 
the work done to achieve Aim 2 and Aim 3 and Chapter 5 describes the work towards Aim 
4 (Figure 1.15). 
 
 
 
Figure 1.15: Diagram depicting the focus of subsequent chapters in this thesis. 
 
 
  
 
 
Chapter 2 
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2. Characterisation of Proteus mirabilis ScsC 
 
2.1 Chapter foreword 
This chapter is a reproduction of a research article that was published in the journal Nature 
Communications. This publication describes the functional and structural characterisation 
of PmScsC, revealing that it is a trimeric, shape-shifting disulfide isomerase. Changes 
have been made to the paper to conform to the thesis submission requirements; these 
include the removal of author contributions (now listed in the thesis preliminary pages), the 
overall formatting and the figure, table and reference numbering. This article is licensed 
under a Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), © the Authors. 
 
2.1.1 Reference 
Furlong, E. J., Lo, A. W., Kurth, F., Premkumar, L., Totsika, M., Achard, M. E. S., Halili, 
M. A., Heras, B., Whitten, A. E., Choudhury, H. G., Schembri, M. A., and Martin, J. L. 
(2017) A shape-shifting redox foldase contributes to Proteus mirabilis copper resistance. 
Nature Communications 8, 16065; doi: 10.1038/ncomms16065.  
 
2.1.2 Contribution 
I substantially contributed to the analysis and interpretation of the research data outlined in 
this publication. I produced the crystals that lead to the transitional and extended PmScsC 
structures, collected diffraction data, then processed the data and solved and refined these 
crystal structures. My analysis of all three structures forms a major part of the publication. 
In addition to this, I designed the PmScsC RHP mutant, created the PmScsC RHP 
expression construct, produced the protein used in experiments and biochemically 
characterized the in vitro activity of PmScsC RHP and interpreted these results. I also had 
a substantial role in drafting the manuscript, designing and creating the figures and 
formatting the manuscript for publication.  
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2.2  Abstract 
Copper resistance is a key virulence trait of the uropathogen Proteus mirabilis. Here we 
show that P. mirabilis ScsC (PmScsC) contributes to this defense mechanism by enabling 
swarming in the presence of copper. We also demonstrate that PmScsC is a thioredoxin-
like disulfide isomerase but, unlike other characterised proteins in this family, it is trimeric.  
PmScsC trimerisation and active site cysteine are required for wild-type swarming activity 
in the presence of copper. Moreover, PmScsC exhibits unprecedented motion as a 
consequence of a shape-shifting motif linking catalytic and trimerisation domains. The 
linker accesses strand, loop and helical conformations enabling the sampling of an 
enormous folding landscape by the catalytic domains. Mutation of the shape-shifting motif 
abolishes disulfide isomerase activity, as does removal of the trimerisation domain, 
showing that both features are essential to foldase function. More broadly, the shape-
shifter peptide has the potential for “plug and play” application in protein engineering. 
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2.3  Introduction 
The Escherichia coli periplasmic Dsb protein family is the best characterised bacterial 
oxidative folding system. E coli DsbA is a monomeric thioredoxin-fold oxidase (7) that 
introduces disulfide bonds into protein substrates (25) whereas E. coli DsbC is a dimeric 
V-shaped thioredoxin-fold protein disulfide isomerase (39) that proof-reads and shuffles 
incorrect disulfide bonds (4). E. coli DsbG is also a dimeric V-shaped thioredoxin-fold 
protein disulfide isomerase and cysteine reducing system (70) that protects cysteines of 
periplasmic proteins from inappropriate oxidation (67).  
 
Here, we characterise a putative DsbA-like protein from P. mirabilis and show it plays a 
key role in virulence by enabling swarming during copper stress. We find that it is not 
DsbA-like, as it does not catalyse disulfide bond formation. Rather, it is a disulfide 
isomerase that shuffles incorrect disulfide bonds in proteins. Further, we show that this 
thioredoxin fold protein is unlike any other characterised to date - it is trimeric - and we 
demonstrate that its function depends on a shape-shifting motif that could potentially be 
used as a “plug and play” peptide module.  
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2.4  Results 
Proteus mirabilis UniProt C2LPE2 is a predicted thioredoxin-fold protein, and the purified 
protein exhibits redox properties characteristic of the thioredoxin fold family. It is highly 
oxidising (–108 mV), has an acidic active site cysteine (pKa 3.1) and the oxidised disulfide 
form of the active site destabilises the protein compared with the reduced form 
(Supplementary Figure 2.1A-C).  
 
The encoded protein plays an important role in P. mirabilis virulence. Copper intoxication 
is a component of nutritional immunity having a number of detrimental effects on bacterial 
cells. Copper can react with host-generated hydrogen peroxide to generate free radicals, 
which damage biological molecules (95); cycling between Cu(I) and Cu(II) can lead to 
detrimental redox reactions in bacteria; and copper can bind to protein thiols in place of 
other metal co-factors (88,94). Overcoming these antibacterial effects of copper is a key 
bacterial defence mechanism. The P. mirabilis C2LPE2 is located within a cluster of four 
predicted suppressor of copper sensitivity (Scs) genes and we proposed that encoded 
protein (hereafter called PmScsC) would contribute to bacterial copper resistance. Indeed, 
inactivation of scsC in two independent P. mirabilis clinical isolates significantly inhibited 
swarming motility (a key virulence trait of P. mirabilis) in the presence of copper (Figure 
2.1B, Supplementary Figures 2.2, 2.3 and 2.4). This phenotype could be complemented by 
introduction of a plasmid encoding wild-type PmScsC, but not a plasmid encoding an 
inactive PmScsC (Figure 2.1A, B). Although it is annotated DsbA-like, PmScsC is a 
powerful protein disulfide isomerase (Figure 2.1C) that is able to refold and reactivate the 
scrambled disulfide form of the model substrate RNase A just as rapidly as the archetypal 
disulfide isomerase E. coli DsbC. It has negligible DsbA-like dithiol oxidase activity 
(Supplementary Figure 2.1D).  
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Figure 2.1: PmScsC function. A. Linear representation of the domain organisation of 
PmScsC mutants. The trimerisation domain is coloured magenta, the catalytic domain is 
green, with the CXXC motif represented as an orange circle, and the linker region is 
shown in cyan. The rigid helical linker is shown in black.  B. Swarming motility of wild type 
P. mirabilis strain PM54 (black), PmScsC deletion mutant PM54scsC (grey), and 
PM54scsC containing control and complementation plasmids: PM54scsC(pSU2718) 
(vector control; cyan), PM54scsC(pScsC) (wild-type; green), PM54scsC(pScsC AXXC) 
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(active site mutant; orange) and PM54scsC(pScsCΔN) (N-terminal trimerisation domain 
deletion; magenta) in the presence of 1.5 mM CuSO4 on LB agar plates (significant 
difference, P < 0.0001 for slope calculated by F-test). Data are shown as the mean±s.d., of 
a single experiment performed in triplicate; all data is representative of three independent 
experiments.  C. Disulfide isomerase activity of PmScsC (hollow squares) is similar to that 
of EcDsbC (filled circles). Monomeric PmScsΔN (filled squares) and the PmScsC mutant 
engineered to have a rigid helical peptide (RHP) in place of the flexible peptide (filled 
diamonds) show negligible activity (equivalent to oxidase EcDsbA (hollow circles)). Data 
are shown as the mean ± s.d., of two replicate experiments. 
 
The best-characterised protein disulfide isomerases - EcDsbC and eukaryotic protein 
disulfide isomerase (PDI) - each have two thioredoxin-fold catalytic domains. DsbC is a 
dimer, and PDI is a modular 4-domain protein with two catalytically active thioredoxin 
domains. The presence of two thioredoxin catalytic domains is thought to contribute to 
highly efficient disulfide shuffling activity (41,43). The amino acid sequence of PmScsC 
encodes a single thioredoxin fold, and we therefore expected that its disulfide isomerase 
activity would be a consequence of dimerisation to generate the necessary two catalytic 
domains. We also expected that the protein would adopt the same dimeric architecture as 
V-shaped EcDsbC. However, we were wrong on both counts. 
  
Unexpectedly, evidence from chemical cross-linking (Supplementary Figure 2.5), small 
angle X-ray solution scattering (Figure 2.2A, B) and multi-angle light scattering (Figure 
2.2C) all indicated that PmScsC is trimeric. We confirmed that PmScsC is a trimer by 
determining three independent crystal structures. The three crystal structures – which we 
refer to as compact, transitional, and extended (Figure 2.3A-C, Table 2.1) - reveal an 
extraordinary range of motion in this protein. Importantly, the compact and transitional 
structures have multiple protomers in the asymmetric unit that adopt the same overall 
structures in each case (8 compact trimers, RMSD ~1.5 Å for 645 Cα; 2 transitional 
trimers, RMSD 0.5 Å for 653 Cα) so that crystal symmetry does not appear to impact on 
the observed conformation. Moreover, the compact and transitional conformations were 
determined from crystals grown under similar conditions (2.85 M sodium malonate pH 5.8, 
20 °C with either 0.1 M cobalt or copper added). Nevertheless, comparison of the eight 
compact and the two transitional trimers in these two crystal structures, reveals an 
unprecedented level of conformational re-arrangement (RMSDs > 20 Å). The third 
structure was determined from crystals grown in the presence of 2 mM copper chloride 
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(32% Jeffamine M-600, 0.1 M HEPES pH 8, 20 °C) and reveals a fully extended trimer 
with one protomer in the asymmetric unit. 
 
Figure 2.2: SAXS and MALLS of PmScsC. A. Small-angle X-ray scattering data 
collected from wild type PmScsC (grey) and the calculated scattering profile of the 
ensemble model overlayed in black (SASBDB: SASDB94). The predicted scattering profile 
of each of the crystal structures is also shown (dashed lines: PDB: 4XVW compact, red; 
PDB: 5IDR transitional, blue; PDB: 5ID4 extended, green). The agreement between the 
experimental data and the ensemble model is excellent, yielding χ2=1.0 (compared to 
χ2=863.9 (compact); χ2=1222.0 (transitional); χ2=348.2 (extended)). The Guinier region 
(inset) of the scattering data is linear, consistent with a monodisperse solution. B. Pair 
distance distribution function derived from the scattering data, showing the maximum 
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dimension of the particles in solution is 105 Å. Also shown is the calculated p(r) for each of 
the crystal structures (dashed lines: compact, red; transitional, blue; extended, green), 
showing a maximum dimension of 90, 105 and 100 Å, respectively. The p(r) generated 
from the extended structure (green) is most similar to the experimentally derived p(r), while 
the other p(r) curves are markedly different. C. MALLS profile of PmScsC and PmScsCΔN. 
PmScsC eluted faster (21.5 min) than PmScsCΔN (27.2 min): experimentally determined 
molecular masses are 74 ± 0.3 kDa for PmScsC (theoretical trimer mass 74.3 kDa) and 
18.3 ± 0.3 kDa for PmScsCΔN (theoretical monomer mass 18.1 kDa). 
 
Figure 2.3: PmScsC crystal structures. A. Compact (PDB: 4XVW), B. Transitional 
(PDB: 5IDR) and C. Extended (PDB: 5ID4) crystal structures of PmScsC. Upper panels 
side view, secondary structure with catalytic domains in green, 11-residue peptide linker in 
cyan, and trimerisation domains in magenta or white. Height in this orientation is indicated. 
In each case, one trimerisation domain is shown in magenta for comparison of the 
conformational changes across the three crystal structures. Lower panels top view, 
surface representation (catalytic TRX fold domains green, trimerisation domains white), 
maximum dimension in this orientation is labelled. Active site positions are indicated in 
orange for each protomer.  
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Table 2.1: PmScsC crystal structure statistics. 
 Compact (4XVW) Transitional (5IDR) Extended (5ID4) 
Data collection    
Space group P 21 I4 H32 
Cell dimensions    
     a, b, c (Å) 137.5, 163.9, 181.9 193.1, 193.1, 105.8 86.7, 86.7, 330.9 
     α, β, γ (º) 90, 90, 90 90, 90, 90 90, 90, 120 
Resolution (Å) 
91.15 – 2.60 (2.74 – 
2.60) 
136.51 – 2.56 (2.57-
2.56) 
110.29 – 2.92 (2.93-
2.92) 
Rmerge 0.072 (0.617) 0.083 (0.741) 0.059 (0.625) 
<I/σI> 11.0 (2.0) 14.9 (2.2) 14.2 (2.8) 
Completeness (%) 98.6 (95.4) 99.4 (100.0) 99.2 (100.0) 
Redundancy 3.8 (3.7) 4.1 (4.1) 4.1 (4.2) 
Refinement    
Resolution (Å) 91.15 – 2.60 42.82  - 2.56  40.36 – 2.92 
No. reflections 243409 62069  10652 
Rwork / Rfree (%) 24.8 / 28.2 17.1 / 22.2 25.1 / 26.3 
No. atoms    
     Protein 40850 10262 1720 
     Ligand/ion NA NA NA 
     Water 281 82 0 
B factors (Å2)    
     Protein 59.7 50.6 122.2 
     Ligand/ion NA NA NA 
     Water 41.5 43.0 NA 
RMS deviations     
     Bond length (Å) 0.006 0.008 0.010 
     Bond angles (º) 1.21 1.05 1.17 
Single crystals were used to collect each dataset. Values for highest resolution shell are 
shown in parentheses. 
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PmScsC also exhibits dynamic conformational flexibility in solution. No single PmScsC 
crystal structure is consistent with the experimentally determined SAXS scattering curve. 
However, an ensemble of structures fits the experimental data closely (Figure 2.2A, B) 
supporting the notion that the trimer is highly dynamic in solution. Moreover, the solution 
scattering curve is unchanged by modification of the pH (range 6.0-8.0) or ionic strength 
(150-1500 mM NaCl) (Supplementary Figure 2.6) indicating the dynamic motion is an 
inherent property of the protein. 
 
We can pinpoint the region responsible for the extraordinary range of motion in this 
protein, to an 11-residue peptide linking the trimerisation and catalytic domains (residues 
39-KADEQQAQFRQ-49) (Figure 2.3). The 31 crystallographically characterised PmScsC 
protomers have the same thioredoxin-fold catalytic domains (Figure 2.4A and B) (RMSD 
0.2-1.2 Å for 129 Cα). Similarly, all 31 PmScsC protomers share the same trimeric right-
handed coiled coil stalk formed from the N-terminal residues (Figure 2.3A-C). At the 
secondary structure level, it is only the 11-residue linker peptide that changes significantly 
across the crystal structures (Figure 2.4C, Supplementary Movie 2.1). 
 
The linker is a shape-shifting peptide that can adopt helical, strand or loop conformations. 
In the 24 protomers present in the compact PmScsC crystal structure, the linker forms a 
loop that positions the three catalytic domains close to the trimerisation stalk (Figure 2.3A 
and 4C). In the extended crystal structure the linker is helical, rotating and translating the 
catalytic domain away from the trimerisation domain relative to the compact structure 
(Figure 2.3C and 2.4C). In the transitional PmScsC crystal structure, each of the two 
trimers incorporates protomers in three conformations: compact, extended-like and 
intermediate (Figure 2.3B). The two compact protomer conformations of the transitional 
structure are similar to those in the compact crystal structure (RMSD 0.9-1.8 Å for 188 
Cα). The two extended-like protomer conformations of the transitional structure are similar 
to the protomer in the extended crystal structure though they bend at different points in the 
linker helix, giving rise to somewhat different catalytic domain placements (Figure 2.4C). 
The two intermediate conformations in the transitional crystal structure have a linker that 
forms a short β-strand, and positions the catalytic domain directly above the trimerisation 
stalk (Figure 2.4C).  
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Figure 2.4: PmScsC protomer structure. A. Cartoon representation of the PmScsC 
catalytic domain (equivalent to a DsbA fold, green). Secondary structure elements and N- 
and C- termini are labelled. Position of the active site CXXC motif is shown as an orange 
oval shape.  B. PmScsC topology diagram showing the N-terminal helices α1/2/3 that 
precede the catalytic domain (magenta, flexible linker shown in cyan), and the DsbA 
domain (green) and CXXC active site (orange dots). Secondary structure elements and N- 
and C- termini are labelled. C. The PmScsC protomers are structurally diverse: compact, 
intermediate, extended-like and extended. Colour scheme is as for panel b. N-terminal 
helices α1/2/3 and angles between the helices are labelled. N- and C-termini are also 
labelled. 
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As a consequence of the linker peptide flexibility, the three crystal structures describe 
extraordinarily different PmScsC quaternary shapes and dimensions. The 8 compact 
PmScsC trimers are mushroom-shaped with dimensions 80 Å × 80 Å × 50 Å (Figure 2.3A). 
The two intermediate PmScsC crystal structures are asymmetric flat triangles with 
dimensions 105 Å × 40 Å × 70 Å (Figure 2.3B). The extended PmScsC crystal structure is 
three-leaf-clover shaped with dimensions 75 Å × 80 Å × 80 Å (Figure 2.3C). 
 
We hypothesised that the dynamic motion suggested by the crystal structures and 
supported by solution data is critical to the mechanism of PmScsC. Indeed, replacement of 
the shape-shifting peptide with a rigid helical peptide (PmScsC RHP, 39-
AEAAAKEAAAKA-50) (135) reduced the flexibility of the protein as evidenced by small 
angle scattering data (Supplementary Figure 2.7), and abolished activity in the isomerase 
assay (Figure 2.1C). Furthermore, we showed that trimerisation of PmScsC is critical for 
activity because removal of the N-terminal residues (PmScsCΔN) also abolishes in vitro 
disulfide isomerase activity (Figure 2.1C) and in vivo complementation assays (swarming 
in the presence of copper) (Figure 2.1B).  
 
Curiously, nature has also performed the ScsCΔN experiment. PmScsC shares 58% 
sequence identity with Salmonella enterica serovar Typhimurium StScsC (120) 
(Supplementary Figure 2.8) and both proteins contribute to copper resistance. Whereas 
we showed above that PmScsC is required for swarming motility under copper stress, 
StScsC is required for growth of S. Typhimurium in rich media in the presence of copper. 
By contrast, deletion of scsC in P. mirabilis had no effect on growth in rich media whether 
copper was present or absent (Supplementary Figure 2.2C). These findings imply that the 
two proteins have different target substrates and/or different molecular functions. Indeed, 
StScsC and PmScsC are very different proteins. StScsC lacks the N-terminal residues of 
PmScsC, it is monomeric rather than trimeric, and it has no isomerase activity. Intriguingly, 
the catalytic domains of the two proteins (as assessed by crystal structures) are very 
similar (PDB: 4GXZ) (RMSD 1.0-1.6 Å for 129 Cα). On the basis of this comparison, we 
predicted that removal of the N-terminal trimerisation residues from PmScsC would not 
only convert the trimer into a monomer and abolish isomerase activity, it might also 
convert the enzyme into a dithiol oxidase. Indeed, we confirmed that this was the case 
(Supplementary Figure 2.1D). 
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These two proteins, trimeric disulfide isomerase PmScsC and monomeric dithiol oxidase 
StScsC, are encoded in similar loci and are both associated with copper resistance. Yet, 
they have very different architectures, and different molecular and cellular functions. To 
examine if the region encoding the N-terminal extension of PmScsC is broadly conserved 
in P. mirabilis, the scsC gene was PCR amplified from 25 randomly selected clinical 
isolates and sequenced. We found that the scsC sequence was conserved in all 25 
isolates – including the region encoding the trimerisation domain and shape-shifting motif - 
except for a single synonymous mutation in the signal sequence. This high degree of 
conservation suggests a highly conserved functional role. Caulobacter crescentus ScsC 
also has an extended N-terminal region and is predicted to be dimeric (118). Together with 
our work, this suggests that the N-terminal region of this protein is necessary for 
oligomerisation and that there are at least two very different molecular and functional 
classes of ScsC. 
 
How does the trimeric and highly dynamic molecular architecture of PmScsC compare with 
other structurally characterised disulfide isomerases? Until this point, highly efficient 
disulfide isomerases were thought to function through the presence of two TRX domains 
(each with a CXXC active site) that can simultaneously interact with two substrate 
cysteines (51). The two active sites of V-shaped DsbC and U-shaped PDI are embedded 
within a dynamic framework that enable shuffling of substrate disulfides (47,136-138) 
(Figure 2.5A and B). Trimeric PmScsC also has the potential to interact with multiple 
substrate cysteines simultaneously. However, the evidence presented here shows a much 
more expansive range of motion than observed previously for DsbC or PDI, as depicted in 
morphing movies (Supplementary Movies 2.2-2.4) and static structural comparison (Figure 
2.5C). For example, the distance between active sites of DsbC (PDB: 1JZD-1EEJ) (39,47) 
or PDI (PDB: 4EKZ-4EL1) (137) in reported crystal structures ranges between 31-39 Å 
(26% increase) and 28-40 Å (43%), respectively. By comparison, this distance ranges from 
16-52 Å (225%) in PmScsC. 
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Figure 2.5: Disulfide isomerase range of motion. Top and side views of A. U-shaped 
human PDI with two catalytic domains (PDB: 4EKZ and 4EL1), B. V-shaped homodimeric 
EcDsbC with two catalytic domains (PDB: 1JZD and 1EEJ) and C. homotrimeric PmScsC 
(this work, PDB: 4XVW and 5ID4) showing its expansive twisting and elongation motions. 
Catalytic domains are shown in green, active sites (CXXC) in orange, and oligomerisation 
or non-catalytic domains in white. See also Supplementary Movie 1. 
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2.5 Discussion 
Why is it that other characterised disulfide isomerases do not have the highly flexible, 
trimeric structure of PmScsC? How does the monomeric S. Typhimurium ScsC – not a 
disulfide isomerase – confer copper resistance? How do the very diverse ScsC proteins 
(monomeric, dimeric, or trimeric) form redox relay systems with a predicted partner protein 
ScsB (118) that appears to be highly conserved in bacterial Scs gene clusters. The likely 
explanation for the diversity in architecture and flexibility of ScsC proteins may relate to 
differences in their target specificity. The structural diversity among ScsC homologues may 
simply reflect the fact that each ScsC homologue has evolved to optimise disulfide 
reduction and/or isomerisation of a distinct protein substrate or set of substrates that are 
sensitive to copper-induced damage. Identifying and characterising these specific 
substrates, and understanding why these are not refolded or reduced by other periplasmic 
TRX-fold proteins are key questions that will inform our understanding of bacterial copper 
resistance mechanisms. 
 
In summary, PmScsC is a unique and highly dynamic disulfide isomerase. The N-terminal 
residues bring three catalytic domains together into a trimer, and a unique flexible linker 
enables extraordinary twisting and extending motions that impact on the catalytic domain 
placement. Crystal structure snapshots supported by X-ray scattering data from solution, 
indicate an almost doubling in length of the protein in one dimension, in concert with 
considerable catalytic domain rotation. The combination, extent and diversity of these 
motions would enable mis-folded substrates bound to PmScsC to explore a broad folding 
landscape, consistent with the redox foldase activity of this key P. mirabilis copper 
resistance protein. These findings show in much greater detail than ever before how redox 
proteins with multiple active sites are able to shuffle incorrectly folded substrates. It is 
unclear whether PmScsC directly interacts with copper or how it interacts with other 
proteins required for virulence under copper stress. Nevertheless, the structural data may 
provide a suitable basis for drug discovery targeting a central defense mechanism of an 
important human pathogen (31,32). Importantly, the shape-shifting motif may also 
represent a modular component for dynamic motion that could be used in “plug and play” 
protein engineering applications.  
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2.6  Methods 
2.6.1 Bacterial strains and growth conditions 
BLAST searches of DsbA homologues were performed on the genome of Proteus mirabilis 
HI4320 (126). Clinical isolates of P. mirabilis were cultured from the urine or blood of 
patients with urinary tract infection or bacteremia. The isolates were sourced from the 
Princess Alexandra Hospital or Sullivan Nicolaides Pathology (Brisbane, Australia). E. coli 
Top10 (Invitrogen) was used for plasmid manipulations. E. coli and P. mirabilis were 
cultured in Luria-Bertani (LB) broth (10 g L-1 tryptone, 5 g L-1 yeast extract, 10 g L-1 NaCl) 
on LB agar (LB medium containing 15 g L-1 agar). To prevent swarming of P. mirabilis, LB 
medium containing 30 g L-1 agar and without NaCl was used. Media were supplemented 
with chloramphenicol (30 µg mL-1), ampicillin (100 µg mL-1) or kanamycin (25 µg mL-1) as 
required.  
 
2.6.2 Construction of Proteus mirabilis scsC mutants 
Mutation of the scsC gene in P. mirabilis PM38 and PM54 was performed using the 
TargeTron® gene knockout system (Sigma-Aldrich) as per the manufacturer’s instructions. 
Briefly, optimal intron insertion sites and primer sequences (5827, 5'-
aaaaaagcttataattatccttaagtatcgaagatgtgcgcccagatagggtg, 5828, 5'-
cagattgtacaaatgtggtgataacagataagtcgaagatgctaacttacctttctttgt, 5829, 5'-
tgaacgcaagtttctaatttcgattatacttcgatagaggaaagtgtct) were predicted using the Sigma 
TargeTron online algorithm, followed by a retargeting PCR and cloning of the amplicon 
into the pACD4-K-C shuttle vector, resulting in the generation of plasmid pACD4-K-CscsC. 
Plasmid pAC4K-CscsC and pAR1219 (helper plasmid) were transformed into PM38 and 
PM54; induction and retargeting of the intron containing the kanamycin-resistance gene 
cassette into scsC was performed according to the manufacturer’s instructions. 
Transformants with the correct intron insertion were selected by growth in the presence of 
kanamycin. Mutants with the correct insertion were confirmed by PCR and nucleotide 
sequencing using primers 5914  (5'-atgaaaaaaatttggctggcgttagc) and 5915 (5'-
ttattttttcatcagtaattgattgacgacatcagaataag), and referred to as PM38scsC and PM54scsC, 
respectively. The reprogrammed intron was inserted between nucleotide 528 and 529 in 
the sense strand of scsC. Plasmids pACD4-K-CscsC and pAR1219 were cured by 
passaging on nonselective medium followed by screening for loss of chloramphenicol and 
ampicillin resistance. Plasmid pScsC was constructed by amplifying the scsC gene from 
PM54 using primers PMscsC-pSU2718F (5'- gcgtctagattaactattctttcagaggctaaaggagcc) 
and PMscsCpSU2718R (5'-cgaagcttcgttattttttcactttcgccagttgttctttcac), digestion with XbaI-
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HindIII, and ligation into XbaI-HindIII digested pSU2718. Mutation of the CXXC active site 
(C82A; plasmid pScsC AXXC) and deletion of residues 1-42 (plasmid pScsCΔN) was 
performed by PCR; all constructs were confirmed by sequencing. These mutants retained 
the periplasmic signal sequence. Complementation was performed by introducing 
plasmids pScsC, pScsC AXXC, pScsCΔN, or pSU2718 (vector control) into PM54scsC. 
 
2.6.3 Swarming motility in the presence of CuSO4 
Overnight cultures of P. mirabilis were diluted in fresh LB broth to an OD600 of 0.1. 
Swarming on LB agar was examined in the absence or presence of CuSO4 (final 
concentration of 1.5 mM). For assays performed in the presence of CuSO4, a 10 µL 
sample of the diluted P. mirabilis PM54 and PM54scsC strains, respectively, was 
inoculated onto the center of an agar plate and allowed to soak into the agar (resulting in 
equal diameter for each sample). The plates were incubated at 37 °C. The diameter of the 
swarming zone was measured after 14 h incubation and every one or two hours thereafter 
for a total of 10 h. Swarming of PM54scsC containing pSU2718 (vector control) or 
complementation plasmids (pScsC, pScsC AXXC and pScsCΔN) was performed as 
described above but with the addition of chloramphenicol (30 µg mL-1) and 1mM isopropyl 
β-D-1-thiogalactopyranoside (IPTG) for ScsC induction. Swarming motility at 37 °C on LB 
agar was measured after 6 h and 8 h of incubation. Three replicate experiments were 
performed for all assays. Swarming motility of PM38 wild-type, mutant and complemented 
strains in the presence and absence of copper was performed in the same manner.  
 
2.6.4 Western blotting 
ScsC expression in P. mirabilis wild-type, mutant and complemented strains was 
examined by western blot analysis. Crude cell lysates were prepared from standardised 
overnight cultures. Samples were resolved by SDS-PAGE and transferred onto a 
polyvinylidene difluoride membrane. Blots were probed using a PmScsC specific 
polyclonal antiserum raised in rabbits (WEHI Antibody Facility) at 1:1000 dilution in 
phosphate buffer saline with 0.05% v/v Tween-20. 
 
2.6.5 Protein production 
Codon-optimised PmScsC (see Supplementary Note 1 for the sequence) lacking the first 
21 amino acids (which correspond to the predicted secretion signal) or PmScsCΔN 
(lacking the first 63 residues, starting at A1Q2F3…) was inserted into pMCSG7 (Midwest 
Center for Structural Genomics) by ligation-independent cloning. PmScsC and PmScsCΔN 
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were expressed in BL21(DE3)pLysS cells (Novagen) at 30ºC for 16-20 h using ZYP-5052 
autoinduction media (139). Selenomethionine-labelled PmScsC (mature PmScsC contains 
4 native methionine sites) was expressed in BL21(DE3)pLysS cells grown in minimal 
media (M63) supplemented with 0.05 mg mL-1 D/L-selenomethionine. Recombinant 
protein expression was induced by 0.1 mM IPTG overnight at 30ºC.  
 
After expression, all cells were harvested by centrifugation then resuspended in lysis 
buffer (25 mM Tris pH 7.4, 150 mM NaCl) with added protease inhibitor (1:1000 dilution 
into lysate, BioPioneer, Inc., USA) and DNase I (3.3 µg mL-1 final concentration, Sigma-
Aldrich). The bacterial cells were processed through a Constant Systems (LTD, UK) TS-
Series cell disruptor twice, at pressures of 22 and 24 kpsi. The lysate was clarified by 
centrifugation (40 000 × g, 30 min, 4 °C, rotor JA-25.5, Beckman Coulter, Brea, CA) and 
the soluble fraction was run twice over 2×3 mL of equilibrated Talon® (Clontech) resin to 
bind the His-tagged protein. The resin was washed with 6 column volumes of lysis buffer 
before the protein was eluted with 25 mM Tris pH 7.4, 150mM NaCl, 250 mM imidazole. 
To remove the His6-tag, Tobacco Etch Virus (TEV) protease cleavage was performed at 
room temperature for 2 hours with 1 mg of TEV protease per 50 mg of His-tagged protein. 
The protein mixture was then desalted using a Sephadex® G-25 fine 16/60 column 
connected to an ÄKTATM FPLC system (GE Healthcare) and reverse IMAC (2×2 mL of 
Talon resin) was used to separate cleaved protein from the His-tagged contaminants. 
PmScsC and PmScsCΔN were reduced or oxidised with a 25-fold molar excess of DTT, or 
a 10-fold molar excess of copper(II)/1,10-phenanthroline, respectively. The final step of 
purification for the proteins was size-exclusion chromatography using a Superdex® S75 
column with 10 mM HEPES pH 7.4, 150 mM NaCl. Proteins were concentrated using 
Amicon® Ultra centrifugal filter devices with a 10-kDa cutoff (Merck Millipore, USA). Yields 
for PmScsC derivatives were around 80 mg per litre of culture. SDS-PAGE (NuPAGE® 4-
12% BisTris gel, Invitrogen, Australia) with Coomassie blue stain was used to assess the 
protein quality. Concentration of protein samples was determined using the A280 of the 
sample (read using a Thermo Scientific NanoDropTM 2000c spectrophotometer) and 
calculated extinction coefficients from ProtParam (140). E. coli DsbA and E. coli DsbC, 
lacking the periplasmic leader signal were expressed and purified as described for 
PmScsC. 
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2.6.6 Design of PmScsC rigid helical peptide mutant 
The 11-amino-acid flexible linker peptide in PmScsC (residues 39-KADEQQAQFRQ-49) 
was replaced with a 12-amino-acid rigid helical peptide (39-AEAAAKEAAAKA-50) (135) 
using overlap extension PCR (141) with the primers, 5'-
gcagaagcagcggccaaagaggctgcggctaaagccgcactggctagcgaacatgatgcc and 5'- 
ggctttagccgcagcctctttggccgctgcttctgctttcgtctgcagagccatgattgc. The mutated gene was then 
reinserted into pMCSG7 by ligation-independent cloning. The construct was confirmed by 
sequencing and the protein expressed and purified as described for wild-type PmScsC. 
 
2.6.7 PmScsC sequence conservation 
All clinical isolates were de-identified, and individual informed consent was not required. 
Genomic DNA isolation was performed using the UltraClean® Microbial DNA Isolation Kit 
(MO-BIO Laboratories, #12224) according to the manufacturer’s instructions. Yields varied 
between 100-500 ng µL-1 of DNA. PCR amplification of the scsC gene from P. mirabilis 
strains was performed using a sequence specific primer pair (5'-gtgccgtttaaccagatttatg) 
and (5'-cgtagataaatcagtaagttctg) in combination with Phusion® High-Fidelity DNA 
Polymerase (New England BioLabs Inc., MA, USA). DNA was initially denatured in a 
single step at 98ºC for 30 s followed by 30 cycles of denaturation (98ºC, 10 s), annealing 
(50ºC, 20 s) and elongation (72ºC, 30 s). In a final step fragment elongation was 
completed at 72ºC for 7 min. PCR samples were examined by electrophoresis and 
subsequent DNA sequencing. 
 
2.6.8 Chemical cross-linking 
150 µM of purified PmScsC (in 50 mM HEPES buffer pH 8.5) was reacted with 3 mM 
homobifunctional dithiobis(sulfosuccinimidylpropionate) (DTSSP) (Pierce) for different time 
intervals (30 sec – 30 min) at 23ºC. DTSSP contains one amine-reactive N-
hydroxysulfosuccinimide (sulfo-NHS) ester at each end of its eight carbon spacer arm. The 
sulfo-NHS group reacts preferentially with amines (from lysine residues) between pH = 7-
9, to form a stable amide bond. DTSSP contains a disulfide bond in the spacer arm, which 
can be readily cleaved with dithiothreitol (DTT). Aliquots were removed at various time 
points and mixed with (NH4)HCO3 (50 mM final), to stop the reaction, through hydrolysis of 
remaining functional ester groups in DTSSP. The samples were then run on a non-
reducing SDS-PAGE and subjected to Coomassie staining. As control, 50 mM DTT was 
added to selected samples, which led to cleavage of the internal disulfide bond in DTSSP, 
and consequently disruption of cross-links between PmScsC protomers.  
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2.6.9 MALLS 
A combined approach, using analytical size exclusion chromatography (SEC) and 
multiangle laser light scattering (MALLS) was utilised to determine and compare the 
stoichiometry of PmScsC with PmScsCΔN in solution. The setting consisted of an LC20 
high-performance liquid chromatography (HPLC) system (Shimadzu, Rydalmere, 
Australia) and a DAWN® HELEOS® II laser light detector connected to an Optilab® T-
rEX™ refractive index detector (Wyatt Technology, Dernbach, Germany). Either a 
Superdex 200 or Superdex 75 10/300 GL analytical column (GE Healthcare, USA) was 
connected to the LC20 HPLC system and equilibrated with 25 mM Tris and 150 mM NaCl, 
pH 7.5 overnight. Purified proteins were injected (500 µL of 3 mg mL-1 at a flow rate of 1.0 
mL min-1) into the SEC-MALLS system for analysis. To calibrate the detector, 500 µL of 5 
mg mL-1 bovine serum albumin (BSA) (Sigma-Aldrich, Australia) was used in 25 mM Tris 
and 150 mM NaCl, pH 7.5 at a flow rate of 1.0 mL min-1.  Wyatt Astra V software was used 
for data collection and analysis. 
 
2.6.10 SAXS 
Small angle X-ray scattering data were collected on the SAXS-WAXS beamline at the 
Australian Synchrotron (142). Immediately prior to loading, all samples were centrifuged at 
10,000 g to remove large particles from the solution, and radiation damage was minimised 
by flowing samples (~100 µL) past the beam in 1.5 mm quartz capillaries (Hampton 
Research). Data reduction was carried out using the Australian Synchrotron Scatterbrain 
software (143) correcting for sample transmission and solvent scattering. 
 
Scattering data were collected on reduced PmScsC wildtype and RHP mutant proteins in 
25 mM HEPES pH 7.5, 150 mM NaCl, 1mM DTT. Data were also collected on oxidised 
wildtype PmScsC, but as no significant differences in the scattering were observed, only 
data from the reduced forms are presented. To confirm that the pH and ionic strength of 
the crystallisation conditions do not induce conformational changes in PmScsC, scattering 
data were collected from wildtype PmScsC prepared at 0.50 mg mL-1 in a gradient of 
25mM HEPES pH (6.0, 6.5, 7.0, 7.5, and 8.0) and NaCl (150, 300, 600, 900, and 
1500mM). No significant systematic change in the structural parameters was observed at 
any point of the gradient, hence, it was concluded that neither ionic strength nor pH 
influence the conformation of the complex in the ranges measured. 
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Data quality was assessed by inspection of the linearity of the Guinier region of the data 
(qRg < 1.3), estimated molecular mass of the protein complex, and concentration 
dependence of the scattering. The estimated molecular mass was determined as outlined 
in (144), where the contrast and partial specific volume were estimated from the protein 
sequence (145). The pair-distance distribution function (p(r)) was generated from the 
experimental data using GNOM (146) from which I(0), Rg and Dmax were determined. Rigid 
body modelling of the scattering data from PmScsC wildtype and mutant proteins was 
performed using CORAL (147). C3 symmetry was assumed, and the starting model was 
oriented such the 3-fold axis was parallel with the z-axis, and passed through the centre of 
the oligomerisation domain. Two rigid bodies were then defined for each monomer: 
residues 3-44 (oligomerisation domain); 47-224 (catalytic domain). The position of the 
oligomerisation domain was fixed, and the position and orientation of the catalytic domain 
was then optimised against the measured scattering data. The program was run 16 times 
for each protein, but the models with the lowest penalty function still showed small 
systematic deviations from the experimental data (Wildtype: χ2=3.4; CorMap test (148), 
182 points, C = 51, P = 0.000; RHP mutant: χ2=5.6; CorMap test, 171 points, C = 28, P = 
0.000). Given the crystal structures show significant structural diversity, it is likely that 
these systematic deviations arise from the fact that there is an ensemble of structures 
present in solution. Hence, ensemble optimisation was also performed with the program 
EOM(149). From an initial pool of 1000 structures (the oligomerisation domain possessed 
C3 symmetry in all structures, but the entire trimer was permitted to adopt either C1 or C3 
symmetry), a final ensemble of 6 structures was obtained that yielded an excellent fit to the 
data (Wildtype: χ2=1.0; CorMap test, 182 points, C = 12, P = 0.021; Mutant: χ2=1.8; 
CorMap test, 171 points, C = 11, P = 0.076). The ensemble for the wildtype protein is 
composed of 6 structures and spans a diverse range of conformations. Thus, the SAXS 
data supports the notion that the PmScsC trimer is highly dynamic in solution. The 
ensemble for the mutant protein is composed of 4 structures, all in extended 
conformations. The initial pool of random structures was the same for both WT and RHP 
optimisations, and the number of structures in the final ensemble was not artificially 
limited. The reduction in size of the ensemble (from 6 for WT to 4 for RHP) is consistent 
with the RHP mutation rigidifying the flexible helix, and reducing the conformational space 
sampled by the protein. Details of the data collection and structural parameters are 
summarised in Supplementary Table 2.1. 
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2.6.11 Crystallisation and structure determination 
Crystallisation screenings were performed at the UQ ROCX facility at the University of 
Queensland (uqrocx.imb.uq.edu.au) using commercial screens and the hanging-drop 
vapour diffusion method.  
 
Compact structure 
Selenomethionine-labeled PmScsC crystals were grown at 20 ºC from a drop comprising 
200 nL of 30 mg mL-1 purified protein in 10 mM HEPES pH 7.4 and 200 nL of well solution, 
2.85 M sodium malonate pH 5.8 containing 0.1 M cobalt(II)chloride hexahydrate. Crystals 
grew over a period of 2-3 days. A data set at the Se-edge (wavelength = 0.9792 Å) was 
measured under cryogenic conditions (100 K) at the Australian Synchrotron MX2 beamline 
using the BluIce interface (150). Data were processed in XDS (151) and scaled to space 
group P21212 in AIMLESS (152). A manually guided molecular replacement approach was 
performed using StScsC as the template (PDB ID: 4GXZ) in MOLREP (153). Manual 
selection of solutions based on observed packing, allowed placing of six molecules in the 
asymmetric unit. This solution was improved in the subsequent MR runs in MOLREP 
(153), allowing the addition of eight molecules in the second trial and a total of nine 
molecules in the third run. A SAD-MR approach in PHENIX (154), by combining SAD 
phasing and the partial MR solution (9 molecules), and subsequent density modifications 
resulted in an electron density map with a skew value of 0.82 (1826 residues (190 side 
chain built) in 250 fragments). Successive AutoBuild runs in PHENIX (154) built 1557 
residues (806 side chain) and dropped the R and Rfree values to 38% and 41.5%, 
respectively. Extensive manual building was required to complete one copy of PmScsC. 
Molecular replacement using this model as template in PHASER (155) allowed placing of 
12 molecules in the asymmetric unit. After several rounds of manual building in Coot (156) 
and PHENIX (154) refinements R/Rfree values dropped to 29.1 and 32.3%, but further 
refinement cycles were unsuccessful. Careful examination of Ctruncate (157) indicated the 
presence of nearly perfect pseudo-merohedral twinning (-h,-k,l) and led to a 
reconsideration of space group. Reprocessing the data set to a resolution of 2.6 Å in 
space group P21 yielded lower R-merge (0.072 vs 0.097 for data processed in P21212). A 
new molecular replacement run using the reprocessed data in P21 space group and the 
PmScsC template with a resolution cut off set to 3.2 Å finally identified 24 copies in 
PHASER (155). Rigid body refinement in REFMAC (158) showed that refinement 
considering the twin operator (-h,-k,l) produced better R-factors (37% vs 42%, no 
twinning). After manual correction of two chains that were placed inaccurately during 
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molecular replacement by PHASER (155), and several rounds of refinement in PHENIX 
(154) and REFMAC (158) the final R/Rfree values are 24.8/28.2% at 2.6 Å resolution. The 
Ramachandran favoured/outlier statistics for the structure are 95%/0.9%. A stereo image 
of representative electron density for this structure is show in Supplementary Figure 2.9A. 
 
Transitional structure 
Crystals were grown at 20 °C from drops containing 1 µL of 48 mg mL-1 oxidised PmScsC 
in 10 mM HEPES pH 7.4 and 1 µL of 2.85 M sodium malonate pH 5.8 containing 0.1 M 
copper (II) chloride. Crystals formed after 2-3 days and were cryoprotected with 3.4 M 
sodium malonate pH 5.8 and flash frozen in liquid nitrogen. Data were collected using the 
BluIce software (150) on the MX2 beamline of the Australian Synchrotron at a wavelength 
of 0.9792 Å under cryogenic conditions (100 K). The data were processed with XDS (151) 
and scaled in AIMLESS (152) using the autoPROC framework (159). The space group 
was determined to be I4 and molecular replacement using PHASER (155), as 
implemented in the CCP4 suite (160), was performed with a single catalytic domain from 
the compact structure (residues 46-224). Five molecules were initially found in the 
asymmetric unit and after assessing the crystal packing one of these was deleted and a 
subsequent round of PHASER (155) was run with the altered solution as an additional 
input model. This resulted in the placement of 6 molecules in the asymmetric unit, which is 
consistent with the presence of two trimers. Manual building of the trimerisation domain 
was performed in Coot and rounds of autobuild using Buccaneer (161) in CCP4 and 
refinement using REFMAC (158) and BUSTER (162,163) were performed to improve the 
structure. Several rounds of manual adjustment in Coot (156) and refinement in PHENIX 
(154) were performed to yield final R/Rfree values of 17.1% and 22.2%. Validation in 
MolProbity (164) was used throughout the refinement process, and the final 
Ramachandran favoured/outlier statistics for the structure are 98%/0.5%. A stereo image 
of representative electron density for this structure is show in Supplementary Figure 2.9B. 
 
Extended structure 
Crystals were grown at 20 °C from drops containing 1 µL of 20 mg mL-1 oxidised PmScsC 
in 10 mM HEPES pH 7.4, 150 mM NaCl and 2.5 mM copper (II) chloride (added to protein 
solution immediately before crystallisation) and 1 µL of 32% Jeffamine M-600 pH 7 in 0.1 
M HEPES pH 8. Crystal formation occurred within minutes of set up and crystals continued 
to grow until day two. Crystals were cryoprotected with 32% Jeffamine M-600 pH 7, 0.1 M 
HEPES pH 8 and 20% ethylene glycol and frozen in liquid nitrogen. Data were collected 
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using the BluIce software (150) on the MX2 beamline of the Australian Synchrotron at a 
wavelength of 0.9537 Å under cryogenic conditions (100 K). Using the autoPROC 
framework (159) the data were processed with XDS (151) and scaled in AIMLESS (152). 
The Wilson B factor for the data was relatively high (~double that of the data for the other 
two crystal structures). The space group was determined to be H32 and molecular 
replacement using PHASER (155), as implemented in the CCP4 suite (160), was 
performed with a single catalytic domain from the compact structure (residues 46-224). 
Only one molecule was found in the asymmetric unit (the trimer is generated by crystal 
symmetry). Manual building of the trimerisation domain was performed in Coot with rounds 
of autobuild (Buccaneer (161)) and refinement (BUSTER (163)) performed to improve the 
structure. Several rounds of manual adjustment in Coot (156) and refinement in PHENIX 
(154), including the use of TLS, were performed to yield final R/Rfree values of 25.1% and 
26.3%. Validation in MolProbity (164) was used throughout the refinement process and the 
final Ramachandran favoured/outlier statistics for the structure are 98%/0.5%. A stereo 
image of representative electron density for this structure is show in Supplementary Figure 
2.9C. 
 
Residues in all three crystal structures were numbered based on their position after the 
TEV cleavage site in the construct. MUSTANG-MR (165,166) was used for structure 
alignment and RMSD calculations and PyMOL was used to create images of the 
structures and perform other measurements. The distance range between active sites in 
DsbC, PDI and PmScsC structures was measured using the Cβ positions of the more N-
terminal of the two catalytic cysteines. Supplementary Movie 1 was created in Pymol by 
generating morphs between each of the PmScsC crystal structures, as well as morphs 
between each of the available structures for E. coli DsbC (PDB: 1JZD-1EEJ) and human 
PDI (PDB: 4EKZ-4EL1). 
 
2.6.12 Measurement of PmScsC redox potential and pKa values 
The redox potential of PmScsC was determined by incubating 2 µM PmScsC with 1 mM 
GSSG in combination with varying concentrations of GSH (4 -15 mM) for ∼12 h at 24 °C in 
100 mM sodium phosphate buffer, pH 7.0, and 1 mm EDTA. Trichloroacetic acid, 10% v/v, 
was used to precipitate the protein samples and the pellets were washed with ice-cold 
acetone. The samples were then treated with 2 mM 4-acetamido-4′-maleimidylstilbene-
2,2′-disulfonic acid, in 50 mM Tris-HCl, pH 8.0, and 1% SDS, which blocks free thiols and 
increases the weight of the reduced protein by ~1 kDa. The reduced and oxidised forms of 
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PmScsC were separated on a 12% non-reducing SDS-PAGE (NuPAGE) and stained with 
Coomassie Brilliant Blue. The fraction of reduced protein, R, was determined via 
densitometric analysis of the stained SDS-PAGE gel using ImageJ (167), and the 
equilibrium constant Keq was calculated via R = ([GSH]2/[GSSH])/(Keq + ([GSH]2/[GSSH])) 
(168). The Nernst equation, E0 = E0GSH/GSSG − (RT/nF)·lnKeq, where E0GSH/GSSG is the 
standard potential of −240 mV (169), was used to calculate the redox potential of 
PmScsC. 
 
The pH-dependent absorbance of the catalytic thiolate anion of PmScsC was determined 
at 240 nm (8) using a CARY 50 UV/VIS spectrophotometer (Agilent Technologies, USA). 
The pH titration measurements of oxidised or reduced PmScsC (40 µM) were conducted 
at 22 ºC in 2 mL reaction buffer (10 mM Tris, 10 mM sodium citrate, 10 mM K2HPO4, 10 
mM KH2PO4, 200 mM KCl, and 1 mM EDTA). Absorbance (λ = 240 and 280 nm) was 
measured between pH 6.5 and 1.5 in 0.25 increments. The pKa value was calculated from 
the fitted curves of three replicates using the Henderson-Hasselbalch equation (pH = pKa - 
???????????? ????????????????? ?????????????????????????????????Ka experiments were each 
repeated three times.  
 
2.6.13 Relative stability of oxidised and reduced PmScsCΔN  
Unfolding of PmScsCΔN was monitored using the change in the far-UV circular dichroism 
(CD) signal (83). The largest difference in molar ellipticity for oxidised and reduced 
enzymes was calculated from initial far-UV CD spectra (from 250 nm to 190 nm) recorded 
at 25ºC and 95ºC using a Jasco J-810 circular dichroism (CD) spectropolarimeter (Jasco, 
USA), respectively. The unfolding of oxidised and reduced protein (PmScsCΔNox = 222.5 
nm, PmScsCΔNred = 219.5 nm) was monitored at a constant heat rate of 1 ºC min-1 
starting from 25 ºC and increasing to 95 ºC in a 1 mm quartz cuvette. Unfolding reactions 
were performed using 10 µM protein in 100 mM NaH2PO4/Na2HPO4, 1 mM EDTA at pH 
7.0. Reduced enzyme samples contained 0.75 mM DTT. The CD data was converted to a 
fraction of folded protein via αfolded(T) = (θ(T) - θunfolded)/(θfolded - θunfolded) and αfolded(T) was 
then fitted using a Boltzmann sigmoid function 1 – 1/(1 + eN(Tm-T)), where N is a scaling 
factor that describes the nature of the transition and Tm is the protein melting temperature. 
The thermal unfolding experiment was repeated three times for both the oxidised and 
reduced protein. 
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2.6.14 Protein disulfide isomerase assay 
The bovine pancreatic ribonuclease RNase A contains 4 disulfide bonds that are 
necessary for its enzymatic function. Starting with “scrambled” RNase A (in which the 
cysteines have formed non-native disulfide bonds), one can determine the ability of other 
enzymes to restore its function by spectroscopically monitoring the hydrolysis of 3’,-5’-
cyclic monophosphate (cCMP4), a synthetic substrate of the ribonuclease. Thus, in vitro 
disulfide isomerase activity of PmScsC was monitored by using scrambled RNase A as 
substrate (170). Inactive scrambled RNase A was produced by treating 70 mg of native 
RNase A (Sigma-Aldrich) with 6 M guanidinium chloride and 150 mM DTT in 50mM Tris 
pH 8, incubated at room temperature for 16 h. After adjusting the solution to pH 8, the 
unfolded protein was then desalted and buffer exchanged into 100 mM acetic acid/NaOH 
pH 4. The presence of reduced cysteines was confirmed spectrophotometrically by mixing 
an unfolded RNase A sample with 8-fold higher molar concentration of 5,5-dithio-bis-(2-
nitrobenzoic acid) (DTNB or Ellman’s reagent), which reacts with thiols to absorb at 
412nm. The unfolded RNase A was then air-oxidised over 5 days in 6M guanidinium 
chloride, 50 mM Tris pH 8.5 at room temperature in the dark. After concentration of the 
protein and readjustment of the pH to 8.5, the scrambled RNase A was buffer exchanged 
into 100 mM acetic acid/NaOH pH 4 and concentrated to 11.5 mg/ml for use in assays. 
The absence of reduced cysteines was confirmed as described above. The total reaction 
volume for the scrambled RNase A assay was 750 µL containing 100 mM sodium 
phosphate buffer pH 7.0, 1 mM EDTA, 8.2 µM DTT, and 10 µM PmScsC, PmScsCΔN, 
PmScsC RHP, EcDsbC or EcDsbA and 40 µM of scrambled RNase A. At various time 
intervals, 50 µL sample was removed and mixed with 150 µL of 3 mM cytidine 3’,-5’-cyclic 
monophosphate (cCMP) to measure RNase A activity. Hydrolysis of the cyclic phosphate 
ester bond in cCMP was monitored at 296 nm using a Synergy H1 multimode plate reader 
(BioTek, USA). Samples containing native RNase A and scrambled RNase A in the 
absence of any other enzyme served as positive and negative controls, respectively. The 
disulfide isomerase assays were repeated twice for each protein.  
 
2.6.15 PmScsC dithiol oxidation activity 
The potential of PmScsC/PmScsCΔN to catalyse disulfide bond formation in vitro was 
assessed using a synthetic model peptide (CQQGFDGTQNSCK) as described before 
(171). Dithiol oxidation was determined fluorometrically, using a SynergyTM H1 multimode 
plate reader (BioTek® Instruments, USA) with the excitation wavelength set to 340 nm and 
emission to 615 nm. A 150 µs delay before reading and 100 µs reading time were used for 
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time-resolved fluorescence. The reaction buffer contained 50 mM MES, 50 mM NaCl and 
2 mM EDTA at pH 5.5. The reaction volume was 50 µL in each well of a white 384-well 
plate (Perkin Elmer OptiPlateTM-384, Part #: 6007290), including increasing concentrations 
(80-320 nM) of EcDsbA, EcDsbC, PmScsC, or PmScsCΔN and  2 mM glutathione (GSSG) 
as oxidant. Lastly 8 µM peptide substrate was added to initiate the reaction. EcDsbA 
served as positive control. As negative control, reactions in the absence of proteins were 
used. The initial linear portion of the raw data was used to calculate the rate of oxidation 
as fluorescence increase per minute. The dithiol oxidation activity experiments were 
repeated three times for each protein.  
 
2.7 Data availability 
The UniProt accession code for the P. mirabilis ScsC protein described in this paper is 
C2LPE2 and the accession codes for other proteins described in this study are H9L4C1 
(StScsC), P0AEG4 (EcDsbA), and P0AEG6 (EcDsbC). Coordinates and structure factors 
for the three ScsC crystal structures were deposited in the protein data bank (PDB) with 
accession codes 4XVW (compact), 5IDR (transitional) and 5ID4 (extended). In addition to 
the PDB accession codes listed above, PDB accession code 4GXZ (StScsC) was used as 
a molecular replacement template and 1EEJ and 1JZD (EcDsbC), and 4EKZ and 4EL1 
(hPDI) were used to generate Figure 2.5. Scattering data and models have been 
deposited in SASBDB (172) with accession codes SASDB94 (wild-type PmScsC) and 
SASDBW6 (RHP mutant). All other data are available from the corresponding authors 
upon reasonable request. 
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2.10 Supplementary information 
2.10.1 Supplementary Tables 
Supplementary Table 2.1: SAXS data collection and analysis details. 
Data collection parameters PmScsC (wild type) PmScsC (rigid mutant) 
Instrument SAXS-WAXS (Australian Synchrotron) 
Beam geometry Point 
Wavelength (Å) 1.033 
Camera length (m) 1.576 1.485 
q-range (Å-1) 0.01-0.55 0.01-0.55 
Exposure time (s) 28 (14 × 2 s exposures) 23 (23 × 1 s exposures) 
Protein concentration (mg/mL) 2.15 1.30 
Temperature (°C) 10 10 
Normalisation standard Water Water 
Structural parameters    
I(0) (cm-1) [from p(r)] 0.1006 ± 0.0002 0.06648 ± 0.00007 
Rg (Å) [from p(r)] 36.0 ± 0.1 44.1 ± 0.1 
I(0) (cm-1) [from Guinier] 0.1010 ± 0.0005 0.0663 ± 0.0001 
Rg (Å) [from Guinier] 36.5 ± 0.3 43.8 ± 0.2 
Dmax (Å) 105 ± 5 135 ± 7 
Porod volume (Å3) 97800 ± 9000 108000 ± 10000 
Rg (Å) [crystal structures] 
 
30.5 – 35.8 
Dmax (Å) [crystal structures] 90 – 105 
Dry volume (Å3) [from sequence] 91000 
Molecular mass determination    
Partial specific volume (cm3g-1) 0.73 
Contrast, Δρ (1010 cm-2) 2.75 
Molecular mass Mr [from I(0)]* 69900 ± 3500 76400 ± 3500 
Molecular mass Mr [from sequence] 74100 73300 
Software employed    
Primary data reduction Scatterbrain 
Data processing PRIMUS and GNOM 
Rigid body modelling Coral and EOM 
*For the wild type protein, data were also collected at protein concentrations of 4.50 and 
8.85 mg/mL. The corresponding I(0) values for these concentrations are 0.2120 and 
0.4060 cm-1. These values yield molecular mass estimates of 70.3 and 68.6 kDa. Thus, 
there is no evidence of significant interparticle interactions in the measured concentration 
range. For the rigid mutant protein, data were also collected at protein concentrations of 
0.60, 2.65 and 5.30 mg/mL. The corresponding I(0) values for these concentrations are 
0.0312, 0.1447 and 0.2940 cm-1. These values yield molecular mass estimates of 77.9, 
81.6 and 82.9 kDa. Thus, there is evidence of weak interparticle interactions in the 
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measured concentration range that is deemed negligible at the concentration used for data 
modelling and analysis. 
 
2.10.2 Supplementary Figures 
 
Supplementary Figure 2.1: Functional properties of PmScsC. A. Redox potential. 
PmScsC was equilibrated in a range of glutathione (GSSG/GSH) redox buffers to measure 
the equilibrium constant Keq (34 µM, which corresponds to a redox potential of -108 mV). 
Data are shown as the mean ± s.d., of three replicate experiments. B. Determination of the 
pKa of the highly reactive cysteine in the CXXC active site motif. Presence of the catalytic 
thiolate anion is pH-dependent and can be spectroscopically monitored. The pKa of 
PmScsC CXXC was determined to be 3.1. A representative example of the three replicate 
experiments is shown C. Thermal unfolding of the catalytic core domain PmScsCΔN, 
shows that its reduced state (Tmred = 358 K) is more stable than its oxidised (Tmox = 345 K) 
form. Data are shown as the mean ± s.d., of three replicate experiments. D. Rate of dithiol 
oxidase catalytic activity of 80 nM PmScsC, PmScsCΔN and EcDsbC normalised to the 
activity of the control enzyme EcDsbA. Glutathione was used as the electron donor in the 
reaction. PmScsCΔN has an activity similar to that of the archetypal dithiol oxidase, 
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EcDsbA, whereas trimeric PmScsC, the PmScsC RHP mutant and dimeric EcDsbC have 
negligible activity. Data are shown as the mean ± s.d., of three replicate experiments. 
 
 
Supplementary Figure 2.2: Genotypic and phenotypic analysis of PM54 and 
PM54scsC. A. Agarose gel electrophoresis of scsC PCR fragments obtained from PM54 
and PM54scsC. An amplicon of increased size was obtained from PM54scsC (compared 
to PM54) using primers 5914 and 5915, confirming the correct insertion of the intron and 
kanamycin cassette in the scsC gene. B. Western blot analysis of whole cell lysates 
prepared from PM54, PM54scsC, PM54scsC(pSU2718), PM54scsC(pScsC), 
PM54scsC(pScsC AXXC) and PM54scsC(pScsCΔN) using an ScsC-specific polyclonal 
antiserum. Expression of wild-type ScsC and mutant forms (ScsC AXXC and ScsCΔN) 
was observed; no expression of ScsC was detected in PM54scsC. C. Growth analysis of 
PM54 and PM54scsC in LB broth at 37°C in the presence or absence of 1.5 mM CuSO4. 
There was no significant difference in the growth rate of PM54 (blue) and PM54scsC (red) 
in LB broth, or PM54 (green) and PM54scsC (purple) in LB broth containing 1.5 mM 
CuSO4. Growth was monitored by measuring the optical density at 600nm (OD600nm). Data 
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are shown as the mean ± s.d., of three replicate experiments. D. Analysis of PM54 (black), 
PM54scsC (grey), PM54scsC(pSU2718) (light blue), PM54scsC(pScsC) (red), 
PM54scsC(pScsC AXXC) (dark blue) and PM54scsC(pScsCΔN) (green) swarming on LB 
agar at 37°C at 6 hours and 8 hours post-inoculation. There was no significant difference 
in the swarming of all strains examined on LB agar in the absence of added CuSO4. Data 
are shown as the mean ± s.d. deviation, of three replicate experiments. 
 
 
 
Supplementary Figure 2.3: Mutant phenotype and function of PmScsC. Difference in 
swarming motility between wild type PM38 and PM38scsC in the presence of 1.5 mM 
CuSO4 on LB agar plates after incubation for 14 h at 37 °C. PM38scsC swarming motility 
(blue) was significantly reduced compared to wild type PM38 (black; (P < 0.0001 for slope 
calculated by F-test). Data are shown as the mean ± s.d. deviation, of three replicate 
experiments (in some cases the error bars are too small to be visible).  
 
Chapter 2 
 61 
 
Supplementary Figure 2.4: Genotypic and phenotypic analysis of PM38 and 
PM38scsC. A. Agarose gel electrophoresis of scsC PCR fragments obtained from PM38 
and PM38scsC. An amplicon of increased size was obtained from PM38scsC (compared 
to PM38) using primers 5914 and 5915, confirming the correct insertion of the intron and 
kanamycin cassette in the scsC gene. B. Western blot analysis of whole cell lysates 
prepared from PM38 and PM38scsC using an ScsC-specific polyclonal antiserum. ScsC is 
expressed by PM38 but not by the PM38scsC mutant. C. Growth analysis of PM38 and 
PM38scsC in LB broth at 37°C in the presence or absence of 1.5 mM CuSO4. There was 
no significant difference in the growth rate of PM38 (blue) and PM38scsC (red) in LB 
broth, or PM38 (green) and PM38scsC (purple) in LB broth containing 1.5 mM CuSO4. 
Growth was monitored by measuring the OD600nm. Data are shown as the mean ± s.d., of 
three replicate experiments. D. Analysis of PM38 (blue) and PM38scsC (red) swarming on 
LB agar at 37°C at 8 hours and 10 hours post-inoculation. There was no significant 
difference in the swarming of PM38 and PM38scsC on LB agar in the absence of added 
CuSO4. Data are shown as the mean ± s.d., of three replicate experiments. 
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Supplementary Figure 2.5: SDS gel of cross-linked PmScsC. Denaturing SDS-PAGE 
(-DTT) of purified PmScsC, incubated for 30 s – 30 min with a disulfide-bonded chemical 
cross-linker DTSSP. Within 30 s a trimer is evident (lanes 3-8) that can be disrupted by 
DTT added to the sample after 30 min time (DTSSP + DTT). 
 
 
 
Supplementary Figure 2.6: PmScsC NaCl/pH gradient scattering data. A. The 
variation of the radius of gyration is shown as a function of both pH and NaCl 
concentration. There is no significant or systematic variation with NaCl or pH, indicating 
that the conformation/flexibility of the protein is not dependent on solution conditions, but is 
an inherent property of the protein. B. The variation in the forward scattering, I(0), shown 
as a function of both pH and NaCl concentration. The values are corrected for the change 
in contrast of the protein in the varying concentration of NaCl. The plot shows the 
oligomeric state of the protein is independent of both NaCl concentration and pH. 
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Supplementary Figure 2.7: PmScsC RHP mutant scattering data. A. Small-angle X-ray 
scattering data collected from the PmScsC RHP mutant (grey) and the calculated 
scattering profile of the ensemble model overlayed in black (SASBDB: SASDBW6). The 
predicted scattering profile of each of the crystal structures is also shown (dashed lines: 
PDB: 4XVW compact, red; PDB: 5IDR transitional, blue; PDB: 5ID4 extended, green). The 
agreement between the experimental data and an ensemble model is excellent, yielding 
χ2=1.8 (compared to χ2=1708.1 (compact); χ2=1710.3 (transitional); χ2=1365.5). The 
Guinier region (inset) of the scattering data is linear, consistent with a monodisperse 
solution. B. Pair distance distribution function derived from the scattering data, showing 
the maximum dimension of the particles in solution is 135 Å. Also shown is the calculated 
p(r) for each of the other structures (dashed lines: compact, red; transitional, blue; 
extended, green), showing a maximum dimension of 90, 105, and 100 Å, respectively. The 
p(r) curves from each of the crystal structures are markedly different to the experimentally 
determined p(r) curve. 
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Supplementary Figure 2.8: Sequence alignment of PmScsC and StScsC. Secondary 
structure elements are shown for PmScsC (above the amino acid sequence) and StScsC 
(below the amino acid sequence). Secondary structure elements for PmScsC are coloured 
using the colour scheme from Figure 2.2A/B, whereas those for StScsC are shown in 
orange. The CXXC motif is shaded in yellow, and the cisPro motif found in most 
thioredoxin fold proteins is highlighted in grey. 
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Supplementary Figure 2.9: Stereo images of representative electron density in the 
PmScsC crystal structures. The electron density of the flexible linker region 
in A. compact PmScsC (PDB: 4XVW) B. the intermediate protomer of the transitional 
structure (PDB: 5IDR) and C. extended PmScsC (PDB: 5ID4). In each case the linker 
adopts a different secondary structure, forming A. loop, B. β-strand or C. α-helix. The 
residues 39-KADEQQAQFRQ-49 are shown in cyan in each case and residues that form 
the trimerisation stem are coloured magenta. The likelihood-weighted 2Fo – Fc electron 
density maps (contoured to 1σ) are represented by the wire mesh. The maps were 
generated using phenix.maps and missing Fo were filled with Fc. 
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2.10.3 Supplementary Notes 
 
Supplementary Note 2.1: The codon optimised gene sequence used for expression of  
PmScsC(22-243) is: 
 
GCTGCTCTGAATGCTGCCCAAGAAAAAGAAGTGCGTGCACTGGTTCGCGACACCCTGGTCAGCAAC
CCGGAAATTCTGGAAGAAGCAATCATGGCTCTGCAGACGAAAAAAGCGGATGAACAGCAAGCCCAG
TTTCGTCAAGCACTGGCTAGCGAACATGATGCCCTGTATAACGACGCAGCATCTCCGCGCATTGGT
GCAAAAGATGCCAAACTGGTGCTGGTTTCTTTTACCGACTATAATTGCCCGTACTGTAAACGTTTC
GATCCGCTGCTGGAAAAAATCACGGAACAGTACCCGGACGTCGCAGTGATTATCAAACCGCTGCCG
TTTAAAGGTGAAAGCTCTGCGAAAGCCTCACAGGCTGTTCTGTCGGTCTGGAAAGAAGATCCGAAA
GCATTCCTGGCTCTGCACCAGCGTCTGATGCAGAAGAAAACCATGCTGGATAACGCAAGCATTGAA
GACGCTATGAAAAGTACCAATACGTCCAAAATCAAACTGACCGATGACAGTCTGAAAACGCTGCAG
AACAATCTGGAACTGTCCCGCAAACTGGGCATTCAAGGTACCCCGGCGACGGTTATTGGCGATACC
ATCCTGCCGGGTGCCGTGGACTATGACCAACTGGAAATTATCGTGAAAGAACAACTGGCAAAAGTG
AAAAAATGA 
 
 
2.10.4 Supplementary Movies 
 
Supplementary Movie 2.1: Conformation of the flexible linker throughout morph 
between PmScsC crystal structures. 
https://media.nature.com/original/nature-
assets/ncomms/2017/170719/ncomms16065/extref/ncomms16065-s2.mov 
 
Supplementary Movie 2.2: Morph between EcDsbC crystal structures. 
https://media.nature.com/original/nature-
assets/ncomms/2017/170719/ncomms16065/extref/ncomms16065-s3.mov 
 
Supplementary Movie 2.3: Morph between human PDI crystal structures. 
https://media.nature.com/original/nature-
assets/ncomms/2017/170719/ncomms16065/extref/ncomms16065-s4.mov 
 
Supplementary Movie 2.4: Morph between PmScsC crystal structures. 
https://media.nature.com/original/nature-
assets/ncomms/2017/170719/ncomms16065/extref/ncomms16065-s5.mov 
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3. Characterisation of engineered PmScsC variants 
 
3.1 Chapter foreword 
This chapter is a reproduction of a research article that has been submitted to Acta 
Crystallographica Section D. This manuscript focuses on two engineered PmScsC 
variants, PmScsCΔN and PmScsCΔLinker. The crystal structure of PmScsCΔN is reported 
along with the SAXS analysis of this variant. PmScsCΔLinker is functionally and 
structurally characterised in this paper. Changes have been made to the submitted 
manuscript to conform to the thesis submission requirements; these include the overall 
formatting and numbering of the figures, tables and references. 
 
3.1.1 Reference 
Furlong, E. J., Kurth, F., Premkumar, L., Whitten, A. E., Martin, J. L. (2018) Engineered 
variants provide new insight into the structural properties important for activity of the highly 
dynamic, trimeric protein disulfide isomerase, PmScsC. Available on bioRxiv; doi: 
10.1101/421420. Submitted to Acta Crystallographica Section D.  
 
3.1.2 Contribution 
I significantly contributed to the conception and design of the project, the analysis and 
interpretation of the research data and the drafting of this submitted manuscript. I designed 
the PmScsCΔLinker variant and created the expression construct for this protein. I 
expressed and purified PmScsCΔLinker and assessed the protein for disulfide isomerase 
and dithiol oxidase activity. I crystallised PmScsCΔLinker, collected and processed 
diffraction data and solved and refined the crystal structure of this protein. I analysed both 
PmScsCΔN and PmScsCΔLinker crystal structures and my interpretation of these 
structures is presented in the manuscript. I contributed to the collection of the SAXS data 
reported in this manuscript. I also wrote the first draft of the article and designed and 
created the figures. 
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3.2 Abstract  
Suppressor of copper sensitivity protein C from Proteus mirabilis (PmScsC) is a 
homotrimeric disulfide isomerase that plays a role in copper tolerance – a key virulence 
trait of the uropathogen. Each protomer of the enzyme has an N-terminal trimerisation 
stem (59 residues) containing a flexible linker (11 residues) connected to a thioredoxin-
fold-containing catalytic domain (163 residues). Here, we characterise two PmScsC 
variants, PmScsCΔN and PmScsCΔLinker. PmScsCΔN, is an N-terminally truncated form 
of the protomer with two helices of the trimerisation stem removed, generating a protein 
with dithiol oxidase rather than disulfide isomerase activity. The crystal structure of 
PmScsCΔN reported here reveals – as expected – a monomer that is structurally similar to 
the catalytic domain of native PmScsC. The second variant PmScsCΔLinker was designed 
to remove the 11 amino acid linker and we show that it generates a protein that has 
neither disulfide isomerase nor dithiol oxidase activity. The crystal structure of 
PmScsCΔLinker reveals a trimeric arrangement, with the catalytic domains packed 
together very closely. Small angle X-ray scattering analysis found that native PmScsC is 
predominantly trimeric in solution even at low concentration, whereas PmScsCΔLinker 
exists as an equilibrium between monomeric, dimeric and trimeric states, with the 
monomeric form dominating at low concentrations. These findings increase our 
understanding of disulfide isomerase activity, showing how (i) oligomerisation, (ii) spacing 
between, and (iii) dynamic motion of, catalytic domains in PmScsC all contribute to its 
native function. 
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3.3 Introduction 
Protein disulfide isomerases are enzymes that proofread and shuffle incorrect disulfide 
bonds in misfolded protein substrates, and are important for the correct folding and 
function of many secreted proteins (17,173). The prototypical bacterial disulfide isomerase 
is Disulfide bond (Dsb) protein C from Escherichia coli (EcDsbC) (4,5,42). EcDsbC 
functions as a dimer; when the N-terminal dimerisation domain is deleted the resulting 
protein lacks disulfide isomerase activity (41) and it is also unable to interact with its redox 
partner EcDsbD (44). Each EcDsbC protomer has a thioredoxin-fold catalytic domain with 
a redox active motif consisting of two cysteines separated by two other amino acids 
(CXXC) (39). The disulfide isomerase activity of EcDsbC requires that the catalytic 
cysteines are in the dithiol reduced form (174) and this form is generated by interaction of 
EcDsbC with its redox partner membrane protein EcDsbD (44).  
 
Recently, we reported the structural and functional characterisation of Proteus mirabilis 
suppressor of copper sensitivity protein C (PmScsC) (175). Like DsbC, PmScsC is a 
protein disulfide isomerase with a thioredoxin-fold catalytic domain (175), redox-active 
cysteines (175), and a redox partner membrane protein (PmScsB) that reduces the active 
site cysteines (176). Unlike DsbC, PmScsC is trimeric rather than dimeric (175). Three 
crystal structures and SAXS analysis also revealed that PmScsC is highly dynamic (175). 
The region responsible for this conformational flexibility is an 11 amino acid linker within 
the trimerisation stem of the protein. Replacement of the flexible linker with a rigid helical 
peptide linker (PmScsC RHP), limits the rigid body motion of the catalytic domain relative 
to the trimer stalk, and generates a protein that is inactive as a disulfide isomerase. 
Moreover, PmScsC lacking the trimerisation stem (N-terminal 41 residues, PmScsCΔN) is 
also inactive as a disulfide isomerase but does have dithiol oxidase activity (175). Neither 
the native protein, nor the PmScsC RHP variant, exhibited dithiol oxidase activity. The 
difference in activity profile between the native protein (disulfide isomerase) and 
PmScsCΔN (dithiol oxidase) was proposed to be a consequence of their different 
oligomeric states. 
 
Here we report the structural characterisation of PmScsCΔN and the structural and 
functional characterisation of PmScsCΔLinker (a variant in which the 11-amino acid 
flexible linker is deleted, Figure 3.1). The crystal structure of PmScsCΔN reveals – as 
expected – a monomeric protein that closely resembles the catalytic domain from the full-
length PmScsC protomer. We show that the PmScsCΔLinker variant lacks both disulfide 
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isomerase and dithiol oxidase activity. The crystal structure reveals a trimeric arrangement 
for PmScsCΔLinker with the catalytic domains closely packed against each other. 
Conversely, SAXS analysis indicated that the oligomeric state of PmScsCΔLinker is 
concentration-dependent, with a monomeric form present at low concentrations and a 
dimeric form dominating at higher concentrations. For comparison, we analysed a 
concentration series of full-length native PmScsC by SAXS showing that the dominant 
species of the native protein in solution is trimeric, even at very low concentrations.  
 
 
 
Figure 3.1: Schematic representation of the PmScsC variants used in this study. The 
region corresponding to the catalytic domain is shown in green, the trimerisation stem is 
coloured magenta and the region representing the flexible linker is shown in cyan. The 
orange circle represents the approximate position of the redox active cysteines.  
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3.4 Materials and methods 
3.4.1 Molecular biology, protein expression and purification 
The constructs for the expression of PmScsC and PmScsCΔN were created previously 
(175) using the UniProt sequence B4EV21, without the predicted periplasmic signaling 
sequence (i.e. residues 22-243). To make the PmScsCΔLinker expression construct, the 
DNA encoding the flexible peptide linker (residues 39-KADEQQAQFRQ-49) in PmScsC 
was deleted from the P. mirabilis scsC gene using overlap extension PCR, with the 
primers 5’-GCAATCATGGCTCTGCAGACGAAAGCACTGGCTAGCGAACATGATGCC 
and 5’-GGCATCATGTTCGCTAGCCAGTGCTTTCGTCTGCAGAGCCATGATTGC. 
Ligation independent cloning was then used to insert the mutated gene into pMCSG7. 
Sequencing of the construct confirmed that the encoded protein was in-frame with an N-
terminal His6-tag and TEV protease cleavage site and revealed that residue 6 of 
PmScsCΔLinker was also mutated from asparagine to lysine.  The protein residues are 
numbered based on the sequence of full-length PmScsC, after TEV protease cleavage 
(starting S1N2A3...). All proteins were expressed in E. coli and purified using immobilised 
metal affinity, TEV cleavage and size exclusion chromatography as previously described 
(175). SDS-PAGE with Coomassie stain was used to estimate that the purity of each 
protein was >95%. The concentration of the proteins was determined by measuring the 
A280 of the samples and adjusting for theoretical A280 of a 1 mg/ml solution of the protein 
(Abs 0.1%). The theoretical Abs 0.1% values determined from Protparam (140) were 
0.528, 0.643 and 0.558 for PmScsC, PmScsCΔN and PmScsCΔLinker, respectively.  
 
3.4.2 Disulfide isomerase and dithiol oxidase assays 
The disulfide isomerase and dithiol oxidase activity of PmScsCΔLinker was determined as 
described previously (175). Briefly, to determine the disulfide isomerase activity, the ability 
of the protein to refold scrambled RNase A (scRNase A) was assessed. 10 µM 
PmScsCΔLinker was incubated with 40 µM scRNase A and at various time points, 
samples were taken and the RNAse A activity was measured in a spectrophotometric 
assay with a final concentration of 3 mM cytidine 3’,-5’-cyclic monophosphate (cCMP). 
Results are reported as a percentage of the activity of the RNase only control and are 
adjusted for the scrambled RNase A only negative control. The dithiol oxidase activity of 
PmScsCΔLinker was assessed by measuring the protein’s ability to form a disulfide bond 
between the two cysteines in a synthetic peptide, over time. The peptide substrate has 
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) bound to europium at 
the N-terminus and lysine methoxy-coumarin amide (MCA) at the C-terminus. As the 
Chapter 3 
 74 
cysteines become oxidised, the termini of the peptide are brought within close proximity, 
which causes an increase in fluorescence. PmScsCΔLinker (80 nM) was incubated with 8 
µM of the peptide substrate and the increase in fluorescence over time was monitored 
using a Synergy H1 Hybrid plate reader (BioTek, Vermont, USA) reading fluorescence at 
excitation and emission wavelengths of 340 nm and 615 nm, respectively. The rate of 
peptide oxidation is reported relative to the activity of the prototypical dithiol oxidase 
EcDsbA. The disulfide isomerase and dithiol oxidase assays were repeated two and three 
times, respectively and the mean and standard deviation for each is reported. 
 
3.4.3 Crystallisation 
Initial crystallisation hits for both PmScsCΔN and PmScsCΔLinker were identified in 96-
well hanging-drop vapour-diffusion experiments using commercial crystallisation screens, 
set up with a Mosquito robot (TTP LabTech Ltd, Melbourn, UK) at the University of 
Queensland Remote Operation Crystallisation and X-ray (UQ ROCX) Diffraction Facility. 
All crystallisation experiments were incubated at 293 K and monitored using a Rock 
Imager with Rock Maker software (Formulatrix Inc., Waltham, Massachusetts, USA).  
 
Well diffracting, rod-shaped crystals of PmScsCΔN were obtained in a 96-well screening 
plate in a drop containing 200 nL of the PEGRx™ HT (Hampton Research, Aliso Viejo, 
California, USA) C10 condition, 0.1 M Sodium acetate trihydrate pH 4.5, 30% w/v PEG-
mono methylether 5000, and 200 nL of 38 mg/ml PmScsCΔN in 10 mM HEPES pH 7.4. 
Perfluoropolyether (Hampton Research, Aliso Viejo, California, USA) was used to 
cryoprotect the crystals before they were flash frozen in liquid nitrogen. 
 
Needle-like crystals of PmScsCΔLinker were obtained in well F12 of the commercial 
screen JCSG-plus™ (Molecular Dimensions Limited, New-Market, UK) and then optimised 
in a 24-well plate grid screen around the original condition. This optimisation resulted in 
more robust and well diffracting crystals. Data were collected from a crystal grown in 1 µL 
of 0.1 M HEPES pH 7, 32% v/v Jeffamine M-600 and 1 µL of 40 mg/mL PmScsCΔLinker in 
10 mM HEPES pH 7.4, 150 mM NaCl. The crystal was cryoprotected in the crystallisation 
condition plus 20% ethylene glycol before being flash cooled in a cryostream (100 K). 
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3.4.4 Data collection, structure solution and refinement 
Data for the PmScsCΔN structure were collected using a wavelength of 0.95370 Å at 100 
K on the Australian Synchrotron MX2 beamline using the BluIce software (150). The data 
were processed and scaled with the trigonal space group P312 using XDS (151), Pointless 
(177) and SCALA (177). Phases were obtained by molecular replacement in Phaser (155), 
using Salmonella enterica serovar Typhimurium ScsC (PDB: 4GXZ) as the model. The 
initial model was improved by iterative model building in Coot (178) and refinement in 
PHENIX (154). The quality of the final PmScsCΔN model was assessed using MolProbity 
(164) and had an Rfree value of 21.5% and Rwork value of 19.6%, at a resolution of 2.15 Å. 
The coordinates and structure factors are deposited to the Protein Data Bank (179,180) 
under the code 4YX8. 
 
Data for the PmScsCΔLinker structure were collected at UQ ROCX under cryogenic 
conditions (100 K) using a Rigaku FR-E Superbright X-ray generator, producing X-rays at 
a wavelength of 1.54187 Å, and a Rigaku Saturn 944 CCD area detector. The data 
collection was performed with the Rigaku CrystalClear (v 2.0) program. Data were 
processed in iMosflm (v 7.1.3) (181) with the space group H32 (also known as R32:h) and 
scaled in Aimless (152) as implemented in the CCP4 suite (v 6.5.008) (160). Due to 
detector distance constraints at UQ ROCX, diffraction data were limited to a highest 
resolution of 2.08 Å. The crystals diffracted strongly, resulting in very high mean <I/σI> 
values (27.2 overall and 11.8 in the highest resolution shell). The structure was phased by 
molecular replacement using Phaser (155) and the catalytic domain of the compact 
PmScsC crystal structure (residues 47-224, PDB: 4XVW) was used as the search model. 
The trimerisation domain (without the 11 amino acid flexible linker) was then manually built 
into the electron density in Coot (178). The structure was refined using rounds of 
phenix.refine and manual adjustment in Coot, with reference to MolProbity (164). The final 
Rfree and Rwork values are 20.96% and 17.42% respectively, at a resolution of 2.08 Å. The 
coordinates and structure factors are deposited with the Protein Data Bank (179,180) 
under the code 6MHH. All structural figures were made in PyMOL (182) and structural 
alignments were performed in Coot using the superpose command (178) which aligns Cαs 
by least squares. The Contact program from the CCP4 suite (160) was used to analyse 
the interactions between the trimerisation stems of PmScsC/PmScsCΔLinker.  
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3.4.5 SAXS 
SAXS data were collected on the SAXS-WAXS beamline at the Australian Synchrotron 
(142). Data reduction was carried out using Scatterbrain software (v 2.71) (143), and 
corrected for solvent scattering, sample transmission, and detector sensitivity. The 0.1, 
0.5, 2.0, 5.0 and 10.0 mg/mL samples of PmScsCΔN were made by diluting a 30 mg/mL 
stock in 10 mM HEPES pH 7.4, 150 mM NaCl. For PmScsC and PmScsCΔLinker, 
samples were taken throughout centrifugal concentration and the concentration of these 
samples was adjusted to 0.1, 0.5, 2.0, 5.0 or 10.0 mg/mL in 10 mM HEPES pH 7.4, 150 
mM NaCl. These samples, along with the blank (10 mM HEPES pH 7.4, 150 mM NaCl) 
were loaded into a 96-well plate (Table 2) (183). The estimated molecular mass was 
calculated from the Porod volume (184) and from I(0) using contrast and partial specific 
volumes determined from the protein sequences using MULCh (v 1.1) (145). For 
PmScsCΔN, data processing and Guinier analysis was performed using Primus (v 3.2) 
(185). The pair-distance distribution function (p(r)) was generated from the experimental 
data using GNOM (v 4.6) (146), from which I(0), Rg and Dmax were determined. The 
program DAMMIN (v 5.3) (186) was used to generate 16 dummy-atom models for the 
protein, which were averaged using the program DAMAVER (v 2.8.0) (187), and the 
resolution of the averaged structures was estimated using SASRES (188). All 16 dummy-
atom models were used in the averaging procedure. The model scattering curve for 
PmScsCΔN (SASBDB ID: SASDEK4) was calculated from the crystal structure (PDB 
ID: 4YX8) using CRYSOL (v 2.8.3) (189). 
 
For PmScsC (SASBDB ID: SASDER4) and PmScsCΔLinker (SASBDB ID: SASDEQ4), 
data were modelled as a linear combination of model scattering curves to quantify the 
proportion of different oligomeric states in solution (190). The structure of PmScsC 
monomer (chain ID: A), dimer (chain ID: A, B) and trimer (chain ID: A, B, C) were taken 
from a CORAL model previously optimised against SAXS data for PmScsC (SASDB94) 
(175). The structure of PmScsCΔLinker monomer (chain ID: A), dimer (chain ID: A, B) and 
trimer (chain ID: A, B, C) were taken from the crystal structure of PmScsCΔLinker (PDB 
ID: 6MHH). Scattering curves for each oligomer were calculated using CRYSOL (v 2.8.3) 
(189). The calculated scattering curves (with units of e2) were multiplied by re2 (cm2 e-2) × 
NA (mol-1) × 10-3 (L cm-3) = 4.78181 × 10-5 (cm-1 e-2 mol-1 L). This normalisation permits the 
coefficients arising from a fit to experimental data on an absolute scale to be interpreted as 
the molar concentration of each oligomer present in solution. For PmScsC, a linear 
combination of monomer and trimer scattering curves were fit to the scattering data at 
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each concentration. To reduce the number of free parameters, the concentration of 
monomer for each SAXS curve was optimised together with a common equilibrium 
constant, Kt (3Monomer  Kt↔  Trimer), and the concentration of trimer was calculated from 
Kt and the momomer concentration. For PmScsCΔLinker, a linear combination of 
monomer, dimer and trimer scattering curves were fit to the scattering data at each 
concentration. To reduce the number of free parameters, the concentration of monomer for 
each SAXS curve was optimised together with two common equilibrium constants, Kd 
(2Monomer  Kd
↔
  Dimer), and Kt (Monomer+Dimer  Kt↔  Trimer). The concentration of dimer 
was calculated from Kd and the monomer concentration, while the concentration of trimer 
was calculated from Kt and the concentration of monomer and dimer. 
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3.5 Results  
3.5.1 PmScsCΔN crystal structure and SAXS analysis 
The design and biochemical characterisation of PmScsCΔN has been reported previously 
(175). The present work reports the crystal structure of this variant. Crystals of the 
PmScsCΔN mutant diffracted to a resolution of 2.15 Å at the Australian Synchrotron. The 
crystal structure of the mutant was solved using molecular replacement and there was only 
one PmScsCΔN molecule in the asymmetric unit (Table 3.1, Figure 3.2A, B). In the crystal 
packing, PmScsCΔN makes contact with 6 symmetry related molecules, but none involve 
packing against the catalytic motif or the positively charged surface patch surrounding it. 
The structure of PmScsCΔN is very similar to the structure of the catalytic domain present 
in each of the three previously reported PmScsC structures (Figure 3.2C, RMSD: 0.51-
0.68 Å, Cα atoms of 174 residues aligned, between chain A of each structure). Small-
angle scattering (Table 3.2) was used to determine the low-resolution solution structure of 
PmScsCΔN (Figure 3.3). The scattering data for PmScsCΔN is representative of a 
monomeric globular particle and is consistent with the scattering curve calculated from the 
crystal structure of PmScsCΔN (PDB ID: 4YX8). The crystal structure also shows good 
agreement with the dummy atom model derived from the scattering data (Figure 3.3C).  
 
Figure 3.2: Structural characterisation of PmScsCΔN. A. Structure of the PmScsCΔN 
variant. Structural features are coloured as in Figure 3.1 and the secondary structure 
elements are labelled based on the native PmScsC structures (175). B. Electron density of 
the catalytic region in PmScsCΔN. The wire mesh represents the 2Fo-Fc electron density 
map (generated in phenix.maps) contoured to 1σ and shown within a 2 Å radius of each 
atom. C. The structural alignment of PmScsCΔN (green) with residues 46-221 of chain A 
from the compact (cyan, PDB ID: 4XVW), transitional (yellow, PDB ID: 5IDR) and 
extended (magenta, PDB ID: 5ID4) PmScsC structures (175) (RMSD: 0.51-0.68 Å, 174 
residues aligned). This superimposition shows that the structures are similar whether or 
not the trimerisation domain is present.  
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Table 3.1: Crystallography statistics for PmScsCΔN and PmScsCΔLinker. 
Data collection 
PmScsCΔN 
PDB: 4YX8 
PmScsCΔLinker 
PDB: 6MHH 
Wavelength (Å) 0.9537  1.541870 
Resolution (Å) 45.68-2.15 (2.22-2.15)a 24.99-2.08 (2.14-2.08) 
Space group P312 H32 (R32:h) 
Unit cell dimensions   
  a, b, c (Å) 105.5, 105.5, 35.13 64.04, 64.04, 299.83 
  α, β, γ (º) 90, 90, 120 90, 90, 120 
Number measured reflections 265709 148450 
Number of unique reflections  12203 14715 (1135) 
Rmerge 0.13 (0.861) 0.059 (0.140) 
Mean <I/σI> 21.6 (4.9) 27.2 (11.8) 
Redundancy 21.9 (20.5) 10.1 (7.8) 
Completeness (%) 99.7 (97.0) 99.9 (100.0) 
Wilson-B 28.30 21.85 
Refinement   
Number of monomers in a/u 1 1 
Resolution used in refinement 
(Å) 
35.13-2.15 (2.22-2.15) 24.99-2.08 
Number of unique reflections 12197 14704 
Rfree (%) 21.5 20.96 
Rwork (%) 19.6 17.42 
Number of protein atoms (non-
H) 
1326 1671 
Number of ligand atoms 0 0 
Number of waters 80 131 
B factors (Å2)   
  Average 47.8 30.5 
  Protein atoms 47.5 30.3 
  Ligands NA NA 
  Waters 53.6 33.4 
RMSD Bond length (Å) 0.008 0.003 
RMSD Bond angles (º) 1.065 0.687 
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MolProbity results   
  Ramachandran favoured (%) 98 99.5 
  Ramachandran outlier (%) 0.6 0.0 
  Clashscore 1.13 1.17 
aValues in parentheses refer to the highest resolution shell.  
 
 
Figure 3.3: Small angle X-ray scattering data for PmScsCΔN. A. Measured scattering 
data for PmScsCΔN. The scattering profile of rigid-body models are shown as solid black 
lines overlaid on the scattering data for PmScsCΔN (χ2 = 1.12; CorMap test (148), 302 
points, C=14, P=0.018). Inset: Guinier plot for PmScsCΔN (R2 = 0.991) B. The pair-
distance distribution function, p(r), derived from the scattering data are indicative of a 
globular structure for PmScsCΔN (multiplied by a factor of 4 for clarity) with a maximum 
dimension of ~55 Å. C. Probable shape of PmScsCΔN obtained from the filtered average 
of 16 dummy-atom models (green envelope): χ2 = 1.079 ± 0.001; NSD = 0.522 ± 0.007; 
Resolution = 19 ± 2. Images in C were generated using PyMol, where the grey shapes 
represent the total volume encompassed by the aligned dummy-atom models and the 
corresponding rigid-body model is shown aligned to the filtered model. 
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Table 3.2: SAXS data collection and analysis details. 
Data Collection Parameters PmScsCΔN PmScsC PmScsCΔLinker 
Instrument SAXS-WAXS (Australian Synchrotron) 
Point 
1.033 
3.330 
0.008 – 0.363 
283 
Water 
Beam geometry 
Wavelength (Å) 
Sample to detector distance (m) 
q-range (Å-1) 
Temperature (K) 
Absolute intensity calibration 
Exposure time (s) 38 (38 × 1 s exposures) 
Configuration Concentration series from 96-well plate 
Protein concentration range (mg/mL) 0.1 – 10.0 
Sample details    
Extinction coefficient (A280, 0.1% w/v) 0.643 0.528 0.558 
Partial specific volume (cm3g-1) 0.742 0.741 0.743 
Contrast, Δρ (1010 cm-2) 2.79 2.80 2.78 
Molecular mass [from sequence] (kDa)  20.2 24.8 23.4 
Protein concentration (mg/mL) 0.50* 0.1, 0.5, 2.0, 
5.0, 10.0 
0.1, 0.5, 2.0, 5.0, 
10.0 
Structural parameters    
I(0) (cm-1) [from Guinier] 0.004055 ± 
0.00001 
- - 
Rg (Å) [from Guinier] 17.0 ± 0.1 - - 
I(0) (cm-1) [from p(r)] 0.004053 ± 
0.00001 
- - 
Rg (Å) [from p(r)] 17.0 ± 0.1 - - 
Dmax (Å) 55 ± 2 - - 
Porod volume (Å3) 22200 ± 1000 - - 
Molecular mass determination 
Molecular mass [from I(0)] (kDa) 11 ± 2 - - 
Molecular mass [from Porod] (kDa) 19 ± 1 - - 
*PmScsCΔN: I(0) = 0.00140 ± 0.00002 cm-1, Rg = 16.9± 0.3 Å, M = 19.8  kDa (0.1 mg/mL); 
I(0) = 0.004053 ± 0.000001 cm-1, Rg = 17.0 ± 0.1 Å, M = 19.1 kDa (0.5 mg/mL); I(0) = 
0.01839 ± 0.00003 cm-1, Rg = 17.1 ± 0.1 Å, M = 19.3 kDa (2.0 mg/mL); I(0) = 0.05463 ± 
0.00005 cm-1, Rg = 17.2 ± 0.1 Å, M = 19.6 kDa (5.0 mg/mL); I(0) = 0.10756 ± 0.00005 
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cm-1, Rg = 17.0 ± 0.1 Å, M = 19.2 kDa (10.0 mg/mL). Masses from the Porod volume are 
used as concentration estimates yielding masses from I(0) inconsistent with the expected 
mass. The 0.5 mg/mL was used for subsequent data analysis. 
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3.5.2 Activity of PmScsCΔLinker 
A key structural feature of native PmScsC is an 11 amino acid flexible linker, situated in 
the trimerisation stem and linking to the catalytic domain. This short region facilitates the 
conformational variations observed in the crystal structures and the dynamic motion of the 
trimeric protein observed in SAXS analyses (175). To better understand the role of the 
flexible linker we designed a PmScsCΔLinker variant in which the 11-residue linker is 
deleted, and characterised its function in standard assays. We first assessed the activity of 
PmScsCΔLinker in the scrambled RNase A assay and found that it was poorly active, with 
baseline activity like that of a typical dithiol oxidase such as EcDsbA and PmScsCΔN 
(Figure 3.4A). We then assessed its activity in the model peptide dithiol oxidase assay, in 
which EcDsbA and PmScsCΔN are both active. However, unlike the monomeric proteins 
EcDsbA and PmScsCΔN, PmScsCΔLinker was also inactive in the dithiol oxidase assay 
(Figure 3.4B). Disulfide isomerase activity is thought to be associated with oligomerisation 
of thioredoxin-fold proteins (41,123,175) so we were interested to determine whether 
PmScsCΔLinker forms a trimer - like the full-length native protein - or a monomer - like the 
truncated PmScsCΔN variant. 
 
Figure 3.4: PmScsCΔLinker biochemical activity. A. The ability of PmScsCΔLinker to 
isomerise the incorrect disulfide bonds in scrambled RNase A is poor – i.e. even lower 
than that of the dithiol oxidase EcDsbA. B. PmScsCΔLinker has poor dithiol oxidase 
activity; i.e. much less than monomeric PmScsCΔN and similar to that of protein disulfide 
isomerases EcDsbC and PmScsC. Asterisks indicate data published previously (175). 
Error bars on both panels represent the standard deviation of the mean. 
 
 
Chapter 3 
 84 
3.5.3 The crystal structure reveals a trimeric form of PmScsCΔLinker 
The three crystal structures of native PmScsC reported previously show that the linker 
residues can adopt helical (extended conformation), strand (intermediate conformation) or 
loop (compact conformation) secondary structure (175). In the extended conformation 
crystal structure, the linker adopts a helical conformation thereby creating a very long helix 
(35 residues, approximately 9.5 turns, Figure 3.5A) extending from the trimerisation stalk, 
through into the catalytic domain of PmScsC.  
 
Figure 3.5: PmScsCΔLinker crystal structure. A. Single protomer of the extended 
PmScsC (PDB: 5ID4). B. Single protomer of PmScsCΔLinker. The different features of the 
crystal structures are coloured as in Figure 3.1. The N-terminus of each structure is 
labelled and the positions of the residues flanking the flexible linker in the native structure 
are indicated. C. Electron density around the deleted region in the PmScsCΔLinker 
structure. The wire mesh represents the 2Fo-Fc electron density map (generated in 
phenix.maps) contoured to 1σ and shown within a 2Å radius of each atom. 
 
We solved the crystal structure of PmScsCΔLinker at a resolution of 2.08 Å using 
molecular replacement (Table 3.1, Figure 3.5B, C). The variant crystallised in the same 
space group (H32) and crystallisation condition as the extended conformation PmScsC 
(PDB: 5ID4). However, the unit cell dimensions of PmScsCΔLinker are shorter than those 
of the extended PmScsC structure (64.0 Å, 64.0 Å, 299.8 Å compared to 86.7 Å, 86.7 Å, 
330.0 Å). The crystal structure of PmScsCΔLinker – like the crystal structure of the 
extended form of PmScsC – is trimeric through crystallographic symmetry, with a single 
protomer in the asymmetric unit (Figure 3.6A). The regions on either side of the linker 
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region reported to be helical in the three native PmScsC crystal structures are directly 
connected in PmScsCΔLinker and are also helical.  
 
The crystal structure of PmScsCΔLinker is similar to that of extended PmScsC except for a 
shortening of the long helix by almost three turns (Figure 3.5A, B). This shortened helix in 
the crystal trimer of PmScsCΔLinker brings the three catalytic domains into much closer 
proximity in the variant compared with the native extended conformation. This proximity is 
evident from the distance between the catalytic cysteines of protomers: 15 Å in 
PmScsCΔLinker and 34 Å in the extended native structure (measured between the Cβ 
atoms of C84, Figure 3.6A, B).  
 
The PmScsCΔLinker crystal structure also reveals interactions between each of the 
catalytic domains of the trimer. The surface interface is formed between a positively 
charged patch close to the CXXC motif on the catalytic domain of one protomer and a 
neutral/hydrophobic patch on another (Figure 3.6C). This interface is not formed in the 
extended PmScsC structure, which has both of these regions exposed to solvent and it is 
also not formed by crystal packing in the PmScsCΔN structure.  
 
The trimerisation stems of all three native PmScsC crystal structures are α-helical with a 
hydrophobic core, and hydrogen bonds between surface exposed polar/charged residues. 
These features are conserved in the crystal structure of PmScsCΔLinker (Figure 3.6D and 
E). However, it should be noted that PmScsCΔLinker has an additional unanticipated 
mutation (Asn6Lys) at the N-terminus. In the three native crystal structures the side chain 
of the Asn6 residue forms an intramolecular hydrogen bond to the main chain of Gln9. In 
the PmScsCΔLinker crystal structure, the side chain of Gln9 adopts the same 
conformation as in all three native PmScsC structures but the mutated residue Lys6 does 
not form an equivalent hydrogen bond with the Gln9 main chain. The lack of this specific 
hydrogen bond could potentially increase N-terminal disorder, though the crystal structure 
suggests there is little impact on the hydrogen bonds and hydrophobic contacts that 
contribute to trimerisation.  
 
 
 
 
 
Chapter 3 
 86 
 
 
Figure 3.6: Trimerisation of PmScsCΔLinker. A. Side and top views of the catalytic 
domain of the crystal structure of PmScsCΔLinker. The crystal structure reveals a trimer 
through crystallographic symmetry. In many respects this crystal structure resembles that 
of native extended PmScsC B (PDB: 5ID4). However, the extended helix linking the 
trimerisation domain to the catalytic domain is shorter in PmScsCΔLinker due to deletion 
of the linker (cyan in B). In both A and B, the proteins are coloured using the scheme from 
Figure 3.1. C. The electrostatic surface potential of the catalytic domain of the 
PmScsCΔLinker protomer structure. Electrostatic calculations were performed using APBS 
(11) and contoured to -7.5 (red) and +7.5 kBT/e (blue). A solid orange circle indicates the 
position of the catalytic cysteines and black ovals surround the regions of the catalytic 
domains in close contact with adjacent catalytic domains in the PmScsCΔLinker crystal 
structure. D. The hydrophobic core of the trimerisation stem of PmScsCΔLinker; side 
chains of residues contributing to the hydrophobic core are coloured pink E. Amino acid 
residues mediating side chain polar and electrostatic interactions between the trimerisation 
stems of two PmScsCΔLinker protomers. Black dashed lines represent the hydrogen 
bonds and those residues involved are labelled.  
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3.5.4 SAXS reveals that the oligomeric state of PmScsCΔLinker is concentration 
dependent 
We had previously observed that the PmScsC RHP variant (in which the flexible linker is 
replaced with a rigid helix) forms a trimer - like the native protein - but is inactive in the 
protein disulfide isomerase assay (175). This lack of activity was thought to be a 
consequence of reduced catalytic domain motion observed in solution using small angle 
scattering (175). This finding led to the hypothesis that potent protein disulfide isomerase 
activity requires at least two catalytic domains (e.g. dimer, trimer) which have the ability to 
move independently of each other (175). Our present results show that PmScsCΔLinker 
also forms a trimer and is also inactive as a protein disulfide isomerase. We therefore 
anticipated that the lack of protein disulfide isomerase activity was a consequence of 
reduced catalytic domain rigid body motion, and sought to confirm this in solution using 
small angle scattering.  
 
Unexpectedly, initial SAXS data for PmScsCΔLinker displayed a strong dependence on 
concentration, consistent with an equilibrium between different PmScsCΔLinker oligomeric 
forms (monomer, dimer, trimer). This result raised the possibility that, at low 
concentrations, the wild-type protein may also be present as a mixture of monomer, dimer 
and trimer, and this might also impact on its function or its regulation. To investigate this 
possibility further, SAXS data were collected from native PmScsC (Figure 3.7) and 
PmScsCΔLinker (Figure 3.8) at concentrations between 0.1 and 10.0 mg/mL (Table 3.2). 
At the lowest concentration (0.1 mg/mL), the shape of the p(r) function for native PmScsC 
differed from the shapes of those at higher concentrations, indicating some dissociation of 
the wild-type protein. This effect was quantified by fitting a linear combination of monomer, 
dimer and trimer scattering to the data at each concentration (Figure 3.7 and Table 3.3). 
For PmScsCΔLinker, the results are very different; the shape of the p(r) curve changes 
significantly with each concentration evaluated. Again, this effect was quantified by fitting a 
linear combination of monomer, dimer and trimer scattering to the data at each 
concentration (Figure 3.8 and Table 3.3). The relative amounts of each were constrained 
by common equilibrium constants. The analysis worked well, but was limited by the fact 
that the structures of monomer and dimer forms in solution are not known. In each case, 
we made a simplistic assumption that a monomer adopted the structure of a single 
protomer from the corresponding crystal structure, and a dimer could be represented by 
removing a single protomer from the trimer crystal structure. We also know that native 
PmScsC is dynamic in solution (175). While the fits we obtained of the model curves to the 
Chapter 3 
 88 
scattering data are reasonable, there are systematic differences between the experimental 
data and the model, especially at higher concentrations. The limitations of the modeling 
(lack of accurate models, dynamic motion) explains most of this variation. 
 
Overall, the SAXS analysis suggests that only 1% of native PmScsC is present as 
monomer in solution even at the lowest concentration of 0.1 mg/mL; we conclude that the 
trimer is the dominant form of the native protein in solution even at low concentrations. For 
the variant PmScsCΔLinker, it is a different story; the protein is in equilibrium between 
different oligomerisation states. At 0.1 mg/mL approximately 97% of the PmScsCΔLinker 
solution is monomer, 3% is dimer with negligible trimer. At 10 mg/ml these proportions 
change to 40% monomer, 48% dimer and 12% trimer. 
 
Table 3.3: Oligomer fractions and equilibrium constants. 
Measured 
Concentration 
(mg/mL) 
Calculated 
Concentration 
(mg/mL) 
Monomer 
Fraction 
Dimer  
Fraction 
Trimer 
Fraction 
Native PmScsC (Kt = 6.3 × 10-18 M2) 
0.1 0.05 0.01 - 0.99 
0.5 0.33 0.00 - 1.00 
2.0 1.48 0.00 - 1.00 
5.0 3.74 0.00 - 1.00 
10.0 7.07 0.00 - 1.00 
PmScsCΔLinker (Kd = 2.1 × 10-4 M; Kt = 7.30 × 10-4 M) 
0.1 0.07 0.97 0.03 0.00 
0.5 0.36 0.88 0.12 0.00 
2.0 1.31 0.71 0.27 0.02 
5.0 3.55 0.53 0.41 0.07 
10.0 7.17 0.40 0.48 0.12 
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Figure 3.7: Native PmScsC SAXS data. A. Scattering data collected at ~0.1 mg/mL 
(blue, χ2 = 2.55), ~0.5 mg/mL (orange, χ2 = 7.05), ~2.0 mg/mL (green, χ2 = 72.85), ~5.0 
mg/mL (red, χ2 = 371.94), ~10.0 mg/mL (grey, χ2 = 815.23). The overlaid line (black) on 
each scattering curve is the fitted linear combination of monomer and trimer scattering 
curves. B. The pair-distance distribution function, p(r), derived from the scattering data 
normalised by concentration show the 0.1 mg/mL data set differs slightly from that of the 
other concentrations (which all overlay), indicating the possibility that monomer is present 
in solution at the lowest concentration. C. The fraction of protein present as monomer and 
trimer, derived from the fitted models, shows that at total protein concentrations above 10 
µM, the protein is almost exclusively present as a trimer in solution. 
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Figure 3.8: PmScsCΔLinker SAXS data. A. Scattering data collected at ~0.1 mg/mL 
(blue, χ2 = 1.27), ~0.5 mg/mL (orange, χ2 = 2.19), ~2.0 mg/mL (green, χ2 = 6.89), ~5.0 
mg/mL (red, χ2 = 37.59), ~10.0 mg/mL (grey, χ2 = 177.29). The overlaid line (black) on 
each scattering curve is the fitted linear combination of monomer and trimer scattering 
curves. B. The pair-distance distribution function, p(r), derived from the scattering data 
normalised by concentration show that the oligomeric composition of the solution is highly 
dependent on concentration. C. The fraction of protein present as monomer, dimer, and 
trimer, derived from the fitted models, shows the monomeric species is dominant in 
solution until the total protein concentration reaches ~240 µM. The concentration of trimer 
rises slowly, and reaches a protein fraction of ~0.2 at 1.7 mM (40 mg/mL), which is the 
concentration at which the crystallisation was performed. 
 
 
 
 
  
Chapter 3 
 91 
3.6 Discussion 
This study focused on characterising two variants of PmScsC, which - in its native form - is 
a highly dynamic, trimeric disulfide isomerase. The native PmScsC protomer consists of 
an N-terminal trimerisation stem with an 11 amino acid flexible linker connected to a C-
terminal thioredoxin fold catalytic domain harbouring a CXXC active site. To better 
understand the role of the trimerisation stem and flexible linker we designed the variants 
PmScsCΔN and PmScsCΔLinker. PmScsCΔN lacks the first 41 amino acids of the native 
PmScsC construct; its loss of disulfide isomerase activity and gain of dithiol oxidase 
activity has been reported previously (175). PmScsCΔLinker is newly reported here, and 
lacks the 11 amino acids that form the flexible linker. We reported here the structure of 
PmScsCΔN and analysed the structure and biochemical function of PmScsCΔLinker. 
 
The X-ray crystal structure of PmScsCΔN agrees with previous MALLS data showing that 
this variant is monomeric (175). The crystal structure is also consistent with solution SAXS 
data and the low-resolution model obtained from SAXS analysis. Although the PmScsCΔN 
crystal structure is very similar to the structures of the catalytic domains in each of the 
three native PmScsC crystal structures, unlike the native enzyme it lacks disulfide 
isomerase (disulfide shuffling) activity but instead has dithiol oxidase (disulfide forming) 
activity. The PmScsC catalytic domain has an acidic catalytic cysteine and an energetically 
unfavourable disulfide (175) – that are also features of the archetypal but monomeric 
dithiol oxidase EcDsbA – so it is perhaps not surprising that removal of the N-terminal 
trimerisation residues leads to oxidase activity in a model assay. Moreover, the structural 
similarity between monomeric PmScsCΔN and the catalytic domains of native trimeric 
PmScsC supports the notion that it is the N-terminal stem – defining whether the catalytic 
domain is monomeric or trimeric - that is the determinant of isomerase or oxidase activity. 
Put simply, the differential activity we observe between native PmScsC and variant 
PmScsCΔN is not a specific feature of the catalytic domain because the same catalytic 
domain has the propensity for oxidase (monomeric protein) or isomerase (trimeric protein) 
activity depending on its context. The isomerase activity of PmScsC requires both its N-
terminal trimerisation domain and its C-terminal catalytic domain, in the same way that the 
isomerase activity of EcDsbC requires its dimerisation domain and its catalytic domain 
(41).  
 
Our SAXS analysis showed that native PmScsC is a trimer in solution, even at low 
concentrations. However, SAXS analysis of PmScsCΔLinker showed that it exists 
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predominately as a monomer or a low affinity dimer (Kd ~ 200 µM) in preference to a trimer 
in solution even though it crystallises in the trimeric form. Together these data suggest that 
removal of the flexible linker of PmScsC between the trimerisation stem and catalytic 
domains has the unintended consequence of reducing the propensity to form a stable 
trimer in solution.  
 
The crystal structure of PmScsCΔLinker provides insight into why the trimeric form of the 
variant may be energetically unfavourable compared with the monomeric and dimeric 
forms in solution. The trimerisation stem interactions of PmScsCΔLinker are similar to 
those observed in the native enzyme crystal structures, but all three catalytic motifs are in 
closer proximity to each other than in any of the native PmScsC crystal structures. This 
close packing suggests the possibility of unfavorable contacts between catalytic domains 
in PmScsCΔLinker that may contribute to the instability of the trimer. Indeed, the 
PmScsCΔLinker crystal structure reveals a close association of a positively charged patch 
near the catalytic motif on the accessible surface of one protomer with a 
neutral/hydrophobic patch on another. In the crystal packing of the PmScsCΔN structure 
(which does not have the constraint of the trimerisation stem), there are no contacts 
involving the positively charged surface patch near the catalytic motif, suggesting that 
packing against this site is not favoured. Thus, the formation of the PmScsCΔLinker trimer 
is likely to be dependent on the balance of favourable interactions formed between the 
trimerisation stems and unfavourable interactions between the catalytic domains. At lower 
concentrations the unfavourable interactions between the catalytic domains may override 
the favourable interactions but at higher concentrations, with more molecules in close 
contact, it may be more thermodynamically favourable for the hydrophobic portion of the 
trimerisation helices to interact with each other. This interplay between interactions of the 
catalytic domains and trimerisation stems could explain why the oligomeric state of 
PmScsCΔLinker in solution alters with concentration of the protein. Taken together, the 
crystal structure and SAXS analysis of PmScsCΔLinker suggests that the 11 amino acid 
linker plays a dual role by (i) acting as a spacer between the trimerisation and catalytic 
domains to enable formation of a stable trimer and (ii) to provide the necessary functional 
dynamics and cooperativity between the catalytic domains (175).  
 
Removal of the 11 amino acid flexible linker from PmScsC impacts on the activity of the 
protein: unlike the native protein, the PmScsCΔLinker has no disulfide isomerase activity. 
Structural characterisation of PmScsCΔLinker revealed two potential reasons for this 
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result. Firstly, at the concentration used in the assay (10 µM) it is likely that most of the 
protein would be monomeric (Figure 3.8C), and we know from PmScsCΔN variant studies 
that monomeric protein has low protein disulfide isomerase activity (175). Secondly, even 
if there was sufficient trimeric PmScsCΔLinker present in solution, the crystal structure 
suggests there would be limited space between the catalytic domains to bind a misfolded 
protein substrate, and possibly limited motion to allow disulfides to be shuffled. It is 
interesting to note that PmScsCΔLinker is inactive in the dithiol oxidase assay. Given that 
the protein would be predominantly monomeric at the concentration tested in this assay 
(80 nM, Figure 3.8C) we expected that, like monomeric PmScsCΔN, it would have oxidase 
activity. One explanation for this result is that the N-terminal hydrophobic regions of 
PmScsCΔLinker somehow occlude the substrate-binding site that is available in 
monomeric PmScsCΔN. 
 
Overall, our structural and functional characterisation of PmScsCΔN and PmScsCΔLinker 
provides new insight into the importance of unique structural features of the trimeric 
disulfide isomerase PmScsC. We confirmed previous assumptions that disulfide 
isomerases are similar to but differentiated from dithiol oxidases by requiring both an 
oligomerisation domain and a catalytic domain. We further propose that the flexible linker 
of PmScsC is important not just as a shape-shifting peptide, but also as a spacer, to 
enable functional flexibility between the catalytic domains. We suggest that this functional 
flexibility between the catalytic domains is necessary for cooperative enzymatic activity of 
disulfide isomerase PmScsC. Finally, on a more general note, we found that deleting 
amino acids from a protein can have unintended consequences. In this case, deletion of 
the flexible linker unexpectedly changed the oligomerisation kinetics of the protein, even 
though the region directly involved in trimerisation remained intact.  
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4. P. mirabilis ScsBα and ScsC form a functional redox relay 
4.1 Chapter Foreword 
This chapter is a reproduction of a research article that was originally published in the 
Journal of Biological Chemistry. It contains the crystal structure of the N-terminal domain 
of PmScsB (PmScsBα), confirms that this domain is the redox partner of the trimeric 
disulfide isomerase PmScsC and shows a SANS derived model of the PmScsC-PmScsBα 
interaction. Minor changes have been made to the paper to conform to the thesis 
submission requirements. These changes include, the overall formatting, removal of the 
keywords and contributions (which can be found in the preliminary pages) and the 
numbering of tables, figures and references. 
 
4.1.1 Reference 
Furlong, E. J., Choudhury, H. G., Kurth, F., Duff, A. P., Whitten, A. E. and Martin, J. L. 
(2018) Disulfide isomerase activity of the dynamic, trimeric Proteus mirabilis ScsC protein 
is primed by the tandem immunoglobulin-fold domain of ScsB. Journal of Biological 
Chemistry 293(16): 5793-5805; doi: 10.1074/jbc.RA118.001860. © The Authors. 
 
4.1.2 Contribution 
I made a significant contribution to the experimental design of the work outlined in this 
publication, the analysis of results and the production of the publication. I designed the 
cysteine variants and chose the assays to use to investigate the interaction between 
PmScsC and PmScsBα. I also optimised the PmScsBα crystallisation, collected and 
processed diffraction data and solved and refined the structure of this protein. I performed 
the interaction assays between PmScsC and PmScsBα and analysed the data. I created 
the cysteine mutants of PmScsC and PmScsBα and produced the 3:1 PmScsC-PmScsBα 
complex for SANS analysis. I wrote the first draft of the paper and designed and created 
the figures.  
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4.2 Abstract 
Correct disulfide bond formation is essential for proper folding of many proteins, including 
bacterial virulence factors. The suppressor of copper sensitivity (Scs) proteins have roles 
in dithiol/disulfide interchange and the bacterial response to copper stress. Encoded in a 
four-gene cassette (ScsABCD) present in many Gram-negative bacteria, the Scs proteins 
are enigmatic and poorly characterised. Here, we show that the periplasmic α domain of 
the membrane protein ScsB in the Gram-negative bacterium Proteus mirabilis forms a 
redox relay with the soluble periplasmic protein PmScsC. We also found that the 
periplasmic α domain is sufficient to activate the disulfide isomerase activity of PmScsC. 
The crystal structure of PmScsBα at a resolution of 1.54 Å revealed that it comprises two 
structurally similar immunoglobulin-like folds, one of which includes a putative redox-active 
site with the sequence CXXXC. We confirmed the importance of these cysteine residues 
for PmScsBα function and in addition, we engineered cysteine variants that produced a 
stable complex between PmScsC and PmScsBα. Using small-angle X-ray and neutron 
scattering analyses with contrast variation, we determined a low-resolution structure of the 
PmScsC-PmScsBα complex. The structural model of this complex suggested that 
PmScsBα uses both of its immunoglobulin-like folds to interact with PmScsC and also 
revealed that the highly dynamic PmScsC becomes ordered upon PmScsBα binding. 
These findings add to our understanding of the poorly characterised Scs proteins. 
 
4.3 Introduction 
The correct formation of disulfide bonds is an essential component in the folding of many 
proteins, including bacterial virulence factors. In bacteria, disulfide bond forming (Dsb) 
proteins are responsible for introducing disulfide bonds into substrate proteins (DsbA and 
B) (7,25) as well as reducing and isomerising (proof-reading and shuffling) disulfide bonds 
that have been incorrectly introduced (DsbC and D) (39,44). Dsb proteins function through 
the redox action of two catalytic cysteines that are often embedded in a thioredoxin fold. 
These systems are well characterised in E. coli; however, homologues of Dsb proteins 
exist in a range of Gram-negative bacteria. A group of related and poorly studied proteins 
found most commonly in Proteobacteria are the suppressor of copper sensitivity (Scs) 
proteins (118). The Scs proteins contribute to the bacterial virulence trait of resistance to 
copper stress (111,120). Originally identified in Salmonella enterica serovar Typhimurium 
(111), the scs locus encodes four proteins ScsA-D, all of which have predicted catalytic 
motifs consisting of two cysteines (CXXC or CXXXC). Three of these (ScsB-D) incorporate 
a predicted thioredoxin fold and one of the four (ScsA) has a predicted copper-binding 
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motif. ScsD has a predicted N-terminal membrane anchor linked to a predicted periplasmic 
thioredoxin-fold domain (111), reminiscent of proteins involved in cytochrome c biogenesis 
such as DsbE/CcmG (69,124). The best studied of the four Scs proteins is the soluble 
periplasmic protein, ScsC (118,120,175). An extraordinary feature is the variation in 
structure and function of ScsC proteins across different bacteria. Caulobacter crescentus 
ScsC (CcScsC) is reported to be a dimeric disulfide isomerase (118), Salmonella enterica 
serovar Typhimurium ScsC (StScsC) is a monomeric redox protein with no disulfide 
isomerase activity (120) and Proteus mirabilis ScsC (PmScsC) is a highly dynamic “shape-
shifting” trimeric disulfide isomerase (175).  
 
The present work focuses on the structure and function of P. mirabilis ScsB, a putative 
redox partner of P. mirabilis ScsC. ScsB resembles E. coli DsbD in many respects (118). 
EcDsbD is the membrane protein partner of the archetypal disulfide isomerase E. coli 
DsbC. Like EcDsbD, the ScsB protein is predicted to comprise three domains: an N-
terminal periplasmic domain (DsbDα/ScsBα), a transmembrane domain (DsbDβ/ScsBβ) of 
eight helices; and a periplasmic C-terminal thioredoxin-fold domain (DsbDγ/ScsBγ) 
(Figures 4.1A, B). Each of the three domains in both EcDsbD and ScsB have two catalytic 
cysteine residues. In DsbD, these cysteine pairs in each domain form a reduction cascade 
that originates from thioredoxin reductase (TR) and NADPH in the cytoplasm, is passed 
through thioredoxin to DsbDβ, DsbDγ, and then DsbDα, which reduces the cysteines in 
specific substrate proteins, such as DsbC (60,191) (Figure 4.1A). The similarity between 
the predicted architectures of EcDsbD and ScsB suggests the ScsB protein forms a similar 
redox relay system. Indeed, C. crescentus ScsB has been shown to interact with CcScsC 
and to maintain CcScsC in its reduced state, which is necessary for disulfide isomerase 
activity (118). A major difference between EcDsbD and ScsB is the size of their N-terminal 
α-domains. DsbDα comprises ~165 residues whereas ScsBα is much larger at ~255 
residues, and there is no detectable sequence identity between the α-domains of DsbD 
and ScsB. Since the α-domain of EcDsbD interacts directly with substrates - such as 
EcDsbC  - the different size and sequence of the ScsB α-domain suggests that the 
proteins interact with different substrates (118).  
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Figure 4.1: Schematic representation of bacterial disulfide isomerases and their 
redox relay partners. A. EcDsbC is reduced by EcDsbDα, which obtains its reducing 
power from a reduction cascade that starts with thioredoxin reductase in the bacterial 
cytoplasm. B. PmScsC and PmScsBα are putative interaction partners and the source of 
PmScsB’s reducing power is yet to be determined (represented by the question marks). 
The catalytic cysteines in each protein are shown as orange spheres. 
 
In the present study we investigated the structure and function of P. mirabilis ScsBα, 
showing that it forms a functional redox relay with the highly dynamic, trimeric disulfide 
isomerase PmScsC. We also report the first crystal structure of any ScsBα, revealing 
unexpectedly the presence of tandem immunoglobulin folds in PmScsBα, and showing 
that this same arrangement is likely to be shared in ScsBs encoded by other organisms. 
We created a stable PmScsC-PmScsBα (trimer-monomer) complex, and analysed small-
angle X-ray scattering (SAXS) data and small-angle neutron (SANS) data with contrast 
variation to produce a low-resolution model of the complex. This model revealed that the 
highly dynamic PmScsC protein becomes more symmetric and ordered upon interaction 
with PmScsBα and that both immunoglobulin folds of PmScsBα interact with one protomer 
of PmScsC.  
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4.4 Results 
4.4.1 PmScsC and PmScsBα form a specific redox relay system 
From sequence analogy with the C. crescentus proteins CcScsB and CcScsC, PmScsBα 
is predicted to be the redox partner of PmScsC. If this functional relationship holds true, 
PmScsBα would specifically reduce oxidised PmScsC to convert it to the active reduced 
form. To confirm that a redox relay occurs between PmScsC and PmScsBα, we performed 
a redox gel-shift assay. First, we mixed PmScsC with PmScsBα and then analysed the 
redox states of the two proteins after an incubation period. The redox state was defined by 
analysing the proteins on SDS-PAGE after reaction with 4-acetamido-4′-
maleimidylstilbene-2,2′-disulfonic acid (AMS) (Figure 4.2A). When AMS binds to a reduced 
thiol, the mass is increased by 0.5 kDa thus allowing discrimination between reduced and 
oxidised cysteine forms of a protein on mass-based gel separation. The results showed 
that when oxidised PmScsC was incubated with reduced PmScsBα, both proteins 
changed their redox states, confirming that disulfide exchange occurs between the two 
proteins (Figure 4.2B). The reverse redox reaction did not occur: reduced PmScsC 
remained reduced when mixed with oxidised PmScsBα. Moreover, we were able to 
confirm the residues involved in the change in redox state because addition of the variant 
PmScsBα C114A to oxidised PmScsC did not catalyse disulfide exchange. However, there 
was some evidence for formation of a PmScsC-PmScsBα C114A complex (band marked 
X, Figure 4.2B).  
 
Control experiments using PmScsC or PmScsBα alone showed that, under the conditions 
of the experiment, these proteins did not spontaneously change their redox state. These 
results support the notion that PmScsC and PmScsBα form a specific redox relay system 
(Figure 4.2B) and that the residues C114 and C118 of PmScsBα are responsible for the 
redox interaction. 
 
4.4.2 PmScsBα primes the disulfide isomerase activity of PmScsC 
We have previously shown that PmScsC is a disulfide isomerase (175). We tested the 
hypothesis that the redox interaction between PmScsBα and PmScsC might contribute to 
this function of PmScsC. We measured the disulfide isomerase activity of PmScsC using 
scrambled RNase A as substrate (Figure 4.2A). Reduced PmScsC, but not oxidised 
PmScsC, was able to refold scrambled RNase A, and thereby activate the enzyme (175) 
(Figure 4.2C). PmScsBα on its own (oxidised or reduced) had no effect on the activity of 
scrambled RNase A. However, in the presence of reduced PmScsBα the inactive oxidised 
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PmScsC was able to restore the activity of RNase A. This result supports the hypothesis 
that PmScsBα reduces the disulfides of oxidised PmScsC, thereby enabling its disulfide 
isomerase activity (Figure 4.2D). This experiment also confirmed that disulfide exchange in 
this system does not flow in the reverse direction: reduced PmScsC did not lose its ability 
to shuffle scrambled RNase A disulfides when it is incubated with oxidised PmScsBα. This 
may suggest that reduced PmScsC is unable to interact with PmScsBα. Further, the 
cysteine variant in which C114 is mutated to Ala (PmScsBα C114A) does not activate 
oxidised PmScsC, showing that this cysteine is required for the redox relay to operate.  
 
 
Figure 4.2: PmScsBα reduces and activates PmScsC. A. Schematic diagrams of the 
gel-shift and scRNase A experiments. B. A representative gel from the gel shift assay 
showing the interaction between PmScsC and PmScsBα. Dotted lines are a visual aide to 
delineate lanes on the gel. The band marked X is likely to be 1:1 PmScsC-PmScsBα 
C114A complex, as the usually trimeric PmScsC runs as a monomer on SDS-PAGE. C. 
Results from the modified scrambled RNase A assay. Activity is shown relative to native 
RNase A (100%) and scrambled RNase A only (0%) controls. For each sample, the 
activity of three or five replicates and the mean with s.d. is shown. D. Schematic showing 
the redox interaction that occurs between PmScsC and PmScsBα.  
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4.4.3 Crystal structure of PmScsBα  
After removal of the periplasmic signal sequence, the predicted PmScsBα domain 
comprises 255 residues (residues 21-275, of the reported PmScsB protein sequence 
B4EV20). The crystal structure of this domain was solved to a resolution of 1.54 Å by 
using SeMet-labelled protein together with SAD phasing (PDB: 6C29, Table 4.1, Figures 
4.3A-D). The structure revealed a monomer consisting of two immunoglobulin-like folds 
linked by an α-helix. This arrangement was consistent across all three molecules in the 
asymmetric unit (RMSD 0.7-1.0 Å for 247 aligned residues). Curiously, the two 
subdomains A and B are reasonably similar in structure (Figure 4.3D RMSD 2.5 Å for 81 
aligned residues), though the sequence identity for such an alignment is very low (~7%). 
The subdomains are each comprised of two β-sheets, one with three β-strands and the 
other with four β-strands (Figure 4.3A and B). Subdomain A has additional features, 
including: the cysteine motif (C114XXXC118); two β-strands forming a β-hairpin that links the 
two β-sheets of the canonical immunoglobulin fold; and a loop between β2 and β3, located 
on one side of the catalytic cysteines (arrows, Figure 4.3D). The cysteines are present in 
the reduced form in all three molecules in the asymmetric unit. 
 
The presence of an immunoglobulin-like fold in both PmScsBα subdomains resulted in 
many hits in a DALI search against the Protein Data Bank (192). Notably, the top hit was 
the functionally equivalent E. coli DsbDα (PDB: 1JPE, RMSD 2.5 Å, 103 residues aligned), 
though this has only one immunoglobulin-like fold, which can be aligned with subdomain A 
of PmScsBα (Figure 4.4A). Like PmScsBα subdomain A, E. coli DsbDα has two catalytic 
cysteines and a β-hairpin close to the active site, but it does not have the β2-β3 loop of 
PmScsBα. Two other hits in the DALI search were the mouse γ-adaptin appendage 
domain from clathrin-binding adaptor AP-1 (PDB: 2A7B, RMSD 2.4 Å, 106 residues 
aligned) and the GAE domain of the clathrin-binding adaptor GGA protein from 
Saccharomyces cerevisiae (PDB: 3MNM, RMSD 2.4 Å, 102 residues aligned) (Figure 4.4B 
and C). These proteins have typical immunoglobulin-like folds, with no catalytic cysteines, 
and like EcDsbDα have one immunoglobulin fold that aligns with subdomain A of 
PmScsBα. These three proteins were also hits in a DALI search against PmScsBα 
subdomain B though with much higher RMSDs (1JPE: RMSD 3.8 Å, 75 residues aligned. 
2A7B: RMSD 3.0 Å, 84 residues aligned. 3MNM: RMSD 2.9 Å, 86 residues aligned). 
Curiously, there were no high-scoring DALI hits that had a tandem immunoglobulin-fold 
arrangement like that of PmScsBα. We did find lower scoring DALI hits with two 
immunoglobulin-like folds (mostly antigen-binding fragments of antibodies e.g. PDB: 5JUE, 
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Z-score: 4.6, RMSD: 3.0 Å, 80 residues aligned), but they lacked the connecting α-helix of 
PmScsBα. 
Table 4.1: Crystallography statistics for PmScsBα. 
Data collection PDB: 6C29 (SeMet) 
Wavelength (Å) 0.9786 
Resolution (Å) 97.06 – 1.538 (1.544-1.538)a 
Space group P212121 
Unit cell dimensions  
a, b, c (Å) 69.98, 97.06, 110.20 
α, β, γ (º) 90, 90, 90 
Number measured reflections 1761650 
Number of unique reflections  111511  
Rmerge 0.146 (2.114) 
Rp.i.m. 0.038 (0.531) 
Mean <I/σI> 16.0 (2.1) 
Redundancy 15.8 (16.3) 
Completeness (%) 99.7 (98.3) 
Wilson-B 15.96 
SAD Phasing  
No. of sites 14 
Figure of Merit 0.42 
Refinement  
Number of monomers in a/u 3 
Resolution used in refinement (Å) 55.10 – 1.538 
Number of reflections 111388 
Rfree (%)/Rwork (%) 19.8/17.3 
Number of protein atoms 5860 
Number of ligand atoms 0 
Number of waters 669 
B factors (Å2)  
Average 25.5 
Protein atoms 24.8 
Ligands NA 
Waters 31.8 
RMSD Bond length (Å)/ angles (º) 0.011/1.332 
Ramachandran favoured / outlier (%) 97/0 
aValues in parentheses refer to the highest resolution shell.  
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Figure 4.3: Structural characterisation of PmScsBα. A. Cartoon representation of the 
crystal structure of PmScsBα (PDB: 6C29). B. Topology diagram of PmScsBα, showing 
the secondary structure features of the protein. C. The OMIT electron density around the 
catalytic loop in chain A of the PmScsBα crystal structure is displayed. The wire mesh 
represents the likelihood-weighted Fo – Fc electron density difference map, which is 
contoured to 3σ and was generated using phenix.refine with the region of interest omitted 
from the structure. D. Superimposition of subdomains A and B structures showing the 
structural similarity between the domains. Arrows indicate the inserted β-hairpin structure 
and the extended loop of subdomain A. In all panels, subdomain A is coloured purple and 
subdomain B is magenta, with the linking α-helix shown in grey. The catalytic cysteines are 
represented as orange spheres. The N- and C-termini are labelled in A and B. 
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Figure 4.4: Structural overlay of PmScsBα subdomain A with selected DALI hits. A. 
PmScsBα subdomain A (purple) aligned with EcDsbDα (PDB: 1JPE) (cyan). The catalytic 
cysteines of both PmScsBα subdomain A and EcDsbDα are shown as spheres and 
coloured in orange and yellow, respectively. An arrow indicates the extended loop in the 
PmScsBα structure. B. PmScsBα subdomain A (purple) aligned with PDB: 2A7B (light 
green). C. PmScsBα subdomain A (purple) aligned with PDB: 3MNM (light pink). Neither 
2A7B nor 3MNM have catalytic cysteines so in both B and C the orange spheres correlate 
to the cysteines of PmScsBα. 
 
4.4.4 Structure-based sequence alignment 
The amino acid sequence of PmScsBα was aligned with that of EcDsbDα using structure-
based alignment, and the sequences of C. crescentus ScsBα (CcScsBα) and 
S. Typhimurium ScsBα (StScsBα) (Figure 4.5). ScsBα from S. Typhimurium and 
C. crescentus were chosen, as these are the only other organisms where the interaction 
partner, ScsC, has been characterised. EcDsbDα was chosen because of the known 
structural and functional relationship. PmScsBα shares 44% sequence identity with 
StScsBα (280 residues), 21% identity with CcScsBα (291 residues) and just 12% identity 
with EcDsbDα (116 residues of PDB: 1JPE). There are several conserved residues across 
the three ScsBα and EcDsbDα protein sequences aside from the catalytic cysteines. Other 
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conserved residues include Leu34 and Ile58 (PmScsBα numbering); their side chains 
interact with each other in the hydrophobic core of both PmScsBα and EcDsbDα, so their 
conservation suggests a key role in folding or stability. Interestingly, the tyrosine hydroxyl 
of the conserved residue Tyr45 (Tyr42 in EcDsbDα) is within 3.5-3.8 Å of the active site 
sulfurs of Cys114 and Cys118 suggesting a potential role in catalysis or substrate binding. 
Two other conserved residues, Tyr87 and Pro72, are located at either end of the β-hairpin. 
The hydroxyl group of Tyr87 is within hydrogen-bonding distance of the main chain oxygen 
of Pro72 (~2.6 Å), suggesting that their conservation may be important in preserving the 
structure of the β-hairpin. The β2-β3 loop is also highly conserved across the ScsBα 
sequences, suggesting an important function.  
 
 
Figure 4.5: Sequence alignments. Sequence and structure-based sequence alignment 
of the PmScsBα crystal structure with StScsBα, CcScsBα sequences and the EcDsbDα 
crystal structure (PDB: 1JPE). Secondary structure elements of PmScsBα are shown 
above the corresponding sequence and are coloured as per the scheme in Figure 4.3. 
Residues that are conserved between all four proteins are highlighted in red; those that 
are conserved only between the ScsBα proteins are coloured blue. 
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4.4.5 Formation of a 3:1 PmScsC-PmScsBα complex 
The interaction between the catalytic cysteines of PmScsC and PmScsBα is transient. For 
this reason the catalytic cysteine variants, PmScsC C87S and PmScsBα C114A, were 
produced. These variants allowed the capture of a stable PmScsC-PmScsBα complex for 
structural studies. Size exclusion chromatography (SEC) and subsequent SDS-PAGE 
analysis suggested that the predominant complex species had a 3:1 ratio of PmScsC to 
PmScsBα, corresponding to one PmScsC trimer bound to one PmScsBα monomer (Figure 
4.6). The predicted molecular weight calculated from SAXS and SANS analysis (Table 4.2) 
also provided evidence to support this stoichiometry. A peak corresponding to a larger 
species was seen on the SEC chromatogram (peak marked Z, Figure 4.6A), suggesting 
that a smaller amount 3:2 and/or 3:3 complex may have also formed.  
 
 
Figure 4.6: Formation of 3:1 PmScsC C87S:PmScsBα C114A complex. A. SEC 
chromatograms from the purification of the 3:1 PmScsC:PmScsBα complex (solid line), 
purified PmScsC C87S (dotted line) and PmScsBα C114A (dashed line). In the purification 
of the complex, excess PmScsC was removed prior to SEC using an IMAC step. The 
leading shoulder (Z) suggests the presence of 3:2 and/or 3:3 PmScsC C87S:PmScsBα 
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C114A complexes. The shaded region highlights the fractions of the 3:1 
PmScsC:PmScsBα peak (solid line) that were pooled for structural analysis. B. The 
fractions from the shaded region of the 3:1 PmScsC:PmScsBα complex peak run on SDS-
PAGE, without and with DTT. PmScsC is a trimer that separates and runs as a monomer 
on SDS-PAGE. The lane labelled –DTT shows that the trimer:monomer complex 
separates into complex (covalently linked protomer of PmScsC with monomer of PmScsBα 
- 55.1 kDa) and uncomplexed PmScsC C87S (24.8 kDa), in an approximate 1:1 ratio. 
When run with DTT (lane labelled +DTT), the higher band dissociates into the two complex 
components in an approximate 3:1 ratio. 
 
4.4.6 SAXS and SANS provide structural insights into the PmScsC-PmScsBα 
interaction  
SANS contrast variation experiments were performed on the 3:1 PmScsC-PmScsBα 
complex, formed using unlabelled PmScsC C87S and deuterium labelled PmScsBα 
C114A (DPmScsBα C114A) (Figure 4.7). Deuterium labelling changes the neutron 
scattering length density of PmScsBα. It is possible to tune the neutron scattering length 
density of the solvent, by changing its deuterium content, such that it matches one of the 
components of the protein complex. This is said to be the match-point of that component, 
and the measured scattering data can then be interpreted as being from the unmatched 
component of the complex alone. Data collected close to the DPmScsBα C114A match-
point (100% D2O, where PmScsC C87S dominates the scattering), indicates the highly 
dynamic PmScsC protein becomes comparatively rigid and adopts a conformation that, at 
low-resolution, appears symmetrical upon interaction with PmScsBα. Specifically, the pair-
distance distribution function is bimodal (Figure 4.8A, green curve) with two well defined 
peaks, and similar to the p(r) generated from the extended symmetrical crystal structure 
(PDB: 5ID4) (Figure 4.8A, black dashed curve) (175). An asymmetric arrangement of the 
PmScsC trimer would yield an asymmetric shaped second peak in the p(r), while 
significant flexibility would see this same peak broaden. 
 
Analysis of the SANS data showed that a plot of I(0) (the scattering intensity at zero-angle) 
normalised by protein concentration versus deuterium content of the solvent was well 
represented by a parabolic function indicating the samples were pure (Figure 4.8B). A 
Stuhrmann plot revealed that the DPmScsBα C114A molecule was located towards the 
centre of the complex (Figure 4.8C). A rigid body model of the complex was optimised 
simultaneously against the SAXS data set and five SANS contrast variation data sets. The 
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resulting model provided an excellent fit to all of the scattering data (Figure 4.9A). The 
configuration adopted by PmScsBα and PmScsC in the model precludes the simultaneous 
binding of two (or three) PmScsBα molecules to PmScsC, helping to explain the 
preferential formation of a trimer:monomer complex (Figure 4.6). The model also highlights 
two potential interfaces between PmScsC and PmScsBα (Figure 4.9A). The most obvious 
interface is that between chain A of PmScsC and subdomain A of PmScsBα for which the 
intermolecular disulfide bond is modelled. The resolution of the model is too low to be 
definitive, but the interface includes residues that could form hydrogen bond interactions. 
The second interface is between chain A of PmScsC and subdomain B (the second 
immunoglobulin domain) of PmScsBα.  
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Figure 4.7: SAXS/SANS scattering curves. SAXS and SANS data (offset for clarity) 
collected from the 3:1 PmScsC C87S-DPmScsBα C114A complex with the model 
scattering curves overlaid (solid black line): 0% (χ2 = 1.16, red, on absolute scale); 20% 
(χ2 = 1.20, grey, offset by a factor of 50-1); 42% (χ2 = 1.00, blue, offset by a factor of 50-2); 
80% (χ2 = 1.11, cyan, offset by a factor of 50-3); 100% (χ2 = 0.86, green, offset by a factor 
of 50-4); X-ray (χ2 = 1.80, orange, offset by a factor of 50-5). A Guinier plot for the SAXS 
data is shown is shown in the inset. The match point of PmScsC C87S is ~42% D2O (blue) 
where DPmScsBα C114A dominates the scattering, while the match point of DPmScsBα 
C114A is ~100% D2O (green) where PmScsC C87S dominates the scattering. 
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Figure 4.8: Other SAXS/SANS results. A. Pair-distance distribution profile, p(r), derived 
from the experimental X-ray scattering data (orange), and the 100% scattering data 
(green), which should approximate the p(r) for PmScsC C87S alone. The p(r) derived from 
the extended crystal structure (PDBID: 5ID4) is shown as a black dotted line for reference. 
B. A plot of I(0) normalised by concentration as a function of D2O content of the supporting 
solvent. The plot is parabolic in shape and reveals that the match-point of the entire 
complex is 59% D2O (vertical dotted line). C. Stuhrmann plot for the 3:1 PmScsC 
C87S-DPmScsBα C114A complex, conforming to Rg
2 = Rm
2 + αΔρ-1- βΔρ-2, where Rm is the 
radius of gyration of that object with homogenous contrast, and α and β are related to the 
contrast variations within the object. The values obtained from a fit to the plot (solid black 
line) are: Rm = 37.5 ± 0.4; α = -210 ± 50; and β = 520 ± 100. The negative value of α 
reveals that the region with higher contrast (i.e. DPmScsBα C114A) lies towards the centre 
of the molecule. D. The composite scattering functions determined from the neutron 
contrast variation data. The I11 curve (green, left y-axis) corresponds to scattering from 
PmScsC C87S, the I22 curve (blue, left y-axis) corresponds to scattering from DPmScsBα 
C114A, and the I12 curve (grey, right y-axis) is related to the arrangement of DPmScsBα 
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C114A relative to PmScsC C87S. Ihomogeneous = I11 + I22 + I12 (red, left y-axis) is the scattering 
curve of an object with the same shape as the PmScsC C87S-DPmScsBα C114A complex, 
but with homogeneous contrast, and is used for estimating the Porod volume and 
molecular mass from the SANS data. 
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Table 4.2: SAS data collection and analysis details for the PmScsC-PmScsBα 
complex. 
Data Collection Parameters SAXS SANS 
Instrument SAXS-WAXS  
(Australian Synchrotron) 
QUOKKA 
(ANSTO) 
Beam geometry Point Point 
Wavelength (Å) 1.033 5.00 
Sample to detector distance (m) 2.680 2.000 (short) 
10.000 (long) 
q-range (Å-1) 0.007 – 0.35 0.03 – 0.40 (short) 
0.01 – 0.09 (long) 
Exposure time (s) 13 (13 × 1 s exposures) 0%S: 7200; 20%S: 10800; 
42%S: 21600; 80%S: 7200; 
100%S: 3600; 0%B: 10800; 
100%B: 7200 
Measurement type Concentration series from 
96-well plate, 1.0 mm 
quartz capillary 
Neutron contrast variation, 
Hellma 120-QS 1.0 mm 
quartz cells 
Protein concentration range (mg/mL) 0.56 – 4.50 - 
Temperature (K) 283 289 
Absolute intensity calibration Water Incident beam intensity 
Sample details   
Extinction coefficient (A280, 0.1% w/v) 0.979 0.979 
Partial specific volume (cm3g-1) 0.737 0.737 
Contrast, Δρ (1010 cm-2) 2.86 3.36 (0%); 2.23 (20%); 1.10 
(42%); -1.17 (80%); -2.30 
(100%) 
Molecular mass [from sequence] (kDa) 105.5 105.5 
Protein concentration (mg/mL)* 0.56 5.30 (0%S); 5.20 (20%S); 
5.10 (42%S); 5.00 (80%S); 
4.90 (100%S) 
Structural parameters   
I(0) (cm-1) [from Guinier] 0.04060 ± 0.00010 - 
Rg (Å) [from Guinier] 39.2 ± 0.2 - 
I(0) (cm-1) [from p(r)] 0.04026 ± 0.00010 0.5020 ± 0.0019    (0%) 
0.2217 ± 0.0013  (20%) 
0.0357 ± 0.0007  (42%) 
0.0561 ± 0.0008  (80%) 
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0.2211 ± 0.0010 (100%) 
Rg (Å) [from p(r)] 38.7 ± 0.1 36.3 ± 0.2    (0%) 
34.6 ± 0.3  (20%) 
24.3 ± 1.1  (42%) 
35.6 ± 0.5  (80%) 
37.0 ± 0.2 (100%) 
Dmax (Å) 115 ± 3 110 ± 3 
Porod volume (Å3) 131300 ± 7000 116000 ± 6000† 
Molecular mass determination   
Molecular mass [from I(0)] (kDa) 97 ± 5 95 ± 5† 
Molecular mass [from Porod] (kDa) 108 ± 5 95 ± 5 
* I(0) = 0.0854 ± 0.0002 cm-1, Rg = 39.0 ± 0.1 Å, M = 103 ± 5 kDa (1.13 mg/mL); I(0) = 0.1779 ± 0.0002 cm-1, 
Rg = 39.0 ± 0.1 Å, M = 107 ± 5 kDa (2.25 mg/mL); I(0) = 0.3476 ± 0.0003 cm-1, Rg = 38.8 ± 0.1 Å, 
M = 105 ± 5 kDa (4.50 mg/mL). There is a small systematic change in Rg but no systematic change in M, 
thus it was deemed that the complex is largely free of concentration dependent effects up to a concentration 
of ~5.0 mg/mL. † The Porod volume calculation is not valid for systems where the Δρ of the particle is not 
homogeneous (such as is the case for the neutron contrast variation experiment reported here). Instead, the 
composite scattering functions (Figure 4.8D) were summed together to give the scattering curve of the 
protein complex with homogeneous contrast (i.e. Ihomogeneous = I11 + I22 + I12), and the Porod volume was 
determined from this curve. The molecular mass derived from the I(0) was also taken from this curve. 
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Figure 4.9: Binding sites in the PmScsC-PmScsBα SANS model and EcDsbC-
EcDsbDα structure (PDB: 1JZD). A. Model of the 3:1 complex generated from the 
SAXS/SANS data, shown in backbone and surface representation. PmScsBα binds to one 
PmScsC (green) protomer with both subdomain A (purple, site 1) and B (magenta, site 2). 
B. Crystal structure of the EcDsbC-EcDbsDα complex. EcDsbDα (purple) binds to both 
protomers of EcDsbC (green, binding sites 1 and 2). In both A and B, the catalytic 
cysteines involved in the intermolecular disulfide bond between the partner proteins are 
shown as orange spheres.  
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4.5 Discussion 
Suppressor of copper sensitivity proteins play a role in the response to copper stress of 
the important human pathogens S. Typhimurium and P. mirabilis (120,175). At least two of 
the four Scs proteins are homologues of Dsb proteins (111), which are essential for the 
correct formation of disulfide bonds in virulence factors of many Gram-negative bacteria 
(16,30,193,194). P. mirabilis ScsC was recently shown to be a trimeric, highly dynamic 
disulfide isomerase (175). The present study aimed to characterise PmScsBα - the 
predicted interaction partner of PmScsC - and investigate the nature of the interaction 
between the two.  
 
The domain architecture of full-length ScsB resembles that of E. coli DsbD, the major 
difference being the size of the periplasmic N-terminal domain. This difference suggested 
that ScsBα would be structurally distinct from DsbDα perhaps because they interact with 
different substrates. We confirmed that PmScsC and PmScsBα are redox partners, and 
are therefore functionally similar to EcDsbC and EcDsbDα. We also reported the structure 
of PmScsBα, showing that it consists of two immunoglobulin-like folds connected by an α-
helix. The structures of the two immunoglobulin-like subdomains of PmScsBα are broadly 
similar with the exception that subdomain A has a catalytic CXXXC motif, as well as a β-
hairpin and extended loop that both cover the CXXXC active site. The positioning of the β-
hairpin and the loop could potentially shield the active site from non-specific interactions or 
facilitate interactions with partner proteins. Unexpectedly, we found that domain A of 
PmScsBα shares the same features of the immunoglobulin fold of EcDsbDα (Figure 4.4, 
RMSD: 2.5 Å, 103 residues aligned) - despite a sequence identity of just 12%. The key 
difference between the structures of subdomain A and EcDsbDα is that EcDsbDα lacks 
the β2-β3 loop of PmScsBα. This β2-β3 loop is conserved in S. Typhimurium and C. 
crescentus ScsBα suggesting that it plays a key functional role. A residue that is 
conserved across the three ScsBαs and EcDsbDα is Tyr45 (PmScsBα numbering). In 
EcDsbDα, the equivalent Tyr42 hydroxyl is thought to be involved in nucleophilic attack of 
Cys103, which resolves the intermolecular disulfide formed between EcDsbDα and its 
substrate (e.g. EcDsbC) (61). The nucleophilic attack in EcDsbDα is proposed to also 
require Asp68 (61), a residue that is not conserved in Pm, Cc or StScsBα. It is unclear 
from the PmScsBα structure what residue, if any, might play an equivalent role to Asp68. 
 
The discovery of tandem immunoglobulin-like folds in PmScsBα raises the question as to 
the function of the second or non-catalytic immunoglobulin-like fold. EcDsbDα has a single 
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immunoglobulin-like fold, which, in the E. coli DsbC-DsbDα crystal structure, spans the 
central cleft of the V-shaped DsbC substrate to interact with both domains of the disulfide 
isomerase (Figure 4.9B) (47). This binding mode is thought to favour binding to dimeric 
EcDsbC; EcDsbDα is unable to interact with monomeric EcDsbC (44,47). By comparison, 
the SANS-derived model of the PmScsC-PmScsBα complex suggests that PmScsBα 
subdomain A interacts with just one of the three PmScsC protomers in the trimer. 
Subdomain B of PmScsBα forms a secondary binding site to PmScsC that may stabilise 
the primary interaction or add specificity (Figure 4.9A). Subdomain B could also be 
required for interactions with other proteins that have yet to be identified.  
 
EcDsbC-EcDsbDα is the redox relay complex formed between dimeric EcDsbC and 
monomeric EcDsbDα. The crystal structure revealed a 2:1 (rather than a 2:2) complex 
between the dimer of EcDsbC and a monomer of EcDsbDα (44,47). On this basis, we 
hypothesised that PmScsC-PmScsBα would form a 3:1 complex between trimeric 
PmScsC and monomeric PmScsBα, and the SANS structure of the complex appears to 
preclude higher stoichiometry. Nevertheless, we did find in vitro evidence suggestive of 
PmScsC forming 3:2 and 3:3 complexes with PmScsBα (Figure 4.6A), showing that 
different arrangements might form with PmScsBα in the absence of the PmScsB β and γ 
domains. We expect that these higher order complexes would not form in the context of 
full-length PmScsB.  
 
How do our findings on PmScsBα and PmScsC inform on interactions between ScsC and 
ScsB in other organisms? A functional interaction between ScsC and ScsB has already 
been reported for C. crescentus (118). With two examples now confirmed, the ScsB-C 
redox relay system is likely to be present in all organisms that encode the 4-gene scs 
cassette. However, there is likely to be a wide diversity of interactions. ScsC is reported to 
be monomeric for StScsC (120), dimeric for CcScsC (118), and trimeric for PmScsC (175). 
By contrast, ScsB shares similar features across the same organisms suggesting that 
StScsBα and CcScsBα both incorporate the tandem immunoglobulin-fold arrangement 
present in PmScsBα. As indicated above, both subdomains of PmScsBα interact with one 
PmScsC protomer, suggesting that this tandem immunoglobulin fold arrangement could 
facilitate the interaction with ScsCs regardless of the ScsC oligomeric state. Future studies 
will be needed to establish whether it is the tandem immunoglobulin-fold architecture that 
permits interactions with monomeric, dimeric and trimeric PmScsCs. Curiously, a BLAST 
search of E. coli DsbD or S. Typhimurium DsbD against the P. mirabilis genome did not 
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identify any hits, suggesting the possibility that PmScsB may also act as the redox partner 
for P. mirabilis DsbC proteins.  
 
4.6 Experimental procedures 
4.6.1 Sequence analysis 
The TMHMM Server v. 2.0 was used to determine the region of the ScsB proteins that 
formed the N-terminal periplasmic domain. EMBOSS Needle (195,196) with residues 1-
275, 1-279 and 1-290 of UniProt entries B4EV20 (PmScsB), AAL20046 (StScsB) and 
Q9ABL0 (CcScsB), respectively, was used to calculate the sequence identities reported 
between these proteins. The DALI sever (192) was used to calculate RMSDs and structure 
based sequence identities. Coot (156) was used to create visuals of the structural 
alignments. The sequences of all four proteins were aligned using PROMALS3D (197) 
with the PDB files of PmScsBα and EcDsbDα (1JPE) instead of the sequence alone. 
Residue numbers quoted in the text were taken from the deposited PDB files for the 
PmScsC and PmScsBα protein structures, which are numbered based on the TEV cleaved 
protein sequence (starting S1N2A3…). 
 
4.6.2 Molecular Biology 
A codon-optimised gene encoding P. mirabilis ScsBα without the predicted signal peptide 
(UniProt ID: B4EV20, residues 21-275, Integrated DNA Technologies) was inserted into 
pMCSG7 (198) using ligation independent cloning. The PmScsC (UniProt ID: C2LPE2/ 
B4EV21) construct used throughout this study was created previously (175). The 
constructs for the variants PmScsC C87S and PmScsBα C114A were created using the 
QuikChange® Lightning Site-Directed Mutagenesis Kit (Agilent Technologies). The wild-
type PmScsC and PmScsBα constructs were used as templates and primers 5’-
gcggatcgaaacgtttagagtacgggcaattatag-3’, 5’-ctataattgcccgtactctaaacgtttcgatccgc-3’ and 5’-
gtcagaatgcatacattgctagcggtactcaatgtaaggacacc-3’,  
5’-ggtgtccttacattgagtaccgctagcaatgtatgcattctgac-3’, respectively, were used to introduce 
the point mutations. PmScsBα was also subcloned into pET24a for deuterated bioreactor 
expression, using restriction enzymes EcoRI and NdeI. All constructs contained an N-
terminal His6 tag followed by a TEV protease cleavage site and were confirmed by 
sequencing. 
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4.6.3 Protein production 
Except for the selenomethionine labelled PmScsBα and deuterated PmScsBα C114A, all 
proteins were expressed and purified as outlined previously (175). The redox state of the 
cysteines was confirmed spectrophotometrically with 5,5-dithio-bis-(2-nitrobenzoic acid) 
(DTNB or Ellman’s reagent) as described previously (199). Yields for PmScsC and 
PmScsBα derivatives were around 80 mg and 40 mg per litre of culture (~15 g cell weight 
harvested), respectively. SDS-PAGE (NuPAGE® system, 4-12% BisTris gel, Invitrogen, 
Australia) with Coomassie blue stain was used to assess the protein quality.  
 
4.6.4 Expression of SeMet labelled PmScsBα 
To express selenomethionine (SeMet) labelled PmScsBα, needed for experimental 
phasing in crystallographic structure determination, a 10 mL starter culture of E. coli BL21 
(DE3) pLysS cells containing pMCSG7-PmScsBα was grown in LB media supplemented 
with the appropriate antibiotics at 37°C for 4-5 h, 220 rpm. This culture was then used to 
inoculate 1L of M9 minimal media supplemented with antibiotics and amino acids (100 mg 
of L-methionine, L-lysine, L-threonine, L-phenylalanine and 50 mg of L-leucine, L-
isoleucine, L-valine), which was incubated overnight at 37°C, 220 rpm. Cells were 
harvested from the overnight culture, washed with 1L of sterile water and resuspended in 
water to an OD600 of ~1. M9 minimal media containing antibiotics but no amino acids was 
then inoculated with the cells to a final OD600 of 0.1. The cells were cultured at 30°C, 220 
rpm for 6-8 h, until an OD600 of 0.5 was reached. Amino acids, including 100 mg of L-
selenomethionine instead of L-methionine, were then added to the culture flasks and after 
15 min at 30°C, IPTG was added to a final concentration of 1 mM to induce expression. 
The cultures were incubated at 30°C, 220 rpm overnight. Cells were harvested and the 
protein was purified as described previously (175) with the addition of 5 mM DTT to all 
purification buffers. Yield of SeMet labelled PmScsBα was 5 mg per litre of culture (~5 g of 
cell pellet). 
 
4.6.5 Expression of Deuterated PmScsBα C114A 
Deuterated PmScsBα C114A was expressed for the small-angle neutron scattering 
(SANS) analysis of the complex between PmScsC C87S and PmScsBα C114A. The 
deuterated protein PmScsBα C114A was produced at the National Deuteration Facility, 
Australian Nuclear Science and Technology Organisation in 1 L “ModC1” media (200) 
containing 90% D2O v/v and unlabelled glycerol (40 g/L). Miniprep plasmid DNA “pET24a-
PmScsBα C114A” was used to transform 50 µL of Invitrogen competent BL21*(DE3) cells, 
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which were then incubated with 250 µL of SOC media for 2 h. The 300 µL culture was 
added to 10 mL of ModC1 media containing 50% D2O, and 40 µg/mL kanamycin, shaking 
at 200 rpm, 37 °C. After 16 h (OD600, 1.2), 9 mL was added to 36 mL fresh media with 
kanamycin at 100% D2O (i.e. 45 mL at 90% D2O). After another 5 h (OD600, 0.9), the 
culture was diluted with fresh 90% D2O media to 102 ml.  After another 5 hours, 100 mL 
(OD600, 0.87) was used to inoculate 900 mL of fresh media 90% D2O with kanamycin in a 
2L Real Time Engineering bioreactor, aerated with air at 0.5 L/min, and with pH held to a 
minimum of 6.2 by addition of 28% NH4OH in H2O (Sigma). Dissolved oxygen tension was 
set to 75% and was above 60% throughout. At OD600 = 14.2, the temperature was 
lowered to 20°C and expression was induced by the addition of 1 mM IPTG. At 17 h post-
induction, with OD600 = 32, the culture was harvested with a wet weight yield of 79.4 g, 
and with excellent expression evident by SDS-PAGE. The deuteration level was 
determined by partial trypsin digest MALDI-TOF comparison of unlabelled and labelled 
samples and was found to be 70.8%. Deuterated PmScsBα C114A was purified as 
described for the unlabelled protein, except the His6-tag was not cleaved, as it was needed 
for the purification of the complex. The yield of purified deuterated PmScsBα was ~240 mg 
per one litre of bioreactor culture (~40 g of cell pellet). 
 
4.6.6 Determination of protein concentration 
The reported protein concentrations were determined using the A280 of the sample (read 
using a Thermoscientific NanoDrop 2000c spectrophotometer) and calculated extinction 
coefficients from ProtParam (140).  
 
4.6.7 Crystal structure of PmScsBα 
A number of conditions from commercial screens resulted in PmScsBα crystals. These 
conditions were replicated in 24-well plates and the best diffracting SeMet labelled 
PmScsBα crystals were obtained in a drop containing 1 µL 43 mg/ml protein in 10 mM 
HEPES pH 7.4, 5 mM DTT and 1 µL of 0.1 M MES monohydrate pH 6, 6% v/v tacsimate 
pH 6 and 24% PEG4000. A commercial additive screen (Hampton Research) was used to 
optimise crystals and those grown over 2 days to ~400 µm with the addition of 4% 2,5-
hexanediol or 4% 1,3-butanediol resulted in the best diffraction. Crystals were 
cryoprotected in the crystallisation condition plus 20% glycerol and flash frozen in liquid 
nitrogen.  
Due to the lack of a suitable model for molecular replacement, experimental phasing was 
required to solve the crystal structure of PmScsBα. A fluorescence scan was used to 
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determine the absorption edge of SeMet labelled crystals and a data set (Table 4.1) was 
collected near the peak absorption wavelength (0.9786) at 100 K. Data processing in 
autoPROC (159), which utilises XDS (151) and AIMLESS (152), determined the space 
group to be P212121. SAD phasing using the SHELX workflow (201) in HKL2MAP (202) 
found 14 Se sites with an occupancy > 0.2. We expected only 12 Se sites - the extra two 
sites were positioned very close to other sites, suggesting alternate conformations, though 
only one SeMet was modelled that way in the final structure. SAD phasing resulted in an 
initial incomplete alanine model of the protein structure (FOM 0.42). This initial model was 
then used for molecular replacement against the same data in Phaser (155) in the CCP4 
suite (160). Two rounds of automated building and refinement using BUCCANEER (161) 
with REFMAC (158), as implemented in CCP4 (160), completed the structure, revealing 
three molecules in the asymmetric unit. Then several rounds of manual adjustment in 
COOT (156) and refinement in PHENIX (154) were performed, with reference to the 
validation program MolProbity (164). Multiple residues in the crystal structure have 
alternate conformers and occupancies of the selenium atoms in the SeMet residues were 
all <1.0. The electron density for some loop regions is poor in chains B and C, particularly 
residues 79-82, 99-100 and 51-52 (Chain B only). R/Rfree values are 17.3% and 19.8% at 
a resolution of 1.54 Å. All structural figures were made in PyMOL (203). 
 
4.6.8 Redox interaction assay 
To confirm the redox interaction between PmScsC and PmScsBα, oxidised PmScsC and 
reduced PmScsBα were incubated together at final concentrations of 10 µM in 100 mM 
sodium phosphate pH 7, 1 mM EDTA for 2 h. As controls, oxidised and reduced forms of 
both proteins, a sample containing reduced PmScsC and oxidised PmScsBα and a sample 
with oxidised PmScsC with PmScsBα C114A were also incubated for 2 h. All samples 
were then treated with 10% TCA to precipitate the protein, and after centrifugation, the 
pellets were washed with 100% cold acetone and dried. The protein pellets were 
resuspended in a solution of 200 µM 4-acetamido-4′-maleimidylstilbene-2,2′-disulfonic acid 
(AMS) in 1% SDS, 50 mM Tris pH 7.0. AMS binds to the reduced cysteines of proteins, 
increasing the molecular weight and allowing the differentiation between the oxidised and 
reduced forms of a protein when run on a gel. Therefore, all samples were run on a non-
reducing, non-denaturing 12% NuPAGE Bis-Tris gel for 2.5 h at 100V. The gel was 
Coomassie stained and imaged using an Odyssey® Fc Imaging system (LI-COR® 
Biosciences) with the 700 nm channel.  
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4.6.9 RNaseA isomerase assay 
To determine whether PmScsBα activates the isomerase PmScsC, an isomerase assay 
utilising scrambled RNaseA (scRNaseA) and the RNase A model substrate, cytidine 2’:3’-
cyclic monophosphate (cCMP) was performed. Bovine RNase A (purchased from Sigma-
Aldrich) was scrambled as previously described (170). The various oxidised and reduced 
protein samples described above for the gel-shift redox interaction assay were again 
prepared but with the addition of 40 µM scRNase A to each sample. After 2 h, 50 µL of the 
protein/scRNase A reactions was taken and added to 150 µL of 4 mM cCMP in a UV-star 
96-well plate (Greiner Bio-One, Austria).  The increase in absorbance at 296 nm was 
monitored over 3 min with a Synergy H1 multimode plate reader (BioTek, USA) and used 
to calculate the rate of cCMP hydrolysis. Native RNase A and scRNase A only samples 
were included as controls and used to determine the relative activity of the RNase A in 
each sample. The results shown are the average and standard deviation of 3 technical 
replicates. 
 
4.6.10 Complex formation 
The PmScsC and PmScsBα cysteine variants were designed following the same approach 
used for the EcDsbC:EcDsbDα interaction (47). Mutation of cysteines in EcDsbC and 
EcDsbDα resulted in a stable complex between the two proteins (44).  Cysteines C87 of 
PmScsC and C114 of PmScsBα are the least accessible of the two cysteines in each 
active site, suggesting they facilitate resolution of intermolecular disulfide bonds. Variants 
PmScsC C87S and PmScsBα C114A were therefore prepared and used in complex 
formation studies.  
The 3:1 PmScsC C87S:PmScsBα C114A complex was formed by mixing the two proteins 
together in a 3:1 ratio at concentrations of approximately 200 mg/ml and incubating the 
mixture at 37°C for 3 days. To separate the complex and free PmScsBα from PmScsC, 
PmScsBα was left His-tagged and the protein mixture was then run over 2 mL of fresh 
TALON resin, twice. Columns were washed with 25 mM Tris pH 7.4, 150mM NaCl and the 
complex and free PmScsBα were eluted with 25 mM Tris pH 7.4, 150mM NaCl, 250 mM 
imidazole. This was then run over a Superdex 200 10/300 Increase size exclusion column 
on an ÅKTA system to separate PmScsBα from complex. A peak on SEC eluted earlier 
than for ScsC, suggesting that a complex between the two proteins had formed (Figure 
4.6A). Running the fractions from the peak corresponding to the 3:1 complex on non-
reducing SDS-PAGE resulted in three bands (Figure 4.6B). The lower bands correlated to 
free PmScsC C87S (24.8 kDa) and a small amount of PmScsBα C114A (30.3 kDa) and 
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the upper band corresponded to the molecular weight of one PmScsC C87S molecule 
bound to one PmScsBα C114A molecule (55.1 kDa). The upper band dissociated when 
reducing agent was added, leaving two bands correlating to monomeric PmScsC C87S 
and PmScsBα C114A, in an approximate 3:1 ratio (Figure 4.6B). There was also evidence 
for the formation of small amounts of complex containing PmScsC C87S and PmScsBα 
C114A in ratios of 3:3 and 3:2 but only those SEC fractions containing 3:1 complex were 
collected for further analysis. The complex formation process was repeated multiple times 
to gain enough sample for SAXS/SANS analysis as the overall yield of 3:1 complex was 
~2.5%. 
 
4.6.11 Small-angle solution scattering 
Small-angle neutron scattering data shown in Table 4.2 were collected on the QUOKKA 
instrument at the Australian Nuclear Science and Technology Organisation (Table 4.2) 
(204). Two aliquots of PmScsC C87S-DPmScsBα C114A complex at ~5 mg/mL were 
dialysed – one against a buffer with a D2O content of 0% and the other against a buffer 
with a D2O content of ~100%. Samples with D2O contents of 20%, 42%, and 80% were 
obtained by mixing the two original solutions and the appropriate ratios. The two-
dimensional data were normalised to a common incident neutron count and corrected for 
sample transmission, background radiation, empty cell scattering, detector sensitivity and 
radially averaged to produce I(q) vs. q profiles. Scattering data from the two different 
sample-detector distances were then merged and buffer scattering data were then 
subtracted from the protein + buffer data to give the protein scattering profiles (the 20%, 
42%, and 80% buffer scattering curves were taken as a linear combination of the 0% and 
100% buffer scattering curves). To correct for the effects of incoherent scattering by 1H-
rich samples, backgrounds levels were adjusted by a small constant such that the high-q 
scattering displayed q−4 dependence. 
Small-angle X-ray scattering data were collected on the SAXS-WAXS beamline at the 
Australian Synchrotron (Table 4.2) (142). Serial dilutions of the stock solution of PmScsC 
C87S-DPmScsBα C114A complex were made to give four concentrations between 0.55 
and 4.5 mg/mL that were centrifuged at 10,000 × g immediately before loading into a 96-
well plate. To reduce radiation damage, samples (~100 µL) were drawn into a capillary 
from the 96-well plate and flowed past the beam. All measured two-dimensional data were 
averaged and corrected for sample transmission, solvent scattering, detector sensitivity, 
and radially averaged to produce I(q) vs. q profiles using Scatterbrain (v 2.7.1) (143). 
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The estimated molecular masses were calculated using values for contrast and partial 
specific volume predicted from the protein sequence using MULCh (v 1.1) (145). Data 
processing and Guinier analysis was performed using Primus (v 3.2) (185). The pair-
distance distribution function, p(r), was generated from the experimental data using GNOM 
(v 4.6) (4), from which I(0), Rg and Dmax were determined. For the SANS data, analysis of 
the dependence of Rg upon contrast, and calculation of the composite scattering functions, 
was also calculated using MULCh (Figure 4.8D). Co-refinement of a rigid-body model 
against SANS and SAXS data was performed using SASREF (v 7.d) (205) where the 
crystal structure of PmScsC (PDB: 4XVW – Chain A) was broken into three rigid sections: 
1) residues A3 – Q43 that were fixed as to preserve the structure of the trimerisation 
domain observed in the crystal structure; 2) residues Q44 – F47 were defined as a short 
linker with a restraint between residues Q43 and Q44 to keep them in close proximity; 3) 
residues R48 – K224 were defined as the catalytic domain free to move with a restraint 
between residues F47 and R48 to keep them in close proximity. The additional PmScsC 
chains were generated by symmetry (assuming a C3 point group). The crystal structure of 
PmScsBα (residues A2 – A248) was included in the optimisation with a distance restraint 
between C84 of a PmScsC monomer and C118 of PmScsBα of 8 Å. Thus, while the 
complex overall is not symmetrical, the PmScsC portion of the model possesses 3-fold 
symmetry. The optimisation was run 16 times and the model that provided the best global 
fit to the scattering data is reported here, however, all models obtained are similar in 
structure. 
 
4.7 Footnotes 
The atomic coordinates and structure factors of PmScsBα have been deposited in the 
Protein Data Bank under the ID # 6C29. SAXS/SANS data and model of the 3:1 PmScsC-
PmScsBα complex have been submitted to SASBDB under the ID # SASDC48. 
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5. Expression and Purification of PmScsB 
 
5.1 Introduction 
Thus far this thesis has described the characterisation of the trimeric disulfide isomerase 
PmScsC, the structure of PmScsBα and the interaction between these two proteins. The 
next logical step is the investigation of the full-length transmembrane protein, PmScsB, 
including the PmScsBβ and γ domains. ScsB was found to be essential for growth in 
Caulobacter crescentus and the same study reported three substrates of CcScsB (118). 
No biochemical or structural studies of the whole transmembrane protein have been 
performed, though bioinformatic analyses identified that ScsB proteins form a class within 
the DsbD superfamily (118). 
 
5.1.1 DsbD  
DsbD from E. coli has been well characterised and functions as a transmembrane electron 
transporter, providing reducing power to the oxidative environment of the periplasm (56). 
DsbD consists of three domains, DsbDα, DsbDβ and DsbDγ and each domain contains 
two redox-active cysteines that are essential for its electron transporting activity (Figure 
5.1) (57,58). DsbDα is the N-terminal periplasmic domain and has an immunoglobulin-like 
fold (47,61). DsbDβ is the transmembrane region that consists of 8 predicted 
transmembrane helices, with the two catalytic cysteines on transmembrane helices 1 and 
4 (58). DsbDγ has a thioredoxin fold and is the C-terminal periplasmic domain (63).  
 
E. coli DsbD (EcDsbD) is embedded in the inner membrane and transports electrons from 
the cytoplasm to the periplasm through a disulfide exchange cascade (59,191) (Figure 
5.1). Unlike other electron transporters it does not rely on a cofactor for activity (206). The 
disulfide exchange cascade begins in the cytoplasm with NADPH-dependent thioredoxin 
reductase reducing thioredoxin, which in turn reduces the catalytic cysteines in EcDsbDβ 
(48). Transmembrane helices 1 and 4 of EcDsbDβ are suggested to be in an inverted 
pseudo-symmetrical arrangement that forms an hourglass shaped cavity enabling the 
catalytic cysteines to be accessed from either side of the membrane (Figure 5.1 inset) 
(65,66). This arrangement allows thioredoxin to reduce the catalytic cysteines from the 
cytoplasmic side of the membrane and the reducing power to be passed onto the mobile 
arm-like domain EcDsbDγ (63) on the periplasmic side of the membrane (59,65,66). 
EcDsbDγ then reduces EcDsbDα, which in turn interacts with different substrates to 
reduce their cysteines (59). The known substrates of EcDsbD include, EcDsbC, EcDsbG 
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and EcCcmG (44,56,59,68), all of which have thioredoxin folds each with two catalytic 
cysteines that need to be reduced for activity (39,70,124). EcDsbC is responsible for the 
isomerisation of disulfide bonds in periplasmic proteins (53), EcDsbG protects single 
cysteines of periplasmic proteins from oxidation to sulfenic acid (67) and EcCcmG is 
involved in cytochrome c biogenesis (69). 
 
 
Figure 5.1:  EcDsbD structure and function. The schematic depicts the disulfide 
exchange cascade that allows the transfer of electrons from the cytoplasm to the 
periplasm. The inset figure depicts the inverted pseudo-symmetrical arrangement of 
transmembrane (TM) helices 1 and 4. 
 
To date, crystal structures have been solved of the α- (PDB ID: 1JPE/1L6P) (47,61) and γ-
domains (PDB: 1UC7) (63) of EcDsbD, the complex between EcDsbDα and -γ (PDB ID: 
1VRS) (64) and the complex between EcDsbDα and substrates (PDB: 1JZD, 1Z5Y) 
(47,125) (Figure 5.2 A-E). The structure of the full-length transmembrane protein, 
however, remains elusive. Two NMR structures of the EcDsbD homologue, CcdA (207), 
from Archaeoglobus fulgidus (PDB ID: 2N4X) (208) and Thermus thermophilus (PDB ID: 
5VKV) (209) have been solved (Figure 5.2 F,G). CcdA is the simplest form of the electron 
transporter, consisting only of 6 transmembrane helices, whereas EcDsbDβ is predicted to 
have 8 transmembrane helices. The two NMR structures that have been solved are 
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substantially different from each other, despite high sequence similarity (29% identity, 60% 
similarity) (208,209) raising questions as to how applicable the findings are to EcDsbDβ. 
The T. thermophilus structure, however, is more consistent with the results from solvent 
accessibility assays involving EcDsbD (209). Interestingly, both studies propose four-state 
mechanisms, throughout which CcdA undergoes significant conformational changes to 
pass the reducing power from thioredoxin in the cytoplasm to thioredoxin-like proteins in 
the periplasm (208,209). 
 
Figure 5.2: Structures of CcdA and the soluble domains of EcDsbD and their 
interactions. A. Crystal structure of EcDsbDα (PDB ID: 1JPE). B. Crystal structure of 
EcDsbDγ (PDB: 1UC7). C. Crystal structure of the complex between EcDsbDα (cyan) and 
EcDsbDγ (dark pink) (PDB: 1VRS).  D. Crystal structure of the complex between the N-
terminal domain of EcCcmG (dark green) and EcDsbDα (cyan) (PDB: 1Z5Y). E. Crystal 
structure of the complex between EcDsbC (light green) and EcDsbDα (cyan) (PDB: 1JZD). 
NMR structures of CcdA from F A. fulgidus (PDB ID: 2N4X) and G T. thermophilus (PDB 
ID: 5VKV). In all structures, orange spheres represent the positions of the catalytic 
cysteines. 
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5.1.2 PmScsB 
Unlike CcdA, the predicted architecture of PmScsB is very similar to EcDsbD (210) with 
PmScsB predicted to have both periplasmic domains separated by 8 transmembrane 
helices (Figure 5.3). The major difference is the structure of the N-terminal or α- domain 
which, (as described in chapter 4), consists of two immunoglobulin-like folds in PmScsBα 
and only one in EcDsbDα. I used Phyre2 (211) to produce a homology model of the 
PmScsBγ domain and this model contains a thioredoxin fold like EcDsbDγ (63). Each 
domain of PmScsB also has a predicted redox active cysteine pair.  
 
Given the predicted structural similarities between EcDsbD and PmScsB, we hypothesise 
that PmScsB will also transport electrons like EcDsbD. Functionally and structurally 
characterising PmScsB will provide more information about the diversity of membrane 
electron transporters and improve our understanding of the Scs proteins. The first step 
towards the characterisation of PmScsB is to develop an expression and purification 
protocol to produce high yields of the purified protein. This chapter describes the work 
performed towards achieving this goal. 
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Figure 5.3: PmScsB. The crystal structure of PmScsBα (purple, PDB ID: 6C29) has two 
immunoglobulin-like folds. Topology prediction using CCTOP (210) suggests PmScsBβ 
consists of eight transmembrane α-helices. The homology model of PmScsBγ, which I 
generated using Phyre2 (211), contains a thioredoxin fold. The topology diagram of 
PmScsBβ was made in Protter (212).  
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5.1.3 Membrane proteins 
Working with membrane proteins presents many challenges. They are often poorly 
expressed, unstable and insoluble in aqueous solutions therefore requiring detergents to 
enhance their stability. Generally they are not as easily crystallised as soluble proteins and 
the limited number of membrane protein structures available in the Protein Data Bank 
(PDB) exemplifies this. As of the 16th of July 2018, only 3.4% of all PDB structures were 
membrane proteins (www.rcsb.org). Membrane proteins have very important biological 
roles however, and represent the largest class of drug targets (213,214). This highlights 
the need for more research on the structural and functional characterisation of these 
proteins. To enable this, specific methods and reagents have been developed to assist 
with membrane protein expression, purification and crystallisation.  
 
One key development has been the membrane protein overexpression and purification 
pipeline developed by Drew et al. (215-217) that utilises Green Fluorescent Protein (GFP). 
By tagging membrane proteins with GFP, they can be more easily tracked throughout 
expression and purification, making screening and optimisation much more efficient 
(Figure 5.4). The combination of fluorescence detection and size-exclusion 
chromatography (FSEC) allows the monodispersity of the protein in detergent to be easily 
assessed prior to purification (218). 
 
 
Figure 5.4: GFP-based membrane protein expression and purification pipeline. 
Between the screening steps in the pipeline the fluorescence is measured to assess the 
quality and quantity of the membrane protein-GFP fusion. 
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A limitation of the GFP-based pipeline is that the C-terminus of the membrane protein has 
to be cytoplasmic for GFP to fold (219). This is a problem for proteins like PmScsB that 
have a periplasmic C-terminus. However, a “superfolder” GFP (sfGFP) variant has been 
engineered, which contains multiple mutations that improve the folding of GFP (220) and 
has been shown to fold in the periplasm (221). Theoretically, sfGFP could be used as a 
tag on the periplasmic C-terminus of PmScsB. 
 
Different strains of E. coli have also been developed specifically for membrane protein 
overexpression. Given that endogenous membrane proteins are typically at low 
abundance in cells, recombinant overexpression in E. coli makes the purification of high 
yields of membrane protein much easier. Unfortunately membrane protein overexpression 
in the classical T7-promoter expression strains (such as BL21 (DE3)) is often toxic to the 
cells and results in aggregation of the protein (222). This is thought to happen because the 
machinery that embeds the protein in the cytoplasmic membrane becomes saturated 
(222). The Walker strains, C41 (DE3) and C43 (DE3) are derivatives of the BL21 (DE3) E. 
coli strain, which have mutations that make them amenable to membrane protein 
overexpression (223). One of these mutations is in the lacUV5 promoter of the T7 RNA 
polymerase gene, which reduces the expression of the polymerase (224) but there are 
potentially other uncharacterised mutations in the strains. Another strain is Lemo21, which 
is the BL21 (DE3) strain containing pLemo (224). The plasmid pLemo harbours the gene 
encoding T7 lysozyme (inhibitor of T7 RNA polymerase) under an L-rhamnose inducible 
and titratable promoter (224,225). T7 lysozyme is also encoded on other plasmids like 
pLysS and pLysE (226), but pLemo is more favourable because it allows the optimisation 
of T7 lysozyme expression simply by varying the concentration of L-rhamnose in the 
media.  
 
Detergents are used throughout membrane protein purification to solubilise and keep 
membrane proteins stable in solution. Detergents generally have a hydrophilic head group 
and a hydrophobic tail but there is a broad range of commercially available detergents and 
these vary in structure and chemical properties (Figure 5.5). Some detergents, such as n-
dodecyl-β-D-maltopyranoside (DDM), are considered to be mild because of their large, 
non-ionic head groups. Other detergents, such as N,N-dimethyldodecylamine N-oxide 
(LDAO), are harsher because of their smaller, ionic head groups (227). Detergents can 
exist in solution as monomers and as micelles, though micelle formation only occurs above 
the critical micelle concentration (CMC). The micelle size can impact on crystal formation, 
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as larger micelles prevent the protein from making crystal contacts, therefore, new 
detergents have been designed to increase the stability of solubilised membrane proteins 
and overcome problems associated with crystallisation (227). Detergent screening 
techniques, such as the unfolding assay utilising the dye N-[4-(7-diethylamino-4-methyl-3-
coumarinyl)phenyl]-maleimide (CPM) (228), have also been developed to identify optimal 
detergents for stabilisation of different membrane proteins (229). 
 
 
Figure 5.5: Structure of detergents. Detergents generally consist of a hydrophilic head 
group and a hydrophobic tail, however the chemical properties of these components can 
vary significantly. DDM and LDAO are shown in the figure to exemplify the diversity in 
detergent head group structure. 
 
Detergents, however, do not replicate the membrane environment very well, so some 
membrane proteins may not be stable in detergent micelles. Membrane mimetics, such as 
liposomes and nanodiscs can instead be used in the characterisation of membrane 
proteins (230,231). Lipidic cubic phase (LCP), which is a membrane-mimetic matrix, can 
also be used for crystallisation in combination with specific membrane protein 
crystallisation screens that have been developed (232). The advances in single particle 
analysis with cryo-electron microscopy have also assisted in membrane protein structure 
determination, as this technique does not require crystals or large amounts of material, 
which are needed for crystallography (233,234). 
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This chapter details the steps I have taken toward the expression and purification of the 
full-length transmembrane protein, PmScsB. A construct encoding PmScsB with a C-
terminal sfGFP tag and His8-tag was designed and a GFP-based approach (217) was 
used to screen different expression strains, media and suitable detergents for 
solubilisation. Large-scale expression was performed and purified PmScsB was obtained 
through the use of immobilised metal affinity chromatography and size-exclusion 
chromatography. These findings will assist in future work on the characterisation of this 
integral membrane protein. 
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5.2 Methods 
5.2.1 Generation of the PmScsB-sfGFP expression construct 
The PmScsB gene (encoding Uniprot ID: B4EV20) was codon optimised for expression in 
E. coli using GeneOptimizer (Thermo Fisher Scientific, Massachusetts, USA). The gene 
without the predicted periplasmic signalling sequence (residues 1-21) was ordered from 
GENEWIZ (New Jersey, USA) and inserted into pET20b(+) (Novagen®, Merck, 
Darmstadt, Germany) which contains a PelB leader sequence allowing targeted 
expression of the protein to the periplasm of E. coli (235). Using this construct, it was 
difficult to determine expression levels of PmScsB and trace the protein throughout the 
purification process. After personal communication with Dr David Drew (Stockholm 
University), a new strategy was employed and primers were designed (Table 5.1) to 
incorporate the native predicted periplasmic signalling sequence of PmScsB and to insert 
the gene into pWaldo-sfGFPd (plasmid provided by Dr David Drew, Stockholm University, 
Sweden) (217,220,236). The plasmid pWaldo-sfGFPd is a protein expression construct 
that contains superfolder GFP (sfGFP) downstream of restriction enzyme sites  (Figure 
5.6A). Overlap extension PCR was used to mutate an NdeI cleavage site in the PmScsB 
gene and the gene was then amplified with primers encoding the signal peptide sequence 
and NdeI and KpnI cleavage sites. The PmScsB PCR product and pWaldo-sfGFPd vector 
were cut with the restriction enzymes and ligated according to the manufacturers 
instructions (New England Biolabs, Massachusetts, USA). The ligation product was 
transformed into E. coli TOP10 (Invitrogen, California, USA) competent cells and plated on 
lysogeny broth (LB) agar supplemented with 50 µg/ml kanamycin. Resulting colonies were 
cultured in LB with 50 µg/mL kanamycin and the construct was extracted using the 
QIAGEN (Hilden, Germany) miniprep kit. The final construct, pEF014, contained the codon 
optimised PmScsB gene (encoding Uniprot ID: B4EV20, residues 1-678) followed by a 
TEV protease cleavage site, superfolder GFP and a His8 tag and this was confirmed by 
sequencing (Figure 5.6B). After TEV protease cleavage there are an additional 11 amino 
acids (RVPGSENLYFQ) on the C-terminal end of the protein. 
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Figure 5.6: Visual representation of the constructs used in chapter 5. A. pWaldo-
sfGFPd construct contains sfGFP downstream from restriction enzyme sites. B. The 
pEF014 construct was made for the expression of PmScsB-sfGFP. The elements on the 
constructs are not drawn to scale and the schematic was adapted from diagrams 
published previously (217). 
 
Table 5.1: Primers used in chapter 5. Mutated and overhanging nucleotides are shown 
in bold. 
Name Description Sequence (5’?3’) 
EF-028 
 
Rev NdeI cut site 
mutation 
GCGATCAGGGCATAGGCAACTGCGGTGCC 
EF-029 
 
Fwd NdeI cut site 
mutation 
GGCACCGCAGTTGCCTATGCCCTGATCGC 
EF-030 
 
Rev PmScsB with 
KpnI cut site 
GCGGCGGGTACCCGCTGTGCGCCTTTTG 
 
EF-031 
 
Fwd PmScsB 
signal sequence 
(1) 
CTGATTGCACTGATGCTGATGCTGTTTAGCCTGAGCAG
CCTGGCAGCAGATACCGGTTGG 
EF-032 
Fwd PmScsB 
signal sequence 
(2) with NdeI site 
CGCCGCCATATGGTTCGCAGCTTTCTGATTGCACTGAT
GC 
 
5.2.2 Small-scale expression screen 
Test expression of the PmScsB-sfGFP construct in various E. coli strains and media was 
carried out to determine the optimal strain and media for large-scale expression. Three 
E. coli strains, (LEMO21, BL21 (DE3) pLysS and C43, Table 5.2) and three types of media 
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(LB and two types of autoinduction media, ZYP and PASM, Table 5.3) were screened. 
Fresh transformations of pEF014 in the different strains of E. coli were used to inoculate 
10 mL aliquots of LB, with 50 µg/mL kanamycin and, if appropriate, 34 µg/mL 
chloramphenicol. Cultures were grown overnight at 37°C. For the test expressions, 200 µL 
of the overnight cultures was added to 10 mL (1 in 50 dilution) of each type of media, 
containing the appropriate antibiotics. The test cultures were incubated at 37°C until an 
OD600 of ~0.4-0.5 (1-2 h) was reached. At this point, the incubation temperature was 
lowered to 25°C and the LB cultures were induced with 0.4 mM IPTG. All cultures were 
grown overnight. After approximately 22 h post induction, the OD600 was measured and 1 
mL samples of each condition were taken. The cells in these samples were spun down, 
washed in 1×PBS and resuspended in 100 µL of 1×PBS. These 100 µL suspensions were 
added to Greiner black 96-well plates with clear flat bottom wells (Merck, Darmstadt, 
Germany).  The whole cell fluorescence was measured in a Synergy H1 Hybrid plate 
reader (BioTek, Vermont, USA) using the bottom read mode, a gain of 60 and excitation 
and emission wavelengths of 485 and 520 nm, respectively. The fluorescence reported for 
each small-scale sample was adjusted for the background fluorescence of PBS and 
normalised to an OD600 of 1. The whole cells were also run on a Novex 4-12% Tris-Glycine 
SDS-PAGE gel (Thermo Fisher Scientific, Massachusetts, USA) and analysed using a Bio-
Rad (California, USA) ChemiDoc™ MP imaging system with a 530/28 nm filter and blue 
epi-illumination setting.  
 
Table 5.2: E. coli strains screened. 
Strain Description Source 
Lemo21 (DE3) 
BL21 (DE3) strain with pLemo, which is 
maintained by chloramphenicol 
New England Biolabs 
(Massachusetts, USA)  
BL21 (DE3) pLysS 
BL21 (DE3) strain containing the 
plasmid pLysS, which is maintained by 
chloramphenicol 
Invitrogen Australia 
C43 (DE3) 
Strain derived from BL21 (DE3) with 
mutations that make it more capable of 
membrane protein overexpression 
Lucigen (Wisconsin, USA) 
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Table 5.3: Types of media used in expression screening. ZYP and PASM were 
prepared based on the protocols described previously (139). For maintenance of pEF014, 
the media was supplemented with 50 µg/mL kanamycin and 34 µg/mL chloramphenicol 
was also added to the media for growth of Lemo21 and BL21 (DE3) pLysS strains. 
Media Components Induction 
LB ???????????????????????? 
??????????ryptone 
??????????????? 
IPTG 
ZYP ????????????0.5% w/v yeast extract, 1% w/v tryptone) 
?? ?× 5052 (0.5% w/v glycerol, 0.05% w/v glucose, 0.2% 
w/v α-lactose) 
?? ?× NPS (25 mM (NH4)2SO4, 50 mM KH2PO4, 50 mM 
Na2HPO4) 
???× Trace metals mix (50 µM FeCl3?6H2O, 20 µM CaCl2, 
10 µM MnCl2?4H2O, 10 µM ZnSO4?7H2O, 2 µM 
CoCl2?6H2O, 2 µM CuCl2?2H2O, 2 µM NiCl2?6H2O, 2 µM 
Na2MoO4?5H2O, 2 µM Na2SeO3?5H2O, 2 µM H3BO3) 
???????????4 
Autoinduction 
PASM ?? ?× 5052 (0.5% w/v glycerol, 0.05% w/v glucose, 0.2% 
w/v α-lactose) 
?? ?× NPS (25 mM (NH4)2SO4, 50 mM KH2PO4, 50 mM 
Na2HPO4) 
?????× Trace metals mix (10 µM FeCl3?6H2O, 4 µM CaCl2, 
2 µM MnCl2?4H2O, 2 µM ZnSO4?7H2O, 0.4 µM 
CoCl2?6H2O, 0.4 µM CuCl2?2H2O, 0.4 µM NiCl2?6H2O, 
0.4 µM Na2MoO4?5H2O, 0.4 µM Na2SeO3?5H2O, 0.4 µM 
H3BO3) 
??? mM MgSO4 
??200 µg/mL of each amino acid (except cysteine) 
???????????????????? 
Autoinduction 
 
5.2.3 Large-scale expression 
Two conditions were selected from the small-scale expression screen to scale up. These 
were E. coli Lemo21 in ZYP and E. coli C43 in LB, with 0.4 mM IPTG induction. Fresh 
transformants were used to grow 100 mL overnight cultures in LB, supplemented with 
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antibiotics. 20 mL of these overnight cultures was used to inoculate 2.5 L baffled shaker 
flasks containing 1 L of the appropriate expression media with antibiotics. These were 
incubated at 37°C, 220 rpm to an OD600 of ~0.4 (1-2 h), before the temperature was 
reduced to 25°C and the LB cultures were induced with 0.4 mM IPTG. The expression 
cultures were grown overnight before the cells were harvested by centrifugation and stored 
at -80°C. OD600 and whole cell fluorescence was measured to determine expression levels 
of PmScsB-sfGFP. 
 
5.2.4 Membrane preparation 
The harvested cells were resuspended in 3 mL of 1× PBS per gram of cell pellet and 
protease inhibitor (1 in 1000 dilution in lysate, BioPioneer, Inc., USA) and DNase (3.3 
µg/ml final concentration) were added. The cells were lysed using a Constant Systems 
Cell Disruptor with two passes at 25 kpsi. The lysate was centrifuged at 10,000 rpm, 15 
min, 4°C to remove the unlysed cells and cell debris. Ultracentrifugation at 42,500 rpm, 
1 h, 4°C was used to separate the membranes from the soluble fraction. The membranes 
were resuspended in 1× PBS to a final volume of 15 mL per litre of initial expression 
culture, flash frozen in liquid nitrogen and stored at -80°C. The fluorescence of 100 µL of 
the 1× PBS membrane suspension was measured as described for the whole cell 
measurement. 
 
5.2.5 Detergent screen 
Eight different detergents (Table 5.4) were screened for their ability to solubilise PmScsB-
sfGFP. The membranes were diluted to 20,000 RFU and 100 µL of 10% w/v or v/v 
detergent was added to 900 uL of membrane suspension to give a final detergent 
concentration of 1%. The membrane-detergent mixtures were incubated at 4°C for 2 h, 
mixing on a roller mixer. The unsolubilised membranes were removed by 
ultracentrifugation (29,300 rpm, 4°C for 30 min) and the fluorescence of 100 µL of the 
detergent solubilised material was analysed as previously described. The three detergent 
solubilised samples that had the highest fluorescence reading were then analysed by 
FSEC to determine if PmScsB-sfGFP was stable. One hundred µL from each of the crude 
LDAO-, UDM- and DDM-solubilised membranes was applied to a Superose 6 Increase 
10/300 column (GE Healthcare, Chicago, USA) on an ÄKTApurifier (GE Healthcare, 
Chicago, USA) with an in-line Jasco (Maryland, USA) FP-2020 plus fluorescence detector 
(Excitation: 488 nm, Emission: 512 nm). The buffer used for the FSEC analysis was 1× 
PBS with the addition of the detergent of interest at a concentration of 5 times the CMC. 
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Table 5.4: Detergents screened for solubilisation efficiency of PmScsB-sfGFP. 
Abbreviation Full name 
DM  n-Decyl-β-D-maltopyranoside 
DDM n-Dodecyl-β-D-maltopyranoside 
NM n-Nonyl-β-D-maltopyranoside 
UDM n-Undecyl-β-D-maltopyranoside 
OG n-Octyl-β-D-glucopyranoside 
LDAO N,N-Dimethyldodecylamine N-oxide 
LMNG 
2,2-Didecylpropane-1,3-bis-β-D-maltopyranoside / Lauryl Maltose 
Neopentyl Glycol  
Triton-X Polyethylene glycol p-(1,1,3,3-tetramethylbutyl)-phenyl ether 
 
5.2.6 Purification 
The membranes (prepared as described previously) at a fluorescence of ~20,000 RFU 
were solubilised using 1% w/v DDM in 1× PBS and 20 mM imidazole. The solubilisation 
mixture was incubated at 4°C, stirring gently, for 2 h after which ultracentrifugation at 
29,300 rpm, 4°C for 30 min was used to pellet any unsolubilised membranes. Using a 
peristaltic pump, the supernatant was applied, at approximately 1 mL/min, over a 5 mL 
His-trap (GE Healthcare, Chicago, USA) nickel column equilibrated with 1× PBS, 20 mM 
imidazole to capture the His-tagged PmScsB-sfGFP. The column was then washed with 5 
column volumes each of IMAC wash buffers 1 and 2 (Table 5.5) and the captured protein 
was eluted from the column in 10 mL of IMAC elution buffer. Tobacco etch virus (TEV) 
protease was added to the eluted protein, in an approximately 1:1 (TEV protease: protein) 
molar ratio to remove the sfGFP-His8tag from PmScsB. The mixture was dialysed in 3kDa 
cut-off dialysis tubing suspended in 2 L of dialysis buffer (Table 5.5) by stirring overnight at 
4°C. The protein was removed from the dialysis tubing and imidazole concentration 
adjusted to 20 mM. The 5 mL His-trap nickel column was washed, equilibrated and 
reverse IMAC was performed to remove any His-tagged contaminants. The flow through 
from the reverse IMAC, which should contain PmScsB, was then concentrated to 5 mL 
using a 100 kDa cut-off centrifugal concentrator (Merck, Darmstadt, Germany) and 
injected into an FPLC for purification via SEC. The protein was run over a Superdex 200 
16/60, with SEC buffer. Peak fractions were collected and concentrated to ~5 mg/mL using 
100 kDa cut off centrifugal concentrators. Throughout the purification, protein 
concentrations were determined by measuring the A280 using a Nanodrop® 
Spectrophotometer ND-1000 (Thermo Fisher Scientific, Massachusetts, USA) and 
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adjusting for the predicted extinction coefficient (Table 5.6) (140). Samples from each 
stage of the purification were analysed with SDS-PAGE, run on a 4-12% Tris-Glycine gel 
and stained with Coomassie blue. This was also used to assess the purity of PmScsB. The 
fluorescence of 100 µL samples taken at appropriate stages of the purification was also 
analysed as described previously. 
 
Table 5.5: Buffers used in PmScsB purification. 
Buffer Components 
1× PBS 2.7 mM KCl, 137 mM NaCl, 1.76 K2PO4 pH 7.4 
IMAC wash buffer 1 20 mM Imidazole, 1× PBS, 0.05% w/v DDM 
IMAC wash buffer 2 40 mM Imidazole, 1× PBS, 0.05% w/v DDM 
IMAC elution buffer 250 mM Imidazole, 1× PBS, 0.05% w/v DDM 
Dialysis buffer 1× PBS, 0.03% w/v DDM 
SEC buffer 20 mM HEPES pH 7.5, 150 mM NaCl, 0.01% w/v DDM 
 
Table 5.6: Theoretical molecular weight and the absorbance at 280 nm of a 1 mg/mL 
solution (Abs 0.1%) of different PmScsB-sfGFP products (140). 
Protein Molecular Weight (kDa) Abs 0.1% (reduced/oxidised) 
*PmScsB-sfGFP-His 101.4 1.561/1.567 
*PmScsB- 73.2 1.903/1.909 
-sfGFP-His 28.1 Not necessary 
*With no signalling sequence (residues 1-20), as this should be cleaved. 
 
5.2.7 Mass spectrometry analysis of the purified protein 
A 5 mg/ml sample of the purified protein was sent for mass spectrometry analysis to 
confirm its identity. Dr Gordon King (UQROCX) performed this work by digesting the 
protein with trypsin and analysing the molecular weight of the peptides using matrix 
assisted laser desorption/ionisation (MALDI).  Tandem mass spectrometry (MS/MS) was 
used to determine the sequence of some peptides. The observed masses and sequences 
were compared to those peptides predicted by the in silico digest of PmScsB with trypsin 
(PeptideMass tool, ExPASy (140)). 
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5.3 Results 
5.3.1 Small-scale expression screen 
Three different E. coli strains and three different types of media were screened, to find 
suitable conditions for the expression of ScsB. The three strains screened were, Lemo21 
(DE3), C43 (DE3) and BL21 (DE3) pLysS and the types of media screened were, LB with 
0.4 mM IPTG induction and ZYP and PASM, a rich and minimal autoinduction media, 
respectively. Out of the nine different combinations, two conditions, Lemo21 (DE3) grown 
in ZYP and C43 (DE3) grown in LB with 0.4 mM IPTG induction, had a much higher level 
of whole cell fluorescence than the others (Figure 5.7A). To ensure the fluorescence was 
not a consequence of free GFP, samples were taken for analysis by SDS-PAGE in-gel 
fluorescence. The results from this analysis suggested that most of the conditions, 
including the top two, contained a fluorescent protein at the approximate size of PmScsB-
sfGFP (molecular weight = 101.4 kDa) as well as some free GFP (molecular weight = 28.1 
kDa) (Lane 4 and 8, Figure 5.7B).  
 
Figure 5.7: Results from the small-scale expression screen. A. Whole cell 
fluorescence for the conditions screened, normalised to an OD600 of 1. The two bars for 
each condition represent the fluorescence at time 0 (i.e. at induction) and after 22 hours, 
respectively. B. In-gel fluorescence of samples taken from each of the screening 
conditions. The expected molecular weight of PmScsB-GFP-His is 101.4 kDa, however, 
membrane proteins typically run at a lower molecular weight than expected as they are not 
fully denatured (heated) for SDS-PAGE. 
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5.3.2 Expression scale up 
The two conditions identified in 5.3.1 were tested at a 1 L scale to determine if the 
conditions were amenable to scale up. PmScsB expression using the C43 (DE3) strain in 
LB with 0.4 mM IPTG induction resulted in a final OD600 of ~4.8 and a fluorescence 
reading of ~2,300 RFU. The expression in Lemo21 using ZYP gave a final OD600 of ~11.2 
and a fluorescence reading of ~22,000 RFU. The Lemo21 cells were therefore chosen for 
membrane preparation and subsequent large-scale expression of PmScsB used the 
combination of Lemo21 with ZYP media. 
 
5.3.3 Detergent screening 
Membrane proteins require detergents for their solubilisation and subsequent purification. 
There are many detergents that are commercially available and can be assessed to 
determine the optimal detergent that extracts a significant amount of the protein from the 
membrane whilst maintaining the protein’s stability. In the detergent screen for PmScsB, 
eight different detergents were assessed for their ability to extract PmScsB-sfGFP from the 
membrane preparation by measuring the fluorescence of the solubilised material.  Initial 
tests showed that LDAO had the highest fluorescence, followed by UDM and DDM (Figure 
5.8A), so the solubilised material produced by these three detergents was further analysed 
by FSEC. The large peak in the UV trace at ~10 mL in the LDAO chromatogram 
suggested that this detergent produced aggregated material (Figure 5.8B). The 
fluorescence trace also had a large peak corresponding to free GFP (elution volume ~19 
mL) and only a small peak around 15 mL, which is approximately the expected elution 
volume for PmScsB-sfGFP in a detergent micelle (Figure 5.8B). The chromatogram for the 
UDM solubilised membranes also suggested that aggregation and free GFP were 
produced, but the peak at ~15 mL was much larger (Figure 5.8C). DDM produced the best 
FSEC profile, out of those detergents analysed, with a larger, almost monodisperse 
fluorescent peak at ~15 mL, which also correlated to a large peak in the UV trace (Figure 
5.8D). Therefore, for further work DDM was used to solubilise PmScsB-sfGFP and was 
maintained at concentrations above the CMC in the purification buffers to stabilise the 
protein.  
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Figure 5.8: PmScsB detergent screen. A. Fluorescence of solubilised membranes using 
different detergents. B-D. FSEC chromatograms of the crude solubilised membranes from 
three of the screened detergents. The solid black line is the UV trace and the dashed 
green line shows the detected fluorescence. For each FSEC chromatogram, an arrow and 
an asterisk indicate the peaks that are predicted to correspond to PmScsB-sfGFP and 
sfGFP, respectively.  
 
5.3.4 Purification 
PmScsB was successfully purified from expression in E. coli Lemo21 (DE3) using four 
steps; (1) IMAC to separate PmScsB-sfGFP from other solubilised membrane proteins, (2) 
TEV cleavage to remove the sfGFP and His8tag and (3) reverse IMAC to remove His-
tagged and other Nickel binding contaminants followed by (4) SEC. On the SDS-PAGE 
gel, no band corresponding to PmScsB-sfGFP can be seen in solubilised membranes or 
the IMAC flow through and washes (Figure 5.9). The IMAC step is effective at extracting 
the fusion protein as evidenced by (i) the strong band corresponding to the molecular 
weight of PmScsB-sfGFP in the elution sample on SDS-PAGE (Lane 6, Figure 5.9A), (ii) 
the green colour of the eluted protein (Figure 5.9B) and (iii) the decrease in RFU units from 
~15,000 RFU in the solubilised membranes to ~4,700 RFU in the IMAC flow through. TEV 
protease cleavage was also successful, as the band corresponding to PmScsB-sfGFP is 
not present in the post-TEV cleavage sample, but a slightly smaller (less ~28 kDa) band is 
Chapter 5 
 146 
present (Lane 7, Figure 5.9). Reverse IMAC removed most of the contaminants, though 
some PmScsB was present in the reverse IMAC elution and after injection onto SEC, step 
4, the chromatogram obtained shows one broad peak with a tail (Figure 5.10). The SEC 
purification step appears to have resulted in a large loss of protein as close to 10 mg of 
protein was injected but only ~500 µg was obtained from the pooled peak fractions 
(purification from 2.5 L of expression culture, ~ 40 g of E. coli pellet). Overall yield of the 
purification was ~ 200 µg per L of expression culture. 
 
Figure 5.9: Purification of PmScsB. A. SDS-PAGE analysis of samples taken 
throughout the purification of PmScsB. B. Pooled eluted protein from the IMAC purification 
step (Lane 6). 
 
Figure 5.10: SEC step in the purification of PmScsB. A. Chromatogram of the SEC 
purification step of PmScsB B. SDS-PAGE analysis of the fractions in the shaded region 
on the SEC chromatogram (A). 
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5.3.5 Mass spectrometry analysis of the purified protein 
Mass spectrometry analysis, involving a trypsin digest in combination with MALDI, was 
used to determine if the purified protein contained PmScsB. Six of the peptides observed 
in the MALDI spectrum had masses correlating to those predicted by an in silico trypsin 
digest of PmScsB (Figure 5.11). The full sequence of two of these peptides was confirmed 
by MS/MS (Table 5.7). The observed masses also correlated to predicted peptides in all 
domains of the PmScsB protein (Table 5.7). 
 
 
Figure 5.11: MALDI spectrum. Spectrum obtained from a MALDI experiment on the 
trypsin-digested purified protein. Those masses with an asterisk (*) agree with predicted 
peptides from a trypsin digest of PmScsB. 
 
Table 5.7: Correlation between the observed and predicted masses of peptides 
generated by a trypsin digest of PmScsB. The sequences shown in bold were 
confirmed by MS/MS.  
Observed mass 
(m/z) 
Predicted mass 
(monoisotopic) 
(m/z) (140) 
Sequence and position in 
PmScsB 
Missed 
cleavages? 
625.3 625.3 62-TYWR-65 No 
1080.6 1080.5 395-IATAGGQGYSR-405 No 
1169.7 1169.7 610-ALSEPDVVALR-620 No 
1429.8 1429.7 244-ALSFVVTDDGYSR-256 No 
1676.0 1675.9 596-ANKYNVLLRDDVQK-609 2 
1927.0 1926.9 21-ADTGWLTMPDNDHAQVR-37 No 
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5.4 Discussion 
The expression and purification of PmScsB is the first step in structurally and functionally 
characterising this protein. The results from this chapter indicate that preparation of the 
transmembrane protein PmScsB can be achieved through expression of the PmScsB-
sfGFP construct in Lemo21 (DE3) using ZYP media, solubilisation of the membranes in 
DDM and purification using IMAC and SEC. Mass spectrometry analysis confirmed that 
the purified protein is PmScsB. These data suggested that the predicted periplasmic 
signalling peptide (residues 1-20) of PmScsB is removed during expression. The mass of 
1927.0 correlates to residues 21-37 of PmScsB, however there is no trypsin cleavage site 
between residues 20 and 21, which suggests that this site must be cleaved by the signal 
peptidase during translocation. 
 
The fusion of PmScsB with sfGFP allowed the expression of PmScsB to be readily 
optimised. The small-scale screen of different expression strains and media allowed the 
determination of two possible expression conditions, which was reduced to one after 
scale-up of the expression to 1 L. The strain and media combination that was chosen for 
further work was Lemo21 (DE3) in ZYP autoinduction media. Lemo21 (DE3) is a BL21 
strain with the plasmid pLemo, which harbours the T7 Lysozyme gene, under an inducible 
and titratable L-rhamnose promoter. In the screening performed, no L-rhamnose was 
added to the media meaning that little, if any T7 Lysozyme would have been expressed. 
Screening different concentrations of L-rhamnose in the expression media may further 
optimise the expression of PmScsB. The temperature and length of expression are two 
other parameters that were not screened and could be varied to increase the expression of 
PmScsB. 
 
The detergent solubilisation screen identified DDM as an appropriate detergent for 
PmScsB solubilisation. LDAO resulted in the highest solubilised membrane fluorescence 
but is generally considered quite harsh because of its ionic head group and smaller 
micelles (227) and unsurprisingly, PmScsB was not stable after extraction in this 
detergent. UDM gave a reasonable FSEC profile but DDM was chosen for further work, as 
it resulted in less aggregation seen on the UV trace. Unfortunately the large micelle size of 
DDM is considered to be detrimental for crystallisation (237,238), so further work could 
follow up on the other detergents, which were not analysed by FSEC. Of course only 8 
detergents were screened in this study and many others are available that may produce 
better results. It is also possible that different detergents may be better for different stages 
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of the purification protocol and the stability of PmScsB in different detergents should be 
analysed using the unfolding assay with CPM dye. The detergent to protein ratio in the 
solubilisation step was not investigated in this preliminary work, but could impact on the 
amount of PmScsB solubilised. Alternative methods of membrane protein stabilisation, 
such as amphipols (239) and nanodiscs (230), are also worth investigation. 
 
During membrane protein purification, the folding of the protein and GFP can sometimes 
hinder interaction of the His-tag with resin but in this case an IMAC purification step 
efficiently separated PmScsB-sfGFP from the rest of the solubilised membranes. 
Modifications of the IMAC buffers and overall procedure may be possible to improve the 
yield obtained from IMAC. Allowing greater residence time with the binding to the nickel 
column or recycling flowthrough back over the column could potentially improve the yield 
from this step. Changing to a batch method could also be investigated as another method 
of efficiently extracting PmScsB-sfGFP from the crude solubilised membranes. There is 
also the possibility of modifying the IMAC resin and buffer conditions to achieve increased 
binding, stability and ultimately protein yield. 
 
TEV protease cleavage is often a problem in membrane protein purification because the 
detergent interferes or the cleavage site is inaccessible, however, this was not the case for 
the purification of PmScsB. TEV protease cleavage, overnight at 4°C, worked well, with 
very little uncleaved protein observed in the TEV protease treated sample on SDS-PAGE. 
The reverse IMAC removed many of the contaminants though a band corresponding to 
PmScsB was still observed in the reverse IMAC elution, suggesting that more washing or 
altering the buffer conditions may be beneficial to increase yields. 
 
The SEC chromatogram only had one peak and analysis by SDS-PAGE revealed that the 
major component corresponded to PmScsB. This peak was very broad, which may be (i) a 
result of PmScsB being conformationally heterogeneous given the transporter action of the 
membrane domain and two potentially mobile periplasmic domains or (ii) indicate that the 
DDM micelles are of varying sizes. The SEC peak was not very intense and a significant 
proportion of protein was lost during this purification step. Though no aggregation was 
seen on the chromatogram, the concentration of DDM was lowered in the SEC running 
buffer to reduce the formation of detergent only micelles during the final concentration 
step. This could have reduced the stability of the protein and it may also be possible that 
20 mM HEPES pH 7.5 is not the optimal buffer for purification of PmScsB. Analysis of 
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PmScsB stability in various buffers would assist in determining suitable conditions for the 
purification of this protein. 
 
As described above there are many ways in which the expression and purification of 
PmScsB could be further optimised but this initial purification strategy is promising. The 
current protocol could be scaled up to produce enough protein for crystallisation screening 
and the yield is sufficient for analysis by electron microscopy. Future work could also 
involve assays to assess the activity of the purified protein and experiments to determine 
the stoichiometry of the full-length PmScsB-PmScsC complex. 
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6. Conclusions and Future Directions 
 
The suppressor of copper sensitivity (Scs) proteins are Dsb-like proteins involved in the 
bacterial response to copper stress. Very little is known about the Scs proteins and prior to 
this work these proteins had only been studied in two organisms: S. Typhimurium and C. 
crescentus. The work outlined in this thesis focused on the characterisation of two of the 
four proteins - ScsC and ScsB - from the clinically important human uropathogen P. 
mirabilis. This work is summarised in Figure 6.1. 
 
 
Figure 6.1: Summary of the work presented in this thesis. Chapters 2 and 3 describe 
the research into PmScsC showing that it is a trimeric disulfide isomerase. Chapter 4 
describes my characterisation of the interaction between PmScsC and PmScsBα, and 
reports the PmScsBα crystal structure that I solved. The initial outcomes from my research 
to develop a high-yielding expression and purification protocol for full-length PmScsB are 
given in Chapter 5.  
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6.1 Understanding PmScsC 
The first aim of this PhD thesis was to characterise PmScsC. ScsC from S. Typhimurium 
and C. crescentus had previously been characterised, revealing that StScsC is a 
monomeric oxidoreductase and CcScsC is a dimeric disulfide isomerase (118,120).  As 
shown in Chapter 2, PmScsC is different to both StScsC and CcScsC. PmScsC functions 
as a disulfide isomerase but unlike CcScsC and other disulfide isomerases (39,118), 
PmScsC is a homotrimer. Three crystal structures of PmScsC were solved, revealing that 
the protein trimerises via its N-terminal helices and, like other DsbA-like proteins, has 
catalytic domains consisting of a thioredoxin fold and an inserted helical fold. The three 
crystal structures of the trimer had very different conformations. Taken together with SAXS 
data of the protein in solution, it became apparent that the trimeric disulfide isomerase is 
highly dynamic.  
 
Variants of PmScsC were created to understand the role of specific structural elements for 
disulfide isomerase activity. PmScsCΔN lacks the N-terminal 41 amino acids (which form 
the trimerisation stalk α-helices 1 and 2) of the mature PmScsC protein. In chapter 2, this 
variant was functionally characterised showing that it does not form a trimer and does not 
function as an efficient disulfide isomerase. However, PmScsCΔN has a much higher level 
of dithiol oxidase activity (ability to introduce disulphide bonds) than the native protein. 
This confirmed that the N-terminal helices are required for trimerisation and that PmScsC 
needs to be trimeric to have disulfide isomerase activity. Chapter 3 reports the crystal 
structure of PmScsCΔN, showing that it is almost identical to the catalytic domains of the 
native PmScsC crystal structures. This outcome suggested that the acquired dithiol 
oxidase activity of PmScsCΔN is a consequence of the loss of the trimerisation stem and 
the associated change in oligomerisation state.  
 
The region of the protein that facilitates the different protomer conformations in the three 
crystal structures is an 11-amino acid flexible linker, situated within the trimerisation stem. 
This linker is able to adopt different secondary structure conformations to position the 
catalytic domain in different orientations. To assess the role of this linker, two variants of 
PmScsC were created. The first variant, which is described in chapter 2, is the PmScsC 
RHP variant, where I replaced the flexible linker with a rigid helical peptide. The rigid 
helical peptide linker has been reported previously (135), and is stabilised in a helical 
conformation by the formation of salt bridges between glutamate and lysine resides, 
separated by three alanine residues. The PmScsC RHP variant remained trimeric and the 
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catalytic motifs were accessible. SAXS data showed that the protein had significantly 
reduced motion compared with the native protein. My analysis of the RHP variant showed 
that its disulfide isomerase activity in the scrambled RNase A assay was significantly 
reduced. Together these findings suggested that the flexible linker, and thus the range of 
motion it provides, is important for the disulfide isomerase activity of PmScsC. 
 
Chapter 3 describes the second PmScsC linker variant, PmScsCΔLinker. In this variant, 
the residues of the 11-amino acid flexible linker are deleted (and not replaced) from the 
protein sequence. The crystal structure of PmScsCΔLinker is trimeric; however, SAXS 
analysis revealed that in solution the protein exists in an equilibrium between different 
oligomeric states. At low concentrations the protein is primarily monomeric. As the 
concentration increases a low affinity dimer is favoured over the trimeric form. This 
favouring of the dimer form over the trimer form is probably due to unfavourable 
interactions between catalytic domains. In the trimeric PmScsCΔLinker crystal structure 
the catalytic domains are packed very closely together, as a result of the shortened 
trimerisation stem. These findings suggested that the flexible linker is not only important 
for the dynamics of PmScsC but also the formation of the trimer, as it acts as a spacer 
between the catalytic domains. As oligomerisation is important for activity of disulfide 
isomerases (41,123,175), it was unsurprising that the PmScsCΔLinker variant was inactive 
in the disulfide isomerase assay. Unlike PmScsCΔN, this variant is also a poor dithiol 
oxidase despite being predominantly monomeric at the concentration used in the assay. 
One possible explanation for this result is that the trimerisation stem somehow interferes 
with peptide substrate binding.  
 
Given its function as an efficient disulfide isomerase and its highly dynamic nature it is 
possible that PmScsC could be useful in the biotechnology industry, for example to assist 
in the folding of recombinant proteins in E. coli expression systems. An E. coli strain 
expressing cytoplasmic EcDsbC (SHuffle®) is already commercially available to assist 
folding of multi-disulfide bonded proteins (240). Given PmScsC’s trimeric and highly 
dynamic nature, it may be able to refold different or a greater variety of substrates. Future 
work towards this area of research could involve trial co-expressions of PmScsC with 
multi-disulfide bonded proteins that do not fold well in typical E. coli expression systems 
and comparison with the SHuffle® system.  
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Further modifications of the trimerisation stem and flexible linker to alter PmScsC function 
could also be explored. The flexible linker could be replaced entirely with alanine residues 
or alanine scanning could be used to determine which specific amino acids are important 
in the linker. The flexible linker and/or trimerisation stem could also be attached to other 
Dsb-like catalytic domains to determine whether this converts them into trimeric proteins 
and disulfide isomerases.  
 
Further work could focus on understanding the specific in vivo role of PmScsC. In chapter 
2 it was shown that deletion of scsC from P. mirabilis results in reduced swarming motility 
under copper stress and successful complementation occurred only when both catalytic 
cysteines were available and the protein was trimeric. This suggests that PmScsC needs 
to be a trimer and has redox activity in vivo but we do not know the precise role the protein 
plays in the periplasm or how it contributes to copper resistance. We do not know whether 
PmScsC directly binds copper or shuffles incorrect copper-catalysed disulfide bonds in 
substrate proteins or has some other role. Previous work in S. Typhimurium has 
suggested that copper is required to turn the scs operon on (112) but nothing else is 
known about the interaction between copper and the Scs proteins. Identifying PmScsC 
substrates and assessing its copper binding ability will assist in understanding its specific 
function and give insight into its role in copper resistance. Substrates could be predicted 
using bioinformatic tools such as STRING (241) and then these substrates could be 
confirmed in vitro (by recombinantly expressing and purifying the proteins and performing 
interaction assays) or in vivo (by analysing the abundance and function of these proteins in 
scsC deletion strains of P. mirabilis). Copper binding can be determined by the use of size 
exclusion chromatography with spectrophotometric assays (242,243) and the in vitro 
binding affinity can be quantified by analysing the competition between PmScsC and 
copper chelators. The results from these studies may also help explain why PmScsC is 
trimeric whereas ScsC proteins from other bacterial species are monomeric and why 
PmScsC is highly dynamic whereas other disulfide isomerases do not exhibit the same 
dynamic nature. It would also be interesting to investigate if the expression of ScsC and 
other Scs proteins in P. mirabilis is dependent on the presence of copper, as was found for 
S. Typhimurium (112). 
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6.2 PmScsBα and its role in PmScsC activation 
Work by others on ScsB from C. crescentus showed that it maintains ScsC in the reduced 
state and predicted that the N-terminal periplasmic domain of ScsB (ScsBα) was 
responsible for directly interacting with ScsC in that organism (118). These results 
suggested that PmScsC and PmScsB may form a redox relay. My research in chapter 4 of 
this thesis confirmed that disulfide exchange occurs in vitro between reduced ScsBα and 
oxidised ScsC from P. mirabilis, converting PmScsC to the reduced form and restoring its 
isomerase activity.  
 
The crystal structure of PmScsBα, the first ScsBα structure to be solved, was also 
reported in chapter 4. This structure revealed that the PmScsBα domain consists of two 
immunoglobulin-like folds connected by a single α-helix. This arrangement differs from the 
α domain of EcDsbD, which has just one immunoglobulin-like fold. The catalytic cysteines 
are present in the more N-terminal of PmScsBα’s two immunoglobulin-like folds. In both 
PmScsB and EcDsbD both cysteines are required to reduce their substrates PmScsC and 
EcDsbC, respectively.  
 
Chapter 4 also reported the low-resolution structure of the complex between PmScsBα 
and PmScsC. The interaction between the two is transient so to generate a stable complex 
for structural studies, one catalytic cysteine in each of the two proteins was mutated. This 
allowed formation of a stable intermolecular bond between the proteins. SANS analysis 
was used to determine the low-resolution model for the complex, revealing that both 
immunoglobulin-like folds of PmScsBα bind to a single PmScsC protomer within the trimer. 
This interaction differs from that between dimeric disulfide isomerase EcDsbC and its 
redox partner EcDsbDα, in which EcDsbDα interacts with both protomers of the EcDsbC 
homodimer (47,61).  
 
The PmScsC-PmScsBα SANS model suggests that PmScsBα does not interact with two 
of the three protomers or with the trimerisation stem of PmScsC. This finding suggests that 
the mode of interaction we observed could be conserved between ScsBα and non-trimeric 
ScsC proteins, like those from S. Typhimurium (monomeric) and C. crescentus (proposed 
dimeric). Future work is needed to confirm this hypothesis by investigating the interaction 
between PmScsBα and monomeric PmScsCΔN or between ScsB and ScsC proteins from 
other bacterial species. The disulfide exchange between the two proteins could be 
assessed using a gel-shift assay with AMS, which binds to free thiols. If the interaction 
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exists, an intermolecular disulfide bond stabilised complex between the proteins could be 
created, as described previously, and used for structural studies. 
 
It should be noted that PmScsBα is only one domain of a 3-domain protein, the other two 
domains being the transmembrane domain and the C-terminal periplasmic domain. 
Therefore it is possible that the interaction mode between PmScsC and PmScsBα may 
differ in the presence of the additional domains. Future work should follow up on the 
interaction between PmScsC and the full-length transmembrane protein PmScsB. As 
described previously, cysteine variants of the proteins could be produced and used to form 
a stable complex, which would allow the stoichiometry of the interaction to be assessed 
and could be used in structural studies. 
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6.3 Production of PmScsB using a superfolder GFP fusion 
This PhD work also aimed to develop an expression and purification protocol for the 
production of PmScsB. Such a protocol could be applied in future work on the 
characterisation of the full-length protein and its interaction with PmScsC. Chapter 5 
described the work towards this aim and showed that PmScsB can be recombinantly 
expressed in E. coli with a superfolder GFP fusion tag and purified using IMAC, TEV 
protease cleavage and SEC. Future work can build upon this initial expression and 
purification protocol I developed to increase the yield and stability of full-length PmScsB. 
The expression of PmScsB could be further optimised by screening different 
concentrations of L-rhamnose in the expression media. Buffer and detergent screening 
using the unfolding assay with CPM dye (228) may identify conditions that increase the 
stability of PmScsB for use throughout purification. 
 
Given that ScsB is an electron transporter with two mobile periplasmic domains it is likely 
that PmScsB will be conformationally heterogeneous in solution and thus structural studies 
may be challenging. One way to reduce the conformational variability would be to form a 
stable inter-domain disulfide between PmScsBα and PmScsBγ, by mutating one catalytic 
cysteine in each domain. This PmScsB variant could then be used in crystallisation 
screening. Alternatively, forming a stable complex between PmScsB and PmScsC may 
reduce the conformational flexibility of both proteins. This stable complex could be 
generated by oxidising purified PmScsC C87S and PmScsB C114A together, which would 
form an unresolvable intermolecular disulfide bond between the two proteins. As the 
molecular weight of the PmScsB-PmScsC complex would be ~150 kDa, it would be worth 
trying electron microscopy for structural studies. For this, negative stain electron 
microscopy could be used first to determine the homogeneity of the sample and provide 
low-resolution structural information. If the sample was shown to be of good quality, cryo-
electron microscopy could be used to gain higher resolution information. 
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6.4 Other future directions 
The work in this thesis has focused on two of the Scs proteins, ScsC and ScsB, but ScsA 
and ScsD have not been biochemically or structurally characterised in any organism, to 
date. Future work could involve the expression, purification and biochemical and structural 
characterisation of both these transmembrane proteins. It is predicted that ScsD interacts 
with ScsB in S. Typhimurium and C. crescentus, so this interaction could be assessed 
using the same AMS gel-shift approach outlined in section 4.6.8. Standard redox 
biochemical assays could also be used to investigate whether ScsD functions as an 
oxidoreductase and to determine the pKa and redox potential values of the protein. If the 
full-length membrane protein ScsD proves difficult to work with, the N-terminal anchor 
could be removed to work on the more tractable C-terminal periplasmic domain. This 
should be more easily expressed and purified and may be amenable to crystallisation.  
 
ScsA is likely to be more challenging to characterise, as it has no homology to any 
characterised protein. There are no predicted interaction partners but - given that it is 
involved in the bacterial response to oxidative stress - a good starting point would be to 
determine if it has antioxidant activity in vitro. This could be done using the metal-
catalysed oxidation assay that would determine the ability of ScsA to protect DNA from 
oxidative damage caused by reactive oxygen species generated from iron and 
dithiothreitol (244). Analysis of the molecular weight of the mature protein could be 
performed using mass spectrometry or SDS-PAGE to determine if ScsA does have a 
cleavable signal sequence or if it instead forms two transmembrane helices. Structural 
characterisation of ScsA by X-ray crystallography is likely to be challenging given that 
there is no predicted soluble domain, so there would be little opportunity for crystal 
contacts to form. Cryo-electron microscopy is unsuitable because the molecular weight of 
ScsA is only ~15 kDa but this makes it a good candidate for structural characterisation by 
NMR.  
 
Another topic for future study is the functional similarity and interplay between the Scs and 
Dsb proteins. Key research questions to be answered are:  
i. Can PmScsC, StScsC or CcScsC functionally replace EcDsbC in vivo?  
ii. Can EcDsbC replace ScsC functionally in P. mirabilis, C. crescentus or S. 
Typhimurium?   
iii. In organisms, such as P. mirabilis, that encode DsbCs and ScsB but not DsbD, are 
the DsbC proteins reduced by ScsB?  
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iv. In organisms, such as S. Typhimurium, that have all Dsb and Scs proteins, can 
DsbC interact with ScsB and ScsC with DsbD? 
These questions could be answered using the AMS gel-shift assay with purified proteins 
and in vivo experiments with scs and dsb deletion strains of bacteria. The results from 
these experiments would increase our understanding about the functional relatedness of 
and cross talk between these two similar, yet different, bacterial redox machineries. 
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6.5 Concluding remarks 
This PhD thesis describes the characterisation of PmScsC, the crystal structure of 
PmScsBα, the characterisation of the interaction between these two proteins and an initial 
expression and purification protocol for full-length PmScsB is outlined. More broadly, this 
work has increased our understanding of the bacterial suppressor of copper sensitivity 
proteins. Nevertheless, there is still much to discover and key questions remain to be 
answered (Figure 6.2). The specific role that all four Scs proteins play in the bacterial 
response to copper and oxidative stress is unknown and the reason for such diversity in 
ScsC proteins is not understood. The biochemical function and structure of ScsA and 
ScsD is also unknown and it is unclear as to what cross talk or redundancy there is, if any, 
between the Dsb and Scs pathways. Future work could address these knowledge gaps to 
build upon the findings outlined in this thesis.  
 
Figure 6.2: Summary of the future directions that stem from the work outlined in this 
thesis. 
References 
 162 
7. List of References 
1. Bardwell, J. C., McGovern, K., and Beckwith, J. (1991) Identification of a protein 
required for disulfide bond formation in vivo. Cell 67, 581-589 
2. Peek, J. A., and Taylor, R. K. (1992) Characterization of a periplasmic thiol:disulfide 
interchange protein required for the functional maturation of secreted virulence 
factors of Vibrio cholerae. Proc. Natl. Acad. Sci. U. S. A. 89, 6210-6214 
3. Bardwell, J. C., Lee, J. O., Jander, G., Martin, M., Belin, D., and Beckwith, J. (1993) 
A pathway for disulfide bond formation in vivo. Proc. Natl. Acad. Sci. U. S. A. 90, 
1038-1042 
4. Missiakas, D., Georgopoulos, C., and Raina, S. (1994) The Escherichia coli dsbC 
(xprA) gene encodes a periplasmic protein involved in disulfide bond formation. 
EMBO J. 13, 2013-2020 
5. Shevchik, V. E., Condemine, G., and Robert-Baudouy, J. (1994) Characterization of 
DsbC, a periplasmic protein of Erwinia chrysanthemi and Escherichia coli with 
disulfide isomerase activity. EMBO J. 13, 2007-2012 
6. Missiakas, D., Schwager, F., and Raina, S. (1995) Identification and 
characterisation of a new disulfide isomerase-like protein (DsbD) in Eschericia coli. 
EMBO J. 14, 3415-3424 
7. Martin, J. L., Bardwell, J. C., and Kuriyan, J. (1993) Crystal structure of the DsbA 
protein required for disulfide bond formation in vivo. Nature 365, 464-468 
8. Nelson, J. W., and Creighton, T. E. (1994) Reactivity and ionization of the active 
site cysteine residues of DsbA, a protein required for disulfide bond formation in 
vivo. Biochemistry 33, 5974-5983 
9. Zapun, A., Bardwell, J., and Creighton, T. E. (1993) The reactive and destabilizing 
disulfide bond of DsbA, a protein required for protein disulfide bond formation in 
vivo. Biochemistry 32, 5083-5092 
10. Huber-Wunderlich, M., and Glockshuber, R. (1998) A single dipeptide sequence 
modulates the redox properties of a whole enzyme family. Fold. Des. 3, 161-171 
11. Jurrus, E., Engel, D., Star, K., Monson, K., Brandi, J., Felberg, L. E., Brookes, D. H., 
Wilson, L., Chen, J., Liles, K., Chun, M., Li, P., Gohara, D. W., Dolinsky, T., 
Konecny, R., Koes, D. R., Nielsen, J. E., Head-Gordon, T., Geng, W., Krasny, R., 
Wei, G. W., Holst, M. J., McCammon, J. A., and Baker, N. A. (2018) Improvements 
to the APBS biomolecular solvation software suite. Protein Sci. 27, 112-128 
12. Fernandes, P. A., and Ramos, M. J. (2004) Theoretical insights into the mechanism 
for thiol/disulfide exchange. Chem. Eur. J. 10, 257-266 
References 
 163 
13. Bach, R. D., Dmitrenko, O., and Thorpe, C. (2008) Mechanism of thiolate-disulfide 
interchange reactions in biochemistry. J. Org. Chem. 73, 12-21 
14. Frech, C., Wunderlich, M., Glockshuber, R., and Schmid, F. X. (1996) Preferential 
binding of an unfolded protein to DsbA. EMBO J. 15, 392-398 
15. Kadokura, H., and Beckwith, J. (2009) Detecting folding intermediates of a protein 
as it passes through the bacterial translocation channel. Cell 138, 1164-1173 
16. Heras, B., Shouldice, S. R., Totsika, M., Scanlon, M. J., Schembri, M. A., and 
Martin, J. L. (2009) DSB proteins and bacterial pathogenicity. Nat. Rev. Microbiol. 7, 
215-225 
17. Hiniker, A., and Bardwell, J. C. (2004) In vivo substrate specificity of periplasmic 
disulfide oxidoreductases. J. Biol. Chem. 279, 12967-12973 
18. Miki, T., Okada, N., Kim, Y., Abe, A., and Danbara, H. (2008) DsbA directs efficient 
expression of outer membrane secretin EscC of the enteropathogenic Escherichia 
coli type III secretion apparatus. Microb. Pathog. 44, 151-158 
19. Jander, G., Martin, N. L., and Beckwith, J. (1994) Two cysteines in each periplasmic 
domain of the membrane protein DsbB are required for its function in protein 
disulfide bond formation. EMBO J. 13, 5121-5127 
20. Guilhot, C., Jander, G., Martin, N. L., and Beckwith, J. (1995) Evidence that the 
pathway of disulfide bond formation in Escherichia coli involves interactions 
between the cysteines of DsbB and DsbA. Proc. Natl. Acad. Sci. U. S. A. 92, 9895-
9899 
21. Kishigami, S., and Ito, K. (1996) Roles of cysteine residues of DsbB in its activity to 
reoxidize DsbA, the protein disulfide catalyst of Escherichia coli. Genes Cells 1, 
201-208 
22. Kobayashi, T., and Ito, K. (1999) Respiratory chain strongly oxidizes the CXXC 
motif of DsbB in the Escherichia coli disulfide bond formation pathway. EMBO J. 18, 
1192-1198 
23. Bader, M. W., Xie, T., Yu, C. A., and Bardwell, J. C. (2000) Disulfide bonds are 
generated by quinone reduction. J. Biol. Chem. 275, 26082-26088 
24. Bader, M., Muse, W., Ballou, D. P., Gassner, C., and Bardwell, J. C. A. (1999) 
Oxidative protein folding is driven by the electron transport system. Cell 96, 217-227 
25. Inaba, K., Murakami, S., Suzuki, M., Nakagawa, A., Yamashita, E., Okada, K., and 
Ito, K. (2006) Crystal structure of the DsbB-DsbA complex reveals a mechanism of 
disulfide bond generation. Cell 127, 789-801 
References 
 164 
26. Inaba, K., Murakami, S., Nakagawa, A., Iida, H., Kinjo, M., Ito, K., and Suzuki, M. 
(2009) Dynamic nature of disulphide bond formation catalysts revealed by crystal 
structures of DsbB. EMBO J. 28, 770-791 
27. Zhou, Y., Cierpicki, T., Jimenez, R. H., Lukasik, S. M., Ellena, J. F., Cafiso, D. S., 
Kadokura, H., Beckwith, J., and Bushweller, J. H. (2008) NMR solution structure of 
the integral membrane enzyme DsbB: functional insights into DsbB-catalyzed 
disulfide bond formation. Mol. Cell 31, 896-908 
28. Inaba, K., Takahashi, Y. H., Fujieda, N., Kano, K., Miyoshi, H., and Ito, K. (2004) 
DsbB elicits a red-shift of bound ubiquinone during the catalysis of DsbA oxidation. 
J. Biol. Chem. 279, 6761-6768 
29. Inaba, K., Takahashi, Y. H., Ito, K., and Hayashi, S. (2006) Critical role of a thiolate-
quinone charge transfer complex and its adduct form in de novo disulfide bond 
generation by DsbB. Proc. Natl. Acad. Sci. U. S. A. 103, 287-292 
30. Totsika, M., Heras, B., Wurpel, D. J., and Schembri, M. A. (2009) Characterization 
of two homologous disulfide bond systems involved in virulence factor biogenesis in 
uropathogenic Escherichia coli CFT073. J. Bacteriol. 191, 3901-3908 
31. Adams, L. A., Sharma, P., Mohanty, B., Ilyichova, O. V., Mulcair, M. D., Williams, M. 
L., Gleeson, E. C., Totsika, M., Doak, B. C., Caria, S., Rimmer, K., Horne, J., 
Shouldice, S. R., Vazirani, M., Headey, S. J., Plumb, B. R., Martin, J. L., Heras, B., 
Simpson, J. S., and Scanlon, M. J. (2015) Application of fragment-based screening 
to the design of inhibitors of Escherichia coli DsbA. Angew. Chem. Int. Ed. Engl. 54, 
2179-2184 
32. Duprez, W., Premkumar, L., Halili, M. A., Lindahl, F., Reid, R. C., Fairlie, D. P., and 
Martin, J. L. (2015) Peptide inhibitors of the Escherichia coli DsbA oxidative 
machinery essential for bacterial virulence. J. Med. Chem. 58, 577-587 
33. Duprez, W., Bachu, P., Stoermer, M. J., Tay, S., McMahon, R. M., Fairlie, D. P., 
and Martin, J. L. (2015) Virtual screening of peptide and peptidomimetic fragments 
targeted to inhibit bacterial dithiol oxidase DsbA. PLOS ONE 10, e0133805 
34. Landeta, C., Blazyk, J. L., Hatahet, F., Meehan, B. M., Eser, M., Myrick, A., 
Bronstain, L., Minami, S., Arnold, H., Ke, N., Rubin, E. J., Furie, B. C., Furie, B., 
Beckwith, J., Dutton, R., and Boyd, D. (2015) Compounds targeting disulfide bond 
forming enzyme DsbB of Gram-negative bacteria. Nat. Chem. Biol. 11, 292-298 
35. Fruh, V., Zhou, Y., Chen, D., Loch, C., Ab, E., Grinkova, Y. N., Verheij, H., Sligar, S. 
G., Bushweller, J. H., and Siegal, G. (2010) Application of fragment-based drug 
References 
 165 
discovery to membrane proteins: identification of ligands of the integral membrane 
enzyme DsbB. Chem. Biol. 17, 881-891 
36. Halili, M. A., Bachu, P., Lindahl, F., Bechara, C., Mohanty, B., Reid, R. C., Scanlon, 
M. J., Robinson, C. V., Fairlie, D. P., and Martin, J. L. (2015) Small molecule 
inhibitors of disulfide bond formation by the bacterial DsbA-DsbB dual enzyme 
system. ACS Chem. Biol. 10, 957-964 
37. Totsika, M., Vagenas, D., Paxman, J. J., Wang, G., Dhouib, R., Sharma, P., Martin, 
J. L., Scanlon, M. J., and Heras, B. (2018) Inhibition of diverse DsbA enzymes in 
multi-DsbA encoding pathogens. Antioxid. Redox Signal. 29, 653-666 
38. Mohanty, B., Rimmer, K., McMahon, R. M., Headey, S. J., Vazirani, M., Shouldice, 
S. R., Coincon, M., Tay, S., Morton, C. J., Simpson, J. S., Martin, J. L., and 
Scanlon, M. J. (2017) Fragment library screening identifies hits that bind to the non-
catalytic surface of Pseudomonas aeruginosa DsbA1. PLOS ONE 12, e0173436 
39. McCarthy, A. A., Haebel, P. W., Torronen, A., Rybin, V., Baker, E. N., and Metcalf, 
P. (2000) Crystal structure of the protein disulfide isomerase, DsbC, from 
Escherichia coli. Nat. Struct. Biol. 7, 196-199 
40. Sone, M., Akiyama, Y., and Ito, K. (1997) Differential in vivo roles played by DsbA 
and DsbC in the formation of protein disulfide bonds. J. Biol. Chem. 272, 10349-
10352 
41. Sun, X. X., and Wang, C. C. (2000) The N-terminal sequence (residues 1-65) is 
essential for dimerization, activities, and peptide binding of Escherichia coli DsbC. 
J. Biol. Chem. 275, 22743-22749 
42. Zapun, A., Missiakas, D., Raina, S., and Creighton, T. E. (1995) Structural and 
functional characterization of DsbC, a protein involved in disulfide bond formation in 
Escherichia coli. Biochemistry 34, 5075-5089 
43. Zhao, Z., Peng, Y., Hao, S. F., Zeng, Z. H., and Wang, C. C. (2003) Dimerization by 
domain hybridization bestows chaperone and isomerase activities. J. Biol. Chem. 
278, 43292-43298 
44. Goldstone, D., Haebel, P. W., Katzen, F., Bader, M. W., Bardwell, J. C., Beckwith, 
J., and Metcalf, P. (2001) DsbC activation by the N-terminal domain of DsbD. Proc. 
Natl. Acad. Sci. U. S. A. 98, 9551-9556 
45. Bader, M. W., Hiniker, A., Regeimbal, J., Goldstone, D., Haebel, P. W., Riemer, J., 
Metcalf, P., and Bardwell, J. (2001) Turning a disulfide isomerase into an oxidase: 
DsbC mutants that imitate DsbA. EMBO J. 20, 1555-1562 
References 
 166 
46. Chen, J., Song, J., Zhang, S., Wang, Y., Cui, D., and Wang, C. (1999) Chaperone 
activity of DsbC. J. Biol. Chem. 274, 19601-19605 
47. Haebel, P. W., Goldstone, D., Katzen, F., Beckwith, J., and Metcalf, P. (2002) The 
disulfide bond isomerase DsbC is activated by an immunoglobulin-fold thiol 
oxidoreductase: crystal structure of the DsbC-DsbDα complex. EMBO J. 21, 4774-
4784 
48. Rietsch, A., Bessette, P., Georgiou, G., and Beckwith, J. (1997) Reduction of the 
periplasmic disulfide bond isomerase, DsbC, occurs by passage of electrons from 
cytoplasmic thioredoxin. J. Bacteriol. 179, 6602-6608 
49. Shouldice, S. R., Cho, S. H., Boyd, D., Heras, B., Eser, M., Beckwith, J., Riggs, P., 
Martin, J. L., and Berkmen, M. (2010) In vivo oxidative protein folding can be 
facilitated by oxidation-reduction cycling. Mol. Microbiol. 75, 13-28 
50. Maskos, K., Huber-Wunderlich, M., and Glockshuber, R. (2003) DsbA and DsbC-
catalyzed oxidative folding of proteins with complex disulfide bridge patterns in vitro 
and in vivo. J. Mol. Biol. 325, 495-513 
51. Pan, J. L., and Bardwell, J. C. (2006) The origami of thioredoxin-like folds. Protein 
Sci. 15, 2217-2227 
52. Vertommen, D., Depuydt, M., Pan, J., Leverrier, P., Knoops, L., Szikora, J. P., 
Messens, J., Bardwell, J. C., and Collet, J. F. (2008) The disulphide isomerase 
DsbC cooperates with the oxidase DsbA in a DsbD-independent manner. Mol. 
Microbiol. 67, 336-349 
53. Rietsch, A., Belin, D., Martin, N., and Beckwith, J. (1996) An in vivo pathway for 
disulfide bond isomerization in Escherichia coli. Proc. Natl. Acad. Sci. U. S. A. 93, 
13048-13053 
54. Hiniker, A., Collet, J. F., and Bardwell, J. C. (2005) Copper stress causes an in vivo 
requirement for the Escherichia coli disulfide isomerase DsbC. J. Biol. Chem. 280, 
33785-33791 
55. Denoncin, K., Vertommen, D., Arts, I. S., Goemans, C. V., Rahuel-Clermont, S., 
Messens, J., and Collet, J. F. (2014) A new role for Escherichia coli DsbC protein in 
protection against oxidative stress. J. Biol. Chem. 289, 12356-12364 
56. Chung, J., Chen, T., and Missiakas, D. (2000) Transfer of electrons across the 
cytoplasmic membrane by DsbD, a membrane protein involved in thiol-disulphide 
exchange and protein folding in the bacterial periplasm. Mol. Microbiol. 35, 1099-
1109 
References 
 167 
57. Stewart, E. J., Katzen, F., and Beckwith, J. (1999) Six conserved cysteines of the 
membrane protein DsbD are required for the transfer of electrons from the 
cytoplasm to the periplasm of Escherichia coli. EMBO J. 18, 5963-5971 
58. Gordon, E. H. J., Page, M. D., Willis, A. C., and Ferguson, S. J. (2000) Escherichia 
coli DipZ: anatomy of a transmembrane protein disulphide reductase in which three 
pairs of cysteine residues, one in each of three domains, contribute to function. Mol. 
Microbiol. 35, 1360-1374 
59. Katzen, F., and Beckwith, J. (2000) Transmembrane electron transfer by the 
membrane protein DsbD occurs via a disulfide bond cascade. Cell 103, 769-779 
60. Collet, J. F., Riemer, J., Bader, M. W., and Bardwell, J. C. (2002) Reconstitution of 
a disulfide isomerization system. J. Biol. Chem. 277, 26886-26892 
61. Goulding, C. W., Sawaya, M. R., Parseghian, A., Lim, V., Eisenberg, D., and 
Missiakas, D. (2002) Thiol-disulfide exchange in an immunoglobulin-like fold: 
Structure of the N-terminal domain of DsbD. Biochemistry 41, 6920-6927 
62. Stirnimann, C. U., Rozhkova, A., Grauschopf, U., Bockmann, R. A., Glockshuber, 
R., Capitani, G., and Grutter, M. G. (2006) High-resolution structures of Escherichia 
coli cDsbD in different redox states: A combined crystallographic, biochemical and 
computational study. J. Mol. Biol. 358, 829-845 
63. Kim, J. H., Kim, S. J., Jeong, D. G., Son, J. H., and Ryu, S. E. (2003) Crystal 
structure of DsbDγ reveals the mechanism of redox potential shift and substrate 
specificity. FEBS Lett. 543, 164-169 
64. Rozhkova, A., Stirnimann, C. U., Frei, P., Grauschopf, U., Brunisholz, R., Gutter, M. 
G., Capitani, G., and Glockshuber, R. (2004) Structural basis and kinetics of inter- 
and intramolecular disulfide exchange in the redox catalyst DsbD. EMBO J. 23, 
1709-1719 
65. Cho, S. H., and Beckwith, J. (2009) Two snapshots of electron transport across the 
membrane: insights into the structure and function of DsbD. J. Biol. Chem. 284, 
11416-11424 
66. Cho, S. H., Porat, A., Ye, J., and Beckwith, J. (2007) Redox-active cysteines of a 
membrane electron transporter DsbD show dual compartment accessibility. EMBO 
J. 26, 3509-3520 
67. Depuydt, M., Leonard, S. E., Vertommen, D., Denoncin, K., Morsomme, P., Wahni, 
K., Messens, J., Caroll, K. S., and Collet, J. F. (2009) A periplasmic reducing 
system protects single cysteine residues from oxidation. Science 326, 1109-1111 
References 
 168 
68. Bessette, P., Cotto, J. J., Gilbert, H. F., and Georgiou, G. (1999) In vivo and in vitro 
function of the Escherichia coli periplasmic cysteine oxidoreductase DsbG. J. Biol. 
Chem. 274, 7784-7792 
69. Edeling, M. A., Ahuja, U., Heras, B., Thony-Meyer, L., and Martin, J. L. (2004) The 
acidic nature of the CcmG redox-active center is important for cytochrome c 
maturation in Escherichia coli. J. Bacteriol. 186, 4030-4033 
70. Heras, B., Edeling, M. A., Schirra, H. J., Raina, S., and Martin, J. L. (2004) Crystal 
structures of the DsbG disulfide isomerase reveal an unstable disulfide. Proc. Natl. 
Acad. Sci. U. S. A. 101, 8876-8881 
71. Shao, F., Bader, M. W., Jakob, U., and Bardwell, J. C. A. (2000) DsbG, a protein 
disulfide isomerase with chaperone activity. J. Biol. Chem. 275, 13349-13352 
72. Kouidmi, I., Alvarez, L., Collet, J. F., Cava, F., and Paradis-Bleau, C. (2018) The 
chaperone activity of DsbG and Spy restore peptidoglycan biosynthesis arrest in the 
elyC mutant by preventing envelope protein aggregation. J. Bacteriol. 200, e00245-
00218 
73. Mainardi, J. L., Hugonnet, J. E., Rusconi, F., Fourgeaud, M., Dubost, L., Moumi, A. 
N., Delfosse, V., Mayer, C., Gutmann, L., Rice, L. B., and Arthur, M. (2007) 
Unexpected inhibition of peptidoglycan LD-transpeptidase from Enterococcus 
faecium by the β-lactam imipenem. J. Biol. Chem. 282, 30414-30422 
74. Thony-Meyer, L., Fischer, F., Kunzler, P., Ritz, D., and Hennecke, H. (1995) 
Escherichia coli genes required for cytochrome c maturation. J. Bacteriol. 177, 
4321-4326 
75. Fabianek, R. A., Hennecke, H., and Thony-Meyer, L. (1998) The active-site 
cysteines of the periplasmic thioredoxin-like protein CcmG of Escherichia coli are 
important but not essential for cytochrome c maturation in vivo. J. Bacteriol. 180, 
1947-1950 
76. Fabianek, R. A., Hofer, T., and Thony-Meyer, L. (1999) Characterisation of the 
Escherichia coli CcmH protein reveals new insights into the redox pathway for 
cytochrome c maturation. Arch. Microbiol. 171, 92-100 
77. Stevens, J. M., Mavridou, D. A., Hamer, R., Kritsiligkou, P., Goddard, A. D., and 
Ferguson, S. J. (2011) Cytochrome c biogenesis system I. FEBS J. 278, 4170-4178 
78. Ouyang, N., Gao, Y. G., Hu, H. Y., and Xia, Z. X. (2006) Crystal structures of E. coli 
CcmG and its mutants reveal key roles of the N-terminal β-sheet and the fingerprint 
region. Proteins 65, 1021-1031 
References 
 169 
79. Landeta, C., Boyd, D., and Beckwith, J. (2018) Disulfide bond formation in 
prokaryotes. Nat. Microbiol. 3, 270-280 
80. Bocian-Ostrzycka, K. M., Grzeszczuk, M. J., Dziewit, L., and Jagusztyn-Krynicka, E. 
K. (2015) Diversity of the Epsilonproteobacteria Dsb (disulfide bond) systems. 
Front. Microbiol. 6, 570 
81. Dumoulin, A., Grauschopf, U., Bischoff, M., Thony-Meyer, L., and Berger-Bachi, B. 
(2005) Staphylococcus aureus DsbA is a membrane-bound lipoprotein with thiol-
disulfide oxidoreductase activity. Arch. Microbiol. 184, 117-128 
82. Kouwen, T. R., van der Goot, A., Dorenbos, R., Winter, T., Antelmann, H., Plaisier, 
M. C., Quax, W. J., van Dijl, J. M., and Dubois, J. Y. (2007) Thiol-disulphide 
oxidoreductase modules in the low-GC Gram-positive bacteria. Mol. Microbiol. 64, 
984-999 
83. Heras, B., Kurz, M., Jarrott, R., Shouldice, S. R., Frei, P., Robin, G., Cemazar, M., 
Thony-Meyer, L., Glockshuber, R., and Martin, J. L. (2008) Staphylococcus aureus 
DsbA does not have a destabilizing disulfide. A new paradigm for bacterial oxidative 
folding. J. Biol. Chem. 283, 4261-4271 
84. Kwon, A.-R., and Choi, E.-C. (2005) Role of disulfide bond of arylsulfate 
sulfotransferase in catalytic activity. Arch. Pharm. Res. 28, 561-565 
85. Grimshaw, J. P., Stirnimann, C. U., Brozzo, M. S., Malojcic, G., Grutter, M. G., 
Capitani, G., and Glockshuber, R. (2008) DsbL and DsbI form a specific dithiol 
oxidase system for periplasmic arylsulfate sulfotransferase in uropathogenic 
Escherichia coli. J. Mol. Biol. 380, 667-680 
86. Lin, D., Kim, B., and Slauch, J. M. (2009) DsbL and DsbI contribute to periplasmic 
disulfide bond formation in Salmonella enterica serovar Typhimurium. Microbiology 
155, 4014-4024 
87. Heras, B., Totsika, M., Jarrott, R., Shouldice, S. R., Guncar, G., Achard, M. E., 
Wells, T. J., Argente, M. P., McEwan, A. G., and Schembri, M. A. (2010) Structural 
and functional characterization of three DsbA paralogues from Salmonella enterica 
serovar Typhimurium. J. Biol. Chem. 285, 18423-18432 
88. Djoko, K. Y., Ong, C. L., Walker, M. J., and McEwan, A. G. (2015) The role of 
copper and zinc toxicity in innate immune defense against bacterial pathogens. J. 
Biol. Chem. 290, 18954-18961 
89. Crocker, A., Lee, C., Aboko-Cole, G., and Durham, C. (1992) Interaction of nutrition 
and infection: Effect of copper deficiency on resistance to Trypanosoma lewisi. J. 
Natl. Med. Assoc. 84, 697-706 
References 
 170 
90. Jones, D. G., and Suttle, N. F. (1983) The effect of copper deficiency on the 
resistance of mice to infection with Pasteurella haemolytica. J. Comp. Pathol. 93, 
143-149 
91. Newberne, P. M., Hunt, C. E., and Young, V. R. (1968) The role of diet and the 
reticuloendothelial system in the response of rats to Salmonella Typhimurium 
infection. Br. J. Exp. Pathol. 49, 448-457 
92. Subashchandrabose, S., Hazen, T. H., Brumbaugh, A. R., Himpsl, S. D., Smith, S. 
N., Ernst, R. D., Rasko, D. A., and Mobley, H. L. (2014) Host-specific induction of 
Escherichia coli fitness genes during human urinary infection. Proc. Natl. Acad. Sci. 
U. S. A. 111, 18327-18332 
93. Wolschendorf, F., Ackart, D., Shrestha, T. B., Hascall-Dove, L., Nolan, S., 
Lamichhane, G., Wang, Y., Bossmann, S. H., Basaraba, R. J., and Niederweis, M. 
(2011) Copper resistance is essential for virulence of Mycobacterium tuberculosis. 
Proc. Natl. Acad. Sci. U. S. A. 108, 1621-1626 
94. Hodgkinson, V., and Petris, M. J. (2012) Copper homeostasis at the host-pathogen 
interface. J. Biol. Chem. 287, 13549-13555 
95. Achard, M. E., Stafford, S. L., Bokil, N. J., Chartres, J., Bernhardt, P. V., Schembri, 
M. A., Sweet, M. J., and McEwan, A. G. (2012) Copper redistribution in murine 
macrophages in response to Salmonella infection. Biochem. J. 444, 51-57 
96. White, C., Lee, J., Kambe, T., Fritsche, K., and Petris, M. J. (2009) A role for the 
ATP7A copper-transporting ATPase in macrophage bactericidal activity. J. Biol. 
Chem. 284, 33949-33956 
97. Hyre, A. N., Kavanagh, K., Kock, N. D., Donati, G. L., and Subashchandrabose, S. 
(2017) Copper is a host effector mobilized to urine during urinary tract infection to 
impair bacterial colonization. Infect. Immun. 85, e01041-01016 
98. Hurme, R., Namork, E., Nurmiaho-Lassila, E. L., and Rhen, M. (1994) Intermediate 
filament-like network formed in vitro by a bacterial coiled coil protein. J. Biol. Chem. 
269, 10675-10682 
99. Braymer, J. J., and Giedroc, D. P. (2014) Recent developments in copper and zinc 
homeostasis in bacterial pathogens. Curr. Opin. Chem. Biol. 19, 59-66 
100. Macomber, L., and Imlay, J. A. (2009) The iron-sulfur clusters of dehydratases are 
primary intracellular targets of copper toxicity. Proc. Natl. Acad. Sci. U. S. A. 106, 
8344-8349 
References 
 171 
101. Outten, F. W., Outten, C. E., Hale, J., and O'Halloran, T. V. (2000) Transcriptional 
activation of an Escherichia coli copper efflux regulon by the chromosomal MerR 
homologue, cueR. J. Biol. Chem. 275, 31024-31029 
102. Kim, J. S., Kim, M. H., Joe, M. H., Song, S. S., Lee, I. S., and Choi, S. Y. (2002) 
The sctR of Salmonella enterica serova Typhimurium encoding a homologue of 
MerR protein is involved in the copper-responsive regulation of cuiD. FEMS 
Microbiol. Lett. 210, 99-103 
103. Stoyanov, J. V., Hobman, J. L., and Brown, N. L. (2001) CueR (Ybbl) of Escherichia 
coli is a MerR family regulator controlling expression of the copper exporter CopA. 
Mol. Microbiol. 39, 502-511 
104. Grass, G., and Rensing, C. (2001) CueO is a multi-copper oxidase that confers 
copper tolerance in Escherichia coli. Biochem. Biophys. Res. Commun. 286, 902-
908 
105. Singh, S. K., Roberts, S. A., McDevitt, S. F., Weichsel, A., Wildner, G. F., Grass, G. 
B., Rensing, C., and Montfort, W. R. (2011) Crystal structures of multicopper 
oxidase CueO bound to copper(I) and silver(I): functional role of a methionine-rich 
sequence. J. Biol. Chem. 286, 37849-37857 
106. Osman, D., Waldron, K. J., Denton, H., Taylor, C. M., Grant, A. J., Mastroeni, P., 
Robinson, N. J., and Cavet, J. S. (2010) Copper homeostasis in Salmonella is 
atypical and copper-CueP is a major periplasmic metal complex. J. Biol. Chem. 
285, 25259-25268 
107. Djoko, K. Y., Franiek, J. A., Edwards, J. L., Falsetta, M. L., Kidd, S. P., Potter, A. J., 
Chen, N. H., Apicella, M. A., Jennings, M. P., and McEwan, A. G. (2012) 
Phenotypic characterization of a copA mutant of Neisseria gonorrhoeae identifies a 
link between copper and nitrosative stress. Infect. Immun. 80, 1065-1071 
108. Shafeeq, S., Yesilkaya, H., Kloosterman, T. G., Narayanan, G., Wandel, M., 
Andrew, P. W., Kuipers, O. P., and Morrissey, J. A. (2011) The cop operon is 
required for copper homeostasis and contributes to virulence in Streptococcus 
pneumoniae. Mol. Microbiol. 81, 1255-1270 
109. Outten, F. W., Huffman, D. L., Hale, J. A., and O'Halloran, T. V. (2001) The 
independent cue and cus systems confer copper tolerance during aerobic and 
anaerobic growth in Escherichia coli. J. Biol. Chem. 276, 30670-30677 
110. Franke, S., Grass, G., Rensing, C., and Nies, D. H. (2003) Molecular analysis of the 
copper-transporting efflux system CusCFBA of Escherichia coli. J. Bacteriol. 185, 
3804-3812 
References 
 172 
111. Gupta, S. D., Wu, H. C., and Rick, P. D. (1997) A Salmonella Typhimurium genetic 
locus which confers copper tolerance on copper-sensitive mutants of Escherichia 
coli. J. Bacteriol. 179, 4977-4984 
112. Lopez, C., Checa, S. K., and Soncini, F. C. (2018) CpxR/CpxA-controls scsABCD 
transcription to counteract copper and oxidative stress in Salmonella Typhimurium. 
J. Bacteriol. 200, e00126-00118 
113. Kershaw, C. J., Brown, N. L., Constantinidou, C., Patel, M. D., and Hobman, J. L. 
(2005) The expression profile of Escherichia coli K-12 in response to minimal, 
optimal and excess copper concentrations. Microbiology 151, 1187-1198 
114. Pezza, A., Pontel, L. B., Lopez, C., and Soncini, F. C. (2016) Compartment and 
signal-specific codependence in the transcriptional control of Salmonella 
periplasmic copper homeostasis. Proc. Natl. Acad. Sci. U. S. A. 113, 11573-11578 
115. Pontel, L. B., Scampoli, N. L., Porwollik, S., Checa, S. K., McClelland, M., and 
Soncini, F. C. (2014) Identification of a Salmonella ancillary copper detoxification 
mechanism by a comparative analysis of the genome-wide transcriptional response 
to copper and zinc excess. Microbiology 160, 1659-1669 
116. Yamamoto, K., and Ishihama, A. (2005) Transcriptional response of Escherichia coli 
to external copper. Mol. Microbiol. 56, 215-227 
117. Anwar, N., Sem, X. H., and Rhen, M. (2013) Oxidoreductases that act as 
conditional virulence suppressors in Salmonella enterica serovar Typhimurium. 
PLOS ONE 8, e64948 
118. Cho, S. H., Parsonage, D., Thurston, C., Dutton, R. J., Poole, L. B., Collet, J. F., 
and Beckwith, J. (2012) A new family of membrane electron transporters and its 
substrates, including a new cell envelope peroxiredoxin, reveal a broadened 
reductive capacity of the oxidative bacterial cell envelope. mBio 3, 1-11 
119. Verbrugghe, E., Dhaenens, M., Leyman, B., Boyen, F., Shearer, N., Van Parys, A., 
Haesendonck, R., Bert, W., Favoreel, H., Deforce, D., Thompson, A., Haesebrouck, 
F., and Pasmans, F. (2016) Host stress drives Salmonella recrudescence. Sci. Rep. 
6, 20849 
120. Shepherd, M., Heras, B., Achard, M. E., King, G. J., Argente, M. P., Kurth, F., 
Taylor, S. L., Howard, M. J., King, N. P., Schembri, M. A., and McEwan, A. G. 
(2013) Structural and functional characterization of ScsC, a periplasmic thioredoxin-
like protein from Salmonella enterica serovar Typhimurium. Antioxid. Redox Signal. 
19, 1494-1506 
References 
 173 
121. van Straaten, M., Missiakas, D., Raina, S., and Darby, N. J. (1998) The functional 
properties of DsbG, a thiol-disulfide oxidoreductase from the periplasm of 
Escherichia coli. FEBS Lett. 428, 255-258 
122. Ren, G., Stephan, D., Xu, Z., Zheng, Y., Tang, D., Harrison, R. S., Kurz, M., Jarrott, 
R., Shouldice, S. R., Hiniker, A., Martin, J. L., Heras, B., and Bardwell, J. C. (2009) 
Properties of the thioredoxin fold superfamily are modulated by a single amino acid 
residue. J. Biol. Chem. 284, 10150-10159 
123. Ke, H., Zhang, S., Li, J., Howlett, G. J., and Wang, C. (2006) Folding of Escherichia 
coli DsbC: Characterization of a monomeric folding intermediate. Biochemistry 45 
124. Edeling, M. A., Guddat, L. W., Fabianek, R. A., Thony-Meyer, L., and Martin, J. L. 
(2002) Structure of CcmG/DsbE at 1.14 A resolution: High-fidelity reducing activity 
in an indiscriminately oxidizing environment. Structure 10, 973-979 
125. Stirnimann, C. U., Rozhkova, A., Grauschopf, U., Grutter, M. G., Glockshuber, R., 
and Capitani, G. (2005) Structural basis and kinetics of DsbD-dependent 
cytochrome c maturation. Structure 13, 985-993 
126. Pearson, M. M., Sebaihia, M., Churcher, C., Quail, M. A., Seshasayee, A. S., 
Luscombe, N. M., Abdellah, Z., Arrosmith, C., Atkin, B., Chillingworth, T., Hauser, 
H., Jagels, K., Moule, S., Mungall, K., Norbertczak, H., Rabbinowitsch, E., Walker, 
D., Whithead, S., Thomson, N. R., Rather, P. N., Parkhill, J., and Mobley, H. L. 
(2008) Complete genome sequence of uropathogenic Proteus mirabilis, a master of 
both adherence and motility. J. Bacteriol. 190, 4027-4037 
127. Armbruster, C. E., Mobley, H. L. T., and Pearson, M. M. (2018) Pathogenesis of 
Proteus mirabilis infection. EcoSal Plus 8 
128. Eriksson, S., Zbornik, J., Dahnsjö, H., Erlanson, P., Kahlmeter, O., Fritz, H., and 
Bauer, C.-A. (1986) The combination of Pivampicillin and Pivmecillinam versus 
Pivampicillin alone in the treatment of acute pyelonephritis. Scand. J. Infect. Dis. 18, 
431-438 
129. Griffith, D. P., Musher, D. M., and Itin, C. (1976) Urease. The primary cause of 
infection-induced urinary stones. Invest. Urol. 13, 346-350 
130. Bahrani, F. K., Johnson, D. E., Robbins, D., and Mobley, H. L. T. (1991) Proteus 
mirabilis Flagella and MR/P Fimbrae: isolation, purification, N-terminal analysis, and 
serum antibody response following experimental urinary tract infection. Infect. 
Immun. 59, 3574-3580 
131. D'Andrea, M. M., Giani, T., De Angelis, L. H., Ciacci, N., Gniadkowski, M., Miriagou, 
V., Torricelli, F., and Rossolini, G. M. (2016) Draft genome sequence of Proteus 
References 
 174 
mirabilis NO-051/03, representative of a multidrug-resistant clone spreading in 
Europe and expressing the CMY-16 AmpC-Type β-lactamase. Genome Announc. 
4, e01702-e01715 
132. Luzzaro, F., Brigante, G., D'Andrea, M. M., Pini, B., Giani, T., Mantengoli, E., 
Rossolini, G. M., and Toniolo, A. (2009) Spread of multidrug-resistant Proteus 
mirabilis isolates producing an AmpC-type β-lactamase: epidemiology and clinical 
management. Int. J. Antimicrob. Agents 33, 328-333 
133. Burall, L. S., Harro, J. M., Li, X., Lockatell, C. V., Himpsl, S. D., Hebel, J. R., 
Johnson, D. E., and Mobley, H. L. T. (2004) Proteus mirabilis genes that contribute 
to pathogenesis of urinary tract infection: Identification of 25 signature-tagged 
mutants attenuated at least 100-fold. Infect. Immun. 72, 2922-2938 
134. Kurth, F., Duprez, W., Premkumar, L., Schembri, M. A., Fairlie, D. P., and Martin, J. 
L. (2014) Crystal structure of the dithiol oxidase DsbA enzyme from Proteus 
mirabilis bound non-covalently to an active site peptide ligand. J. Biol. Chem. 289, 
19810-19822 
135. Chen, X., Zaro, J. L., and Shen, W. C. (2013) Fusion protein linkers: property, 
design and functionality. Adv. Drug Deliv. Rev. 65, 1357-1369 
136. Tian, G., Kober, F. X., Lewandrowski, U., Sickmann, A., Lennarz, W. J., and 
Schindelin, H. (2008) The catalytic activity of protein-disulfide isomerase requires a 
conformationally flexible molecule. J. Biol. Chem. 283, 33630-33640 
137. Wang, C., Li, W., Ren, J., Fang, J., Ke, H., Gong, W., Feng, W., and Wang, C. C. 
(2013) Structural insights into the redox-regulated dynamic conformations of human 
protein disulfide isomerase. Antioxid. Redox Signal. 19, 36-45 
138. Tian, G., Xiang, S., Noiva, R., Lennarz, W. J., and Schindelin, H. (2006) The crystal 
structure of yeast protein disulfide isomerase suggests cooperativity between its 
active sites. Cell 124, 61-73 
139. Studier, F. W. (2005) Protein production by auto-induction in high-density shaking 
cultures. Protein Expr. Purif. 41, 207-234 
140. Gasteiger, E., Hoogland, C., Gattiker, A., Duvaud, S., Wilkins, M. R., Appel, R. D., 
and Bairoch, A. (2005) Protein identification and analysis tools on the ExPASy 
server. in The Proteomics Protocols Handbook (Walker, J. M. ed.), Humana Press. 
pp 571-607 
141. Heckman, K. L., and Pease, L. R. (2007) Gene splicing and mutagenesis by PCR-
driven overlap extension. Nat. Protoc. 2, 924-932 
References 
 175 
142. Kirby, N. M., Mudie, S. T., Hawley, A. M., Cookson, D. J., Mertens, H. D. T., 
Cowieson, N., and Samardzic-Boban, V. (2013) A low-background-intensity 
focusing small-angle X-ray scattering undulator beamline. J. Appl. Crystallogr. 46, 
1670-1680 
143. Scatterbrain - Software for acquiring, processing and viewing SAXS/WAXS data at 
the Australian Synchrotron. Australian Synchrotron, Clayton, VIC 
144. Orthaber, D., Bergmann, A., and Glatter, O. (2000) SAXS experiments on absolute 
scale with Kratky systems using water as a secondary standard. J. Appl. 
Crystallogr. 33, 218-225 
145. Whitten, A. E., Cai, S., and Trewhella, J. (2008) MULCh: modules for the analysis of 
small-angle neutron contrast variation data from biomolecular assemblies. J. Appl. 
Crystallogr. 41, 222-226 
146. Svergun, D. I. (1992) Determination of the regularization parameter in indirect-
transform methods using perceptual criteria. J. Appl. Crystallogr. 25, 495-503 
147. Petoukhov, M. V., Franke, D., Shkumatov, A. V., Tria, G., Kikhney, A. G., Gajda, M., 
Gorba, C., Mertens, H. D., Konarev, P. V., and Svergun, D. I. (2012) New 
developments in the program package for small-angle scattering data analysis. J. 
Appl. Crystallogr. 45, 342-350 
148. Franke, D., Jeffries, C. M., and Svergun, D. I. (2015) Correlation Map, a goodness-
of-fit test for one-dimensional X-ray scattering spectra. Nat. Methods 12, 419-422 
149. Tria, G., Mertens, H. D., Kachala, M., and Svergun, D. I. (2015) Advanced 
ensemble modelling of flexible macromolecules using X-ray solution scattering. 
IUCrJ 2, 207-217 
150. McPhillips, T. M., McPhillips, S. E., Chiu, H. J., Cohen, A. E., Deacon, A. M., Ellis, 
P. J., Garman, E., Gonzalez, A., Sauter, N. K., Phizackerley, R. P., Soltis, S. M., 
and Kuhn, P. (2002) Blu-Ice and the distributed control system: software for data 
acquisition and instrument control at macromolecular crystallography beamlines. J. 
Synchrotron Radiat. 9, 401-406 
151. Kabsch, W. (2010) XDS. Acta Crystallogr. D Biol. Crystallogr. 66, 125-132 
152. Evans, P. R., and Murshudov, G. N. (2013) How good are my data and what is the 
resolution? Acta Crystallogr. D Biol. Crystallogr. 69, 1204-1214 
153. Vagin, A., and Teplyakov, A. (2000) An approach to multi-copy search in molecular 
replacement. Acta Crystallogr. D Biol. Crystallogr. 56, 1622-1624 
154. Adams, P. D., Afonine, P. V., Bunkoczi, G., Chen, V. B., Davis, I. W., Echols, N., 
Headd, J. J., Hung, L. W., Kapral, G. J., Grosse-Kunstleve, R. W., McCoy, A. J., 
References 
 176 
Moriarty, N. W., Oeffner, R., Read, R. J., Richardson, D. C., Richardson, J. S., 
Terwilliger, T. C., and Zwart, P. H. (2010) PHENIX: a comprehensive Python-based 
system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 
66, 213-221 
155. McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., 
and Read, R. J. (2007) Phaser crystallographic software. J. Appl. Crystallogr. 40, 
658-674 
156. Emsley, P., and Cowtan, K. (2004) Coot: model-building tools for molecular 
graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126-2132 
157. Dauter, Z. (2006) Estimation of anomalous signal in diffraction data. Acta 
Crystallogr. D Biol. Crystallogr. 62, 867-876 
158. Vagin, A. A., Steiner, R. A., Lebedev, A. A., Potterton, L., McNicholas, S., Long, F., 
and Murshudov, G. N. (2004) REFMAC5 dictionary: organization of prior chemical 
knowledge and guidelines for its use. Acta Crystallogr. D Biol. Crystallogr. 60, 2184-
2195 
159. Vonrhein, C., Flensburg, C., Keller, P., Sharff, A., Smart, O., Paciorek, W., 
Womack, T., and Bricogne, G. (2011) Data processing and analysis with the 
autoPROC toolbox. Acta Crystallogr. D Biol. Crystallogr. 67, 293-302 
160. Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., 
Keegan, R. M., Krissinel, E. B., Leslie, A. G., McCoy, A., McNicholas, S. J., 
Murshudov, G. N., Pannu, N. S., Potterton, E. A., Powell, H. R., Read, R. J., Vagin, 
A., and Wilson, K. S. (2011) Overview of the CCP4 suite and current developments. 
Acta Crystallogr. D Biol. Crystallogr. 67, 235-242 
161. Cowtan, K. (2006) The Buccaneer software for automated model building. 1. 
Tracing protein chains. Acta Crystallogr. D Biol. Crystallogr. 62, 1002-1011 
162. Smart, O. S., Womack, T. O., Flensburg, C., Keller, P., Paciorek, W., Sharff, A., 
Vonrhein, C., and Bricogne, G. (2012) Exploiting structure similarity in refinement: 
automated NCS and target-structure restraints in BUSTER. Acta Crystallogr. D Biol. 
Crystallogr. 68, 368-380 
163. Bricogne, G., Blanc, E., Brandl, M., Flensburg, C., Keller, P., Paciorek, W., Roversi, 
P., Sharff, A., Smart, O. S., Vonrhein, C., and Womack, T. O. (2011) BUSTER 
version 2.10.1. Global Phasing Ltd., Cambridge, United Kingdom 
164. Chen, V. B., Arendall, W. B., 3rd, Headd, J. J., Keedy, D. A., Immormino, R. M., 
Kapral, G. J., Murray, L. W., Richardson, J. S., and Richardson, D. C. (2010) 
References 
 177 
MolProbity: all-atom structure validation for macromolecular crystallography. Acta 
Crystallogr. D Biol. Crystallogr. 66, 12-21 
165. Konagurthu, A. S., Whisstock, J. C., Stuckey, P. J., and Lesk, A. M. (2006) 
MUSTANG: a multiple structural alignment algorithm. Proteins 64, 559-574 
166. Konagurthu, A. S., Reboul, C. F., Schmidberger, J. W., Irving, J. A., Lesk, A. M., 
Stuckey, P. J., Whisstock, J. C., and Buckle, A. M. (2010) MUSTANG-MR structural 
sieving server: applications in protein structural analysis and crystallography. PLOS 
ONE 5, e10048 
167. Schneider, C. A., Rasband, W. S., and Eliceiri, K. W. (2012) NIH Image to ImageJ: 
25 years of image analysis. Nat. Meth. 9, 671-675 
168. Wunderlich, M., and Glockshuber, R. (1993) In vivo control of redox potential during 
protein folding catalyzed by bacterial protein disulfide-isomerase (DsbA). J. Biol. 
Chem. 268, 24547-24550 
169. Gilbert, H. F. (1995) Thiol/disulfide exchange equilibria and disulfide bond stability. 
Methods Enzymol. 251, 8-28 
170. Hillson, D. A., Lambert, N., and Freedman, R. B. (1984) Formation and 
isomerisation of disulfide bonds in proteins: Protein disulfide-isomerase. Methods 
Enzymol. 107, 281-294 
171. Vivian, J. P., Scoullar, J., Rimmer, K., Bushell, S. R., Beddoe, T., Wilce, M. C., 
Byres, E., Boyle, T. P., Doak, B., Simpson, J. S., Graham, B., Heras, B., Kahler, C. 
M., Rossjohn, J., and Scanlon, M. J. (2009) Structure and function of the 
oxidoreductase DsbA1 from Neisseria meningitidis. J. Mol. Biol. 394, 931-943 
172. Valentini, E., Kikhney, A. G., Previtali, G., Jeffries, C. M., and Svergun, D. I. (2015) 
SASBDB, a repository for biological small-angle scattering data. Nucleic Acids Res. 
43, D357-D363 
173. Berkmen, M., Boyd, D., and Beckwith, J. (2005) The nonconsecutive disulfide bond 
of Escherichia coli phytase (AppA) renders it dependent on the protein-disulfide 
isomerase, DsbC. J. Biol. Chem. 280, 11387-11394 
174. Darby, N. J., Raina, S., and Creighton, T. E. (1998) Contributions of substrate 
binding to the catalytic activity of DsbC. Biochemistry 37, 783-791 
175. Furlong, E. J., Lo, A. W., Kurth, F., Premkumar, L., Totsika, M., Achard, M. E. S., 
Halili, M. A., Heras, B., Whitten, A. E., Choudhury, H. G., Schembri, M. A., and 
Martin, J. L. (2017) A shape-shifting redox foldase contributes to Proteus mirabilis 
copper resistance. Nat. Commun. 8, 16065 
References 
 178 
176. Furlong, E. J., Choudhury, H. G., Kurth, F., Duff, A. P., Whitten, A. E., and Martin, J. 
L. (2018) Disulfide isomerase activity of the dynamic, trimeric Proteus mirabilis 
ScsC protein is primed by the tandem immunoglobulin-fold domain of ScsB. J. Biol. 
Chem. 293, 5793-5805 
177. Evans, P. (2006) Scaling and assessment of data quality. Acta Crystallogr. D Biol. 
Crystallogr. 62, 72-82 
178. Emsley, P., Lohkamp, B., Scott, W. G., and Cowtan, K. (2010) Features and 
development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486-501 
179. Berman, H. M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T. N., Weissig, H., 
Shindyalov, I. N., and Bourne, P. E. (2000) The Protein Data Bank. Nucleic Acids 
Res. 28, 235-242 
180. Berman, H. M., Henrick, K., and Nakamura, H. (2003) Announcing the worldwide 
Protein Data Bank. Nat. Struct. Biol. 10, 980 
181. Battye, T. G., Kontogiannis, L., Johnson, O., Powell, H. R., and Leslie, A. G. (2011) 
iMOSFLM: a new graphical interface for diffraction-image processing with 
MOSFLM. Acta Crystallogr. D Biol. Crystallogr. 67, 271-281 
182. The PyMOL Molecular Graphics System, Version 1.6. Schrodinger, LLC, New York 
183. Trewhella, J., Duff, A. P., Durand, D., Gabel, F., Guss, J. M., Hendrickson, W. A., 
Hura, G. L., Jacques, D. A., Kirby, N. M., Kwan, A. H., Pérez, J., Pollack, L., Ryan, 
T. M., Sali, A., Schneidman-Duhovny, D., Schwede, T., Svergun, D. I., Sugiyama, 
M., Tainer, J. A., Vachette, P., Westbrook, J., and Whitten, A. E. (2017) 2017 
publication guidelines for structural modelling of small-angle scattering data from 
biomolecules in solution: an update. Acta Crystallographica Section D Structural 
Biology 73, 1-19 
184. Fischer, H., Neto, M. D., Napolitano, H. B., Polikarpov, I., and Craievich, A. F. 
(2010) Determination of the molecular weight of proteins in solution from a single 
small-angle X-ray scattering measurement on a relative scale. J. Appl. Crystallogr. 
43, 101-109 
185. Konarev, P. V., Volkov, V. V., Sokolova, A. V., Koch, M. H. J., and Svergun, D. I. 
(2003) PRIMUS: a Windows PC-based system for small-angle scattering data 
analysis. J. Appl. Crystallogr. 36, 1277-1282 
186. Svergun, D. I. (1999) Restoring low resolution structure of biological 
macromolecules from solution scattering using simulated annealing. Biophys. J. 76, 
2879-2886 
References 
 179 
187. Volkov, V. V., and Svergun, D. I. (2003) Uniqueness of ab initio shape 
determination in small-angle scattering. J. Appl. Crystallogr. 36, 860-864 
188. Tuukkanen, A. T., Kleywegt, G. J., and Svergun, D. I. (2016) Resolution of ab initio 
shapes determined from small-angle scattering. IUCrJ 3, 440-447 
189. Svergun, D., Barberato, C., and Koch, M. H. J. (1995) CRYSOL - A program to 
evaluate X-ray solution scattering of biological macromolecules from atomic 
coordinates. J. Appl. Crystallogr. 28, 768-773 
190. Hu, S. H., Whitten, A. E., King, G. J., Jones, A., Rowland, A. F., James, D. E., and 
Martin, J. L. (2012) The weak complex between RhoGAP protein ARHGAP22 and 
signal regulatory protein 14-3-3 has 1:2 stoichiometry and a single peptide binding 
mode. PLOS ONE 7, e41731 
191. Krupp, R., Chan, C., and Missiakas, D. (2001) DsbD-catalyzed transport of 
electrons across the membrane of Escherichia coli. J. Biol. Chem. 276, 3696-3701 
192. Holm, L., and Rosenstrom, P. (2010) Dali server: conservation mapping in 3D. 
Nucleic Acids Res. 38, W545-549 
193. Ireland, P. M., McMahon, R. M., Marshall, L. E., Halili, M., Furlong, E., Tay, S., 
Martin, J. L., and Sarkar-Tyson, M. (2014) Disarming Burkholderia pseudomallei: 
structural and functional characterization of a disulfide oxidoreductase (DsbA) 
required for virulence in vivo. Antioxid Redox Signal 20, 606-617 
194. Miki, T., Okada, N., and Danbara, H. (2004) Two periplasmic disulfide 
oxidoreductases, DsbA and SrgA, target outer membrane protein SpiA, a 
component of the Salmonella pathogenicity island 2 type III secretion system. J. 
Biol. Chem. 279, 34631-34642 
195. Rice, P., Longden, I., and Bleasby, A. (2000) EMBOSS: The European Molecular 
Biology Open Software Suite. Trends Genet. 16, 276-277 
196. Li, W., Cowley, A., Uludag, M., Gur, T., McWilliam, H., Squizzato, S., Park, Y. M., 
Buso, N., and Lopez, R. (2015) The EMBL-EBI bioinformatics web and 
programmatic tools framework. Nucleic Acids Res. 43, W580-584 
197. Pei, J., Kim, B. H., and Grishin, N. V. (2008) PROMALS3D: a tool for multiple 
protein sequence and structure alignments. Nucleic Acids Res. 36, 2295-2300 
198. Stols, L., Gu, M., Dieckman, L., Raffen, R., Collart, F. R., and Donnelly, M. I. (2002) 
A new vector for high-throughput, ligation-independent cloning encoding a tobacco 
etch virus protease cleavage site. Protein Expr. Purif. 25, 8-15 
199. Walden, P. M., Halili, M. A., Archbold, J. K., Lindahl, F., Fairlie, D. P., Inaba, K., and 
Martin, J. L. (2013) The α-proteobacteria Wolbachia pipientis protein disulfide 
References 
 180 
machinery has a regulatory mechanism absent in γ-proteobacteria. PLOS ONE 8, 
e81440 
200. Duff, A. P., Wilde, K. L., Rekas, A., Lake, V., and Holden, P. J. (2015) Robust high-
yield methodologies for (2)H and (2)H/(15)N/(13)C labeling of proteins for structural 
investigations using neutron scattering and NMR. Methods Enzymol. 565, 3-25 
201. Sheldrick, G. M. (2010) Experimental phasing with SHELXC/D/E: combining chain 
tracing with density modification. Acta Crystallogr. D Biol. Crystallogr. 66, 479-485 
202. Pape, T., and Schneider, T. R. (2004) HKL2MAP: a graphical user interface for 
macromolecular phasing with SHELX programs. J. Appl. Crystallogr. 37, 843-844 
203. Schrodinger, L. (2015) The PyMOL Molecular Graphics System, Version 1.6.   
204. Gilbert, E. P., Schulz, J. C., and Noakes, T. J. (2006) ‘Quokka’—the small-angle 
neutron scattering instrument at OPAL. Physica B: Condensed Matter 385-386, 
1180-1182 
205. Petoukhov, M. V., and Svergun, D. I. (2005) Global rigid body modeling of 
macromolecular complexes against small-angle scattering data. Biophys. J. 89, 
1237-1250 
206. Rozhkova, A., and Glockshuber, R. (2008) Thermodynamic aspects of DsbD-
mediated electron transport. J. Mol. Biol. 380, 783-788 
207. Katzen, F., Deshmukh, M., Daldal, F., and Beckwith, J. (2002) Evolutionary domain 
fusion expanded the substrate specificity of the transmembrane electron transporter 
DsbD. EMBO J. 21, 3960-3969 
208. Williamson, J. A., Cho, S. H., Ye, J., Collet, J. F., Beckwith, J. R., and Chou, J. J. 
(2015) Structure and multistate function of the transmembrane electron transporter 
CcdA. Nat. Struct. Mol. Biol. 22, 809-814 
209. Zhou, Y., and Bushweller, J. H. (2018) Solution structure and elevator mechanism 
of the membrane electron transporter CcdA. Nat. Struct. Mol. Biol. 25, 163-169 
210. Dobson, L., Remenyi, I., and Tusnady, G. E. (2015) CCTOP: a Consensus 
Constrained TOPology prediction web server. Nucleic Acids Res. 43, W408-412 
211. Kelley, L. A., Mezulis, S., Yates, C. M., Wass, M. N., and Sternberg, M. J. (2015) 
The Phyre2 web portal for protein modeling, prediction and analysis. Nat. Protoc. 
10, 845-858 
212. Omasits, U., Ahrens, C. H., Muller, S., and Wollscheid, B. (2014) Protter: interactive 
protein feature visualization and integration with experimental proteomic data. 
Bioinformatics 30, 884-886 
References 
 181 
213. Yin, H., and Flynn, A. D. (2016) Drugging membrane protein interactions. Annu. 
Rev. Biomed. Eng. 18, 51-76 
214. Overington, J. P., Al-Lazikani, B., and Hopkins, A. L. (2006) How many drug targets 
are there? Nat. Rev. Drug Discov. 5, 993-996 
215. Drew, D. E., von Heijne, G., Nordlund, P., and de Gier, J. W. (2001) Green 
fluorescent protein as an indicator to monitor membrane protein overexpression in 
Escherichia coli. FEBS Lett. 507, 220-224 
216. Drew, D., Slotboom, D. J., Friso, G., Reda, T., Genevaux, P., Rapp, M., Meindl-
Beinker, N. M., Lambert, W., Lerch, M., Daley, D. O., Van Wijk, K. J., Hirst, J., Kunji, 
E., and De Gier, J. W. (2005) A scalable, GFP-based pipeline for membrane protein 
overexpression screening and purification. Protein Sci. 14, 2011-2017 
217. Drew, D., Lerch, M., Kunji, E., Slotboom, D. J., and de Gier, J. W. (2006) 
Optimization of membrane protein overexpression and purification using GFP 
fusions. Nat. Methods 3, 303-313 
218. Kawate, T., and Gouaux, E. (2006) Fluorescence-detection size-exclusion 
chromatography for precrystallization screening of integral membrane proteins. 
Structure 14, 673-681 
219. Feilmeier, B. J., Iseminger, G., Schroeder, D., Webber, H., and Phillips, G. J. (2000) 
Green fluorescent protein functions as a reporter for protein localization in 
Escherichia coli. J. Bacteriol. 182, 4068-4076 
220. Pedelacq, J. D., Cabantous, S., Tran, T., Terwilliger, T. C., and Waldo, G. S. (2006) 
Engineering and characterization of a superfolder green fluorescent protein. Nat. 
Biotechnol. 24, 79-88 
221. Dinh, T., and Bernhardt, T. G. (2011) Using superfolder green fluorescent protein 
for periplasmic protein localization studies. J. Bacteriol. 193, 4984-4987 
222. Wagner, S., Baars, L., Ytterberg, A. J., Klussmeier, A., Wagner, C. S., Nord, O., 
Nygren, P., Van Wijk, K. J., and de Gier, J. W. (2007) Consequences of membrane 
protein overexpression in Escherichia coli. Mol. Cell. Proteomics 6, 1527-1550 
223. Miroux, B., and Walker, J. E. (1996) Over-production of proteins in Escherichia coli: 
Mutant hosts that allow synthesis of some membrane proteins and globular proteins 
at high levels. J. Mol. Biol. 260, 289-298 
224. Wagner, S., Klepsch, M. M., Schlegel, S., Appel, A., Draheim, R., Tarry, M., 
Hogbom, M., van Wijk, K. J., Slotboom, D. J., Persson, J. O., and de Gier, J. W. 
(2008) Tuning Escherichia coli for membrane protein overexpression. Proc. Natl. 
Acad. Sci. U. S. A. 105, 14371-14376 
References 
 182 
225. Schlegel, S., Lofblom, J., Lee, C., Hjelm, A., Klepsch, M., Strous, M., Drew, D., 
Slotboom, D. J., and de Gier, J. W. (2012) Optimizing membrane protein 
overexpression in the Escherichia coli strain Lemo21(DE3). J. Mol. Biol. 423, 648-
659 
226. Studier, F. W. (1991) Use of bacteriophage T7 lysozyme to improve an inducible T7 
expression system. J. Mol. Biol. 219, 37-44 
227. Anandan, A., and Vrielink, A. (2016) Detergents in membrane protein purification 
and crystallisation. in The Next Generation in Membrane Protein Structure 
Determination (Moraes, I. ed.), Springer International Publishing, Switzerland. pp 
13-28 
228. Alexandrov, A. I., Mileni, M., Chien, E. Y., Hanson, M. A., and Stevens, R. C. (2008) 
Microscale fluorescent thermal stability assay for membrane proteins. Structure 16, 
351-359 
229. Sonoda, Y., Newstead, S., Hu, N. J., Alguel, Y., Nji, E., Beis, K., Yashiro, S., Lee, 
C., Leung, J., Cameron, A. D., Byrne, B., Iwata, S., and Drew, D. (2011) 
Benchmarking membrane protein detergent stability for improving throughput of 
high-resolution X-ray structures. Structure 19, 17-25 
230. Denisov, I. G., and Sligar, S. G. (2017) Nanodiscs in membrane biochemistry and 
biophysics. Chem. Rev. 117, 4669-4713 
231. Shen, H. H., Lithgow, T., and Martin, L. (2013) Reconstitution of membrane proteins 
into model membranes: seeking better ways to retain protein activities. Int. J. Mol. 
Sci. 14, 1589-1607 
232. Cherezov, V. (2011) Lipidic cubic phase technologies for membrane protein 
structural studies. Curr. Opin. Struct. Biol. 21, 559-566 
233. Frank, J. (2017) Advances in the field of single-particle cryo-electron microscopy 
over the last decade. Nat. Protoc. 12, 209-212 
234. Nogales, E. (2016) The development of cryo-EM into a mainstream structural 
biology technique. Nat. Methods 13, 24-27 
235. Lei, S. P., Lin, H. C., Wang, S. S., Callaway, J., and Wilcox, G. (1987) 
Characterization of the Erwinia carotovora pelB gene and its product pectate lyase. 
J. Bacteriol. 169, 4379-4383 
236. Waldo, G. S., Standish, B. M., Berendzen, J., and Terwilliger, T. C. (1999) Rapid 
protein-folding assay using green fluorescent protein. Nat. Biotechnol. 17 
237. Stetsenko, A., and Guskov, A. (2017) An overview of the top ten detergents used 
for membrane protein crystallization. Crystals 7, 197 
References 
 183 
238. Stroud, R. M. (2011) New tools in membrane protein determination. F1000 Biol. 
Rep. 3, 8 
239. Tribet, C., Audebert, R., and Popot, J. (1996) Amphipols: polymers that keep 
membrane proteins soluble in aqueous solutions. Proc. Natl. Acad. Sci. U. S. A. 93, 
15047-15050 
240. Lobstein, J., Emrich, C. A., Jeans, C., Faulkner, M., Riggs, P., and Berkmen, M. 
(2012) SHuffle, a novel Escherichia coli protein expression strain capable of 
correctly folding disulfide bonded proteins in its cytoplasm. Microb. Cell. Fact. 11, 
56 
241. Szklarczyk, D., Franceschini, A., Wyder, S., Forslund, K., Heller, D., Huerta-Cepas, 
J., Simonovic, M., Roth, A., Santos, A., Tsafou, K. P., Kuhn, M., Bork, P., Jensen, L. 
J., and von Mering, C. (2015) STRING v10: protein-protein interaction networks, 
integrated over the tree of life. Nucleic Acids Res. 43, D447-452 
242. Xiao, Z., Brose, J., Schimo, S., Ackland, S. M., La Fontaine, S., and Wedd, A. G. 
(2011) Unification of the copper(I) binding affinities of the metallo-chaperones Atx1, 
Atox1, and related proteins: detection probes and affinity standards. J. Biol. Chem. 
286, 11047-11055 
243. Xiao, Z., Gottschlich, L., van der Meulen, R., Udagedara, S. R., and Wedd, A. G. 
(2013) Evaluation of quantitative probes for weaker Cu(i) binding sites completes a 
set of four capable of detecting Cu(i) affinities from nanomolar to attomolar. 
Metallomics 5, 501-513 
244. Li, J., Zhang, W.-B., Loukas, A., Lin, R.-Y., Ito, A., Zhang, L.-H., Jones, M., and 
McManus, D. P. (2004) Functional expression and characterization of Echinococcus 
granulosus thioredoxin peroxidase suggests a role in protection against oxidative 
damage. Gene 326, 157-165 
 
